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PLS partial least squares
PR pattern recognition
PYY peptide YY
Q quadrupole
QC quality control
RD relaxation delay
RF radiofrequency
RNA ribonucleic acid
ROESY rotating frame Overhauser effect spectroscopy
ROS reactive oxygen species
rRNA ribosomal RNA
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RT retention time
RYGB Roux-en-Y gastric bypass
s.d. standard deviation
SAT/ATA sodium-coupled amino acid transporter/amino acid transporter A
SCFA short chain fatty acid
SERF selective refocusing
SIMS secondary ion mass spectrometry
SN1 system N
SOD1 superoxide dismutase 1
SR serine racemase
SRM selected reaction monitoring
STOCSY statistical total correlation spectroscopy
t-BuOH tert-butanol
TCA (18-crown-6)-tetracarboxylic acid
TLF time-lag focusing
TLR Toll-like receptor
TMS tetramethylsilane
TNF tumour necrosis factor
TOF time-of-flight
TSP sodium 3-(trimethylsilyl)propionate
UHPLC ultra high pressure liquid chromatography
ULOQ upper limit of quantification
UPLC ultra performance liquid chromatography
UV ultraviolet
VRAC volume-regulated anion channel
WT wild-type SOD1 overexpressing cell line
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Symbols
α selectivity
analytem endogenous analyte response in the matrix
analytems spiked analyte response in the matrix
analyte n normalised analyte response
A free substrate
B free CSA
B1 radiofrequency pulse
B0 magnetic field strength/flux density
c y-intercept
C molar concentration
CA molar concentration of analyte
CIS molar concentration of internal standard
CV cone voltage
dp particle size
δ chemical shift
δobs observed chemical shift
δ x relative error
∆ change in
∆δmax maximum change in chemical shift
e nuclear Zeeman level
eV accelerating voltage
E energy
Ecoll collision energy
f(t) time domain spectrum
Fopt optimal flow rate
g(w) frequency domain spectrum
γ gyromagnetic ratio
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h Planck’s constant
~ h/2pi
I spin quantum number
IS t theoretical internal standard response
k retentivity
ka association constant
kB Boltzmann constant
kd dissociation constant
kR association constant of R-substrate
kS association constant of S -substrate
l flight tube length
L chromatographic column length
m slope
µ magnetic moment
mCA endogenous molar concentration of analyte in the matrix
M0 bulk/macroscopic magnetisation
My transverse magnetisation
MF matrix factor
n number of replicates
N system efficiency
Nhigher higher energy level
Nlower lower energy level
NS number of scans
pi0 probability of null hypothesis being true
P nuclear angular momentum
PA population of free substrate
PAB population of CSA-substrate complexes
r Pearson’s correlation coefficient
rs Spearman’s rank correlation coefficient
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ratioA/IS normalised response ratio
R mass resolution
R2 coefficient of determination
Rs chromatographic resolution
RSD relative standard deviation
σ nuclear shielding constant
S/N signal to noise ratio
t time
tD retention time of (S )-NIFE-D-AA
tL retention time of (S )-NIFE-L-AA
τP pulse length
T temperature
T1 spin-lattice/longitudinal relaxation
T2 spin-spin/transverse relaxation
u linear velocity
v1 pulse frequency
vL Larmor frequency
vreference resonance frequency of reference compound
w chromatographic peak width
wD chromatographic peak width of (S )-NIFE-D-AA
wL chromatographic peak width of (S )-NIFE-L-AA
z magnetic field direction
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Abstract
Metabonomics utilises high resolution analytical platforms to generate spectroscopic profiles
that are rich in latent biological information. At present, the two principal analytical platforms
used routinely in metabonomic studies are nuclear magnetic resonance (NMR) spectroscopy and
mass spectrometry (MS). While these analytical methods in their current state of development
in the field of metabonomics give broad coverage across multiple chemical classes, none report
sufficiently well, if at all, on the absolute configuration of chiral molecules. As a consequence of the
stereospecificity present in biological systems, a very large number of biologically active molecules
exhibit chirality. Therefore, an important aspect of the metabolome remains largely unexplored
by current metabonomic analytical platforms. Current enantioselective methods exist, but these
are largely unsuitable for multi-analyte measurements. The work in this thesis addresses the
need for appropriate chiral analytical methods for metabolic profiling. The aim was to develop a
practical, fit-for-purpose chiral analytical method that will report simultaneously on numerous
endogenous metabolites by untargeted or widely targeted analysis, and importantly, could be
aligned with existing analytical workflows. Initial evaluation of an NMR spectroscopic approach
using chiral solvating agents concluded that additional spectral complexity and interaction-
induced internal reference compound chemical shift instability would prohibit efficient chiral
profiling in a metabonomics workflow. An existing targeted MS-based assay for enantioselective
separation of amino acids was selected for optimisation and further development. Focused
analyses were performed to characterise its performance in the differentiation of individual pairs
of enantiomers, and subsequently expanded, first to cover the panel of proteinogenic amino acids,
and secondly to other detectable metabolites. Each stage of the assay optimisation incorporated
an evaluation in a representative set of samples and was able to provide highly relevant biological
information that would not be accessible using current achiral metabonomic methods. Further
work to expand the number of detectable metabolites and quantitative nature of the assay are
discussed.
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Chapter1
Introduction
1.1 Metabolomics and metabonomics
Metabolism represents an integral part of life. Small molecule metabolites (typically < 1500 Da)
take on a variety of functions in biological systems, including acting as osmolytes, signalling
molecules, inhibitors/regulators, pigments, energy substrates, and building blocks for biological
macromolecules, such as proteins, polysaccharides, and ribonucleic acids. Metabolomics is
defined as the comprehensive and quantitative analysis of all metabolites in a biological unit,
such as a biofluid, tissue extract, organ, or organism, and closely reflects the activities of a
complex biological system at a functional level. Metabonomics is the quantification of changes
across the metabolome through time in response to a given stimulus [Lindon et al., 2011].
"the quantitative measurement of the dynamic multiparametric metabolic response of living
systems to pathophysiological stimuli or genetic modification" [Nicholson et al., 1999].
Thus, although metabonomics captures information on the entire metabolome, both intracellular
and extracellular, focus is then diverted to dealing with those metabolites that are of functional
importance with respect to a pathophysiological state, exposure, or an applied intervention.
The terms metabolomics and metabonomics are often used interchangeably and employ the
same analytical and modelling procedures; however, the latter is preferred as it best describes
the dynamic nature of biological systems together with its intricacy [Nicholson and Lindon,
2008]. Biofluids, such as urine and blood, contain thousands of chemical species reflecting the
underlying complexity of existing biological networks and the pathways by which small molecules
are interconverted to perform their various functions. The true novelty of metabonomics exists
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in the capacity to perform large scale analyses with high-throughput techniques that allow
hundreds to thousands of metabolites to be analysed in a single analytical run ( Fig. 1). This
makes it compatible with serial sampling procedures to perform repeat measurements in quick
succession to monitor the temporal transformation of a physiological state [Ramsden, 2015].
Systems biology is a "top-down" approach to investigate complex biological systems, where
the structure and dynamics of cellular or organism function is explored. This is in contrast to
"bottom-up" approaches that investigate isolated characteristics. A biological system is not simply
comprised of a stationary network of genes, proteins, and metabolites. While investigations in this
sense may prove useful in terms of characterising system structure, it is insufficient to understand
the complexity of system behaviour and control. To do so takes a more dynamic approach,
where each systemic component is assessed for its interactions. Metabonomics is a discipline
that adheres to the philosophy behind systems biology in the sense that it provides an integrated
temporal overview of the biochemistry associated with a complex organism. Metabolites are the
end products of cellular processes; therefore, in metabonomics all influencing factors, genetic
and environmental, are monitored without making assumptions on any single factor to the
outcome. Yet in doing so, it is possible to identify individual predominating contributors to the
outcome and generate hypotheses that can be tested with further investigations. This is due to a
combination of tight homeostatic control of certain sets of metabolites and the specific metabolic
functions of some tissues and organs. Under such conditions, metabolites in body fluids exist
in a dynamic equilibrium and deviations in their ratios or absolute concentrations of sufficient
magnitude, as a result of pathophysiological processes or explicit interventions, may be readily
detected by metabolic profiling. For these reasons, metabonomics is extremely powerful in the
discovery of novel biomarkers as metabolites are often the most revealing markers of disease,
chronic environmental exposures, and the effect of drugs. Consequently, metabonomics has been
successfully applied to a wide range of research fields, including toxicology, nutrition, personalised
healthcare, and clinical diagnostics [Nicholson and Lindon, 2008,Nicholson, 2006,Rezzi et al.,
2007,Robertson, 2005,Bjerrum et al., 2009,Brindle et al., 2002]. More recently, advances in
instrument design and performance have allowed metabolic phenotypes to be measured in the
context of large-scale epidemiological, clinical, and high-throughput in vitro studies, commonly
in conjunction with multivariate measures obtained via other -omics platforms to build a more
comprehensive understanding of biological systems [Gomez-Lechon et al., 2010, Coen et al.,
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Figure 1. Summary of a core metabonomics workflow. A biological sample is prepared
and analysed using either NMR spectroscopy or an MS-based method. The acquired spectra,
which are comprised of hundreds to thousands of metabolic signatures, are translated to a
large multiparametric data table that is analysed using multivariate statistics to extract useful
information. The metabolites responsible for spectral features that cause class separations,
trends, and correlations are identified using a spectral library. Metabolic pathway analysis is
used to determine whether these metabolites of interest conform to common or co-regulated
biochemical pathways. They can also be correlated to additional data matrices acquired through
analytical methods associated with other -omics platforms to provide a more comprehensive
insight into biological systems. NMR, nuclear magnetic resonance; PCA, principal component
analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes.
2008,Wesseling et al., 2013,Jiang et al., 2015].
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1.2 Analytical methods in metabonomics
The two principal analytical techniques that dominate the field of metabonomics are nuclear
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). Both methods can provide
quantitative information on a wide range of metabolites in biological samples simultaneously in
a single analysis and be used for metabolite structure elucidation.
1.2.1 1H NMR spectroscopy
1.2.1.1 Nuclear angular momentum and magnetic moment
Most nuclei possess a nuclear, or intrinsic, angular momentum (P ) that is a vector with a
magnitude that can be quantified using the equation:
P = ~
√
I(I + 1) (1)
where I is the nuclear spin quantum number and ~ = h/2pi, where h is Planck’s constant
(6.626× 10−34 J s). The spin quantum number can have the values I = 0, 1/2, 1, 3/2, 2 ..... 6. P is
associated with a magnetic moment (µ), which is another vector quantity and is proportional to
P :
µ = γP (2)
where γ is the gyromagnetic ratio, the ratio of the magnetic dipole moment to the spin angular
momentum of a particle. The gyromagnetic ratio is constant, yet unique, for each nucleus and
determines the detection sensitivity of a nucleus in an NMR experiment. Nuclei with high values
of γ, such as 1H, are more easily observed by NMR spectroscopy. In the absence of an external
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magnetic field, P and µ are randomly orientated. As a result, there is no net bulk/macroscopic
magnetisation (M0), which is the vector sum of µ for all nuclei in the sample. Applying an
external magnetic field causes P and µ to align along the magnetic field with field direction z
(Pz and µz, respectively) and creates distinct energy levels (e), also called the nuclear Zeeman
levels, where e = I, I − 1, I − 2 .....−I. Therefore, there are a total of 2I + 1 values of e, and
consequently, an equal number of possible orientations of P and µ in the magnetic field. Pz is
represented by the equation:
Pz = e ~ (3)
Hence, by using Eq. 2 for substitution:
µz = e γ ~ (4)
1.2.1.2 Energy levels of nuclei in a static magnetic field
For 1H there are two energy levels in the magnetic field, e = +1/2 and e = −1/2, where the
spins are aligned either parallel or anti-parallel to the magnetic field, respectively. The parallel
alignment is the energetically preferred orientation. Other nuclei with I > 1/2 can have more
than two energy levels. For example, nuclei with I = 1, such as 2H and 14N, have three energy
levels (e = +1, e = 0, and e = −1). The energy (E) of a magnetic dipole in a magnetic field
with a flux density of B0 is:
E = −µz B0 (5)
Then substituting Eq. 4 gives:
E = −e γ ~ B0 (6)
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Figure 2. Precession of nuclear dipoles with I= 1/2 in a magnetic field with field
direction z. The total number of precessing nuclear dipoles N = Nhigher +Nlower.
Therefore, the change in energy (∆E) associated with transitions between energy levels increases
with incrementing values ofB0. The number of nuclei at each energy state can be described by
the Boltzmann distribution. If we represent the higher and lower energy levels of an I = 1/2
system as Nhigher and Nlower, respectively, then:
Nhigher
Nlower
= e−∆E/kBT (7)
where kB is the Boltzmann constant (1.381× 10−23 J K−1) and T is the absolute temperature
in K. Although transitions from Nhigher to Nlower and vice versa are equally probable at room
temperature, both of which are associated with a reversal of spin orientation, there is a slight
population excess at Nlower. Consequently, the application of electromagnetic radiation at the
appropriate frequency (v1) causes an absorption of energy leading to a predominant transition
from Nlower to Nhigher. This causes macroscopic magnetisation along z that is observed as a
peak. The peak intensity is proportional to the population difference (Nhigher −Nlower), which is
proportional to the total number of spins in the sample, and thus concentration [Friebolin and
Becconsall, 1998].
In the classical representation, nuclear dipoles precess around the magnetic field with a field
direction z (Fig. 2). Transitions between energy levels can only occur when v1 matches the
precession frequency (vL), also referred to as the Larmor or resonance frequency. vL is the
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frequency at which nuclear dipoles precess around z and is proportional to B0:
vL = v1 =
∣∣∣ γ
2pi
∣∣∣B0 (8)
1.2.1.3 The pulse NMR method
Typically NMR experiments are performed using the pulsed NMR method, which involves
exciting all nuclei of the same species simultaneously using a radiofrequency pulse (B1). A
radiofrequency generator usually operates at a fixed frequency (v1) that is chosen on the basis
of B0 and the type of nucleus observed. However, when switched on for a short duration (τP)
in the order of a few microseconds, a pulse with a continuous band of frequencies symmetrical
about v1 is obtained. Only part of this frequency band is effective in eliciting transitions. The
pulse length is dependent on the width of the spectrum. For example, when τP = 10−5 s the
frequency band is approximately 105 Hz wide. If v1 is correctly chosen, the frequency band
should encompass all sample resonance frequencies recorded in the spectrum. Since it is desirable
to apply the same amount of radiation to all nuclei as much as possible, short pulses of high
power are used and τP is chosen so that the frequency band exceeds the width of the spectrum
by one or two powers of ten [Friebolin and Becconsall, 1998].
To induce transitions, B1 is applied to the sample along the x -axis (Fig. 3). The pulse interacts
with M0 causing it to tip away from the z -axis (the direction of the static field B0). The angle
by which M0 is tilted is called the pulse angle (θ). θ increases with the amplitude of B1 or the
length of τP:
θ = γ B1 τP (9)
The transverse magnetization (My) is critical in producing an NMR signal. The receiver coil is
orientated in the y-direction; therefore, a 90◦ pulse is required to obtain the maximum signal.
Typically, B1 is kept constant and the parameter τP is increased in steps of 1 µs until the
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Figure 3. 90◦ pulse NMR experiment. Rotation of bulk magnetisation vector M0 to
transverse magnetisation vector My after a 90◦ radiofrequency pulse B1.
90◦ pulse is achieved. Following the 90◦ pulse, the small fraction of spins that were already
preferentially aligned with B0 before the pulse are rotated and precess in phase in My. This is
referred to as phase coherence. All other spins besides this small fraction resume a random phase
distribution, and therefore cancel each other out and do not contribute to the signal. When τP
is increased to the point where θ = 180◦, the signal intensity becomes zero. For greater values of
τP, a signal with a negative amplitude is observed (an inverted peak). Switching off the pulse
(B1 = 0) causes M0 to revert back to its original position. This is called relaxation and can be
described by T1 and T2, where T1 is the spin-lattice, or longitudinal, relaxation time and T2 is
the spin-spin, or transverse, relaxation time. The reciprocals, 1/T1 and 1/T2, correspond to the
rate constants of the two relaxation processes [Friebolin and Becconsall, 1998].
The decay of My during relaxation that is detected by the receiver is called the free induction
decay (FID). This does not take the form of a typical exponential curve due to the detection
method used, but rather a sinusoidal curve where the time interval between successive maxima is
1/∆v (Fig. 4), the reciprocal of the difference in frequency between v1 and resonance frequency
of the nucleus (vL). The rate of the FID is determined by T2 and field inhomogeneities. A sample
containing nuclei with different values of vL or a spectrum with multiplets as a result of spin-spin
coupling (the interaction of neighbouring magnetic dipoles within a molecule through space)
will have superimposed FIDs. Such interfering FIDs cannot be analysed directly; therefore,
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Figure 4. Fourier transformation. The translation of a time domain spectrum (FID) into a
frequency domain spectrum by fourier transformation (FT).
to aid interpretation the time domain spectrum is translated to the frequency domain by a
mathematical function called Fourier transformation (FT):
g(w) =
∫ +∞
−∞
f(t)e−iwtdt (10)
where g(w) is the frequency domain spectrum and f(t) is the time domain spectrum (Fig. 4).
Usually the intensity of each FID is very weak following FT; therefore, the FIDs of many pulses
are accumulated in the computer prior to transformation. During spectrum accumulation the
amplitude of signals always increase by addition as they are always positive, whereas that of
noise does not and is averaged. Therefore, signal-to-noise ratio (S/N) increases with the number
of scans (NS):
S/N ∼
√
NS (11)
The accumulation of many FIDs requires high field-frequency stability to prevent line broadening,
and consequently, a loss of sensitivity. Field-frequency stability is controlled by the lock unit,
which uses a separate radiofrequency channel to measure another nuclear resonance, such as 2H
of a deuterated solvent for 1H NMR experiments. The lock unit will respond automatically to a
change in magnetic field strength or frequency changes that cause a reduction in signal intensity
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by applying a field correction to restore the nuclear resonance from the solvent. The same
correction is also applied to the resonance of the observed nucleus under the assumption that
the same stability conditions apply for both radiofrequency channels [Friebolin and Becconsall,
1998].
1.2.1.4 The chemical shift
The resonance frequency of the observed nucleus differs depending on its molecular environment.
The observed nucleus is surrounded by electrons and other atoms that exert a shielding effect.
As a result, the effective magnetic field (Beff) that is experienced by the nucleus is always less
than the applied magnetic field B0:
Beff = B0 − σB0 = (1− σ)B0 (12)
where σ is the shielding constant, a dimensionless quantity that is solely dependent on the
electronic and magnetic environment of the observed nuclei. By applying Eq. 8 the resonance
condition is therefore:
v1 =
γ
2pi
(1− σ)B0 (13)
With v1 being proportional to the shielding factor (1-σ), separate resonance signals are observed
in the spectrum for nuclei exposed to non-equivalent shielding effects. Resonance signals are
recorded such that σ increases as you move from left to right (upfield) in the spectrum. In NMR
spectroscopy there is no absolute spectral scale as the resonance frequency and magnetic flux
density are interdependent. Therefore, a relative scale is used instead which involves measuring
the frequency differences (∆v) between the resonance signals of the sample and that of a reference
compound. Hence, it is critical to add an internal standard to the sample being analysed in
order for measurements to be made, ideally one that produces a single sharp peak isolated from
resonances arising from the sample. Since ∆v is also dependent on B0, a dimensionless quantity
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called the chemical shift (δ) is then calculated:
δ =
∆v
vreference
× 106 (14)
where vreference is the absolute resonance frequency of the internal standard. A factor of 106 is
used to simplify numerical values; therefore, δ is always given in parts per million (ppm). δ is
field independent, thus facilitating cross-instrumental spectral comparisons.
1.2.1.5 Application in metabonomics
High field NMR spectroscopy is generally employed to detect hydrogen atoms due to its almost
universal presence among metabolites and desirable attributes, such as high natural abundance
(99.985%), a spin number (I) of 1/2, and a high gyromagnetic ratio (γ) of 2.675× 108 s−1 T−1.
Providing the metabolite concentration exceeds the limit of detection, almost all metabolites will
generate a characteristic peak or set of peaks in a 1H NMR spectrum. Thus, a 1H NMR spectrum
of a biofluid represents the superimposition of all metabolic signatures in the sample [Nicholson
and Lindon, 2008].
A major advantage of NMR spectroscopy is its ability to screen the metabolome for a wide range
of metabolites without the need for sample manipulation. The samples also remain intact during
analysis and can be recovered for further analysis. Moreover, NMR spectroscopy is a very robust
quantitative technique with the capacity to produce highly reproducible spectra. In addition
to its use in the context of biofluids, it may also be for investigations of abnormal metabolite
profiles in tissue and cell extracts [Lindon et al., 2000]. Previous studies have shown its utility
for determining the metabolic composition of intact tissues using magic-angle-spinning 1H NMR
spectroscopy [Moka et al., 1998,Beckonert et al., 2010]. Automated NMR spectroscopic analysis
is well-suited to rapid throughput (> 300 samples per day) for the analysis of large biological
sample sets, such as in large scale epidemiological studies [Lindon et al., 2000].
Although effective in the field of metabonomics, NMR spectroscopy is associated with several
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disadvantages, such as poor sensitivity with detection in the micromolar to millimolar range
and the inability to detect particular classes of compounds, such as sulphates. The other major
drawback, particularly in the context of biofluid analysis, is spectral complexity. Such NMR
spectra are congested with overlapping resonances of variable intensity where high abundance
metabolites may mask subtle, yet important, changes in concentrations of low abundance
metabolites. Although such resonances may be subtracted from the spectrum, signals of
endogenous metabolites of interest may be lost in the process, thereby reducing the data quantity
for subsequent multivariate analysis [Plumb et al., 2002].
1.2.2 Mass spectrometry
MS based methods, although not as robust as NMR spectroscopy, are highly sensitive with the
capacity to quantify metabolites in the nanomolar to micromolar range. Consequently, a much
broader spectrum of metabolites can be detected in biofluids and with lower sample volumes.
Thus, it is useful for applications such as targeted trace analysis of low abundance metabolites,
and investigations of intracellular fluxes and biochemical networks using tracer experiments
based on 13C labelled substrates [Valbuena et al., 2015,Wiechert, 2001].
MS detects metabolites on the basis of their mass-to-charge ratio (m/z ) following ionisation and
transference to gas phase. Therefore, mass spectrometers are unable to detect neutral molecules
and free radicals. The mass spectrum represents the relative abundance of detection ions as a
function of m/z. Mass resolution (R) is the ability to separate two ion signals from one another
and is given by the equation:
R =
M1
M1 −M2 (1)
where M1 is the m/z of the first ion and is greater than M2, the m/z of the second ion. This
is the 10% valley definition, where the valley between the two signals is 10% of their height.
For example, a mass resolution of 1000 is required to resolve two ions at m/z 1000 and 1001
with a 10% valley. Mass resolutions of 100 - 500 are considered low, whereas those in the order
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of 1000 - 5000 are moderate and those > 10, 000 are high. When isotopes or components in a
mixture are unresolved, the full width at half maximum (FWHM) is used instead, which is given
by the equation:
R =
M
FWHM
(2)
For example, for an ion at m/z 1000 with a peak width of 2 units at half its height, the mass
resolution is 500 (1000/2). Since both methods are widely employed, it is important to report the
method used to determine mass resolution when reporting its value. For small molecules, the ion
signals originating from heavy isotopes are typically low due to their naturally low abundance.
Therefore, most mass measurements are based on the ion signals from the lightest isotopes and
the resulting molecular weight is called the monoisotopic mass. For carbon-based compounds,
the isotopic distribution of carbon is considered exclusively since the natural abundance of
heavy isotopes for other common elements found in organic compounds are much lower relative
to carbon. When an ion’s isotopes are unresolved, molecular weight measurements based on
the centroid m/z value represents the average mass of all the contributing elemental isotopes.
For large molecules, where the probability of the ion containing heavy isotopes is greater, this
average value can be significantly greater than the monoisotopic mass [Downard, 2004].
Mass spectrometers are now available, or can be built, according to a multitude of designs
depending on the type, rate, and location of sampling as well as the type of detection used.
All mass spectrometers consist of three basic components: ion source, mass analyser, and ion
detector. The ion source is responsible for imparting a charge on introduced molecules. The
charged species are then accelerated to the mass analyser, where they are separated based on
m/z using magnetic and/or electrical fields. Ions that reach the detector produce an electrical
current that is amplified and detected. Mass spectrometers are operated under a vacuum to
prevent the collision of ions with residual gas molecules during their path from the ion source to
the detector [Downard, 2004].
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1.2.2.1 Ionisation methods
Existing ionisation techniques include electron ionisation (EI), field and plasma desorption
ionisation, fast atom bombardment (FAB) ionisation, matrix-assisted laser desorption ionisation
(MALDI), atmospheric pressure chemical ionisation (APCI), and electrospray ionisation (ESI).
For EI, gaseous sample molecules are bombarded by a stream of electrons that are produced
by heating and passing a current through a thin ribbon of metal called a filament, or cathode.
The electrons are then projected across the ion source by using an anode placed on the opposite
side. The energy of electrons can be increased by raising the potential difference between
the cathode and anode. The collision of electrons with sample molecules causes ionisation by
electron loss, where the ionisation energy is dependent on the sample molecule itself. As sample
molecules possess a range of energies depending on factors such as bond strengths and fragment
stability, certain molecules will have sufficient energy to ionise while others will not. Since not
all the energy from electrons is transferred during collision, higher electron energies are typically
required to induce ionisation than that expected. As EI can produce fragments as well as intact
molecular ions it is referred to as a hard ionisation method [Downard, 2004].
Chemical ionisation is also related to electron impact, but that of a reagent gas rather than
sample molecules themselves. The imparted charge is then transferred to sample molecules by a
chemical process, such as proton transfer, charge exchange, or ion-molecule addition. One of the
most common reagent gases used is methane, which is maintained at much higher concentrations
than the sample to prevent direct ionisation of sample molecules. Consequently, the chemical
ionisation source is operated using much higher pressures than an EI source [Downard, 2004].
Field and plasma desorption ionisation were the first ionisation techniques developed for non-
volatile molecules. In brief, field desorption ionisation involves depositing the sample onto a
metal filament coated with carbon, and then applying a potential difference between the filament
and a nearby electrode to desorb ions from the surface. For plasma desorption ionisation, the
sample is deposited onto a foil manufactured from nickel or aluminium-coated nylon. The fission
fragments generated by the radioactive decay of Californium-252, an isotope that serves as a
very efficient neutron source, are passed through the foil and deposit a considerable amount of
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energy into the sample to trigger the release of ions. Both ionisation techniques have largely
been replaced by FAB and MALDI [Downard, 2004].
FAB ionisation is widely applied to study the chemical nature of materials and surfaces, which
is known as secondary ion mass spectrometry (SIMS). In SIMS, a primary beam of high energy
ions, such as Cs+, is used to bombard a solid surface that releases secondary sample ions for
analysis. When the sample is ablated from its position on a surface, the production of secondary
ions diminishes unless the primary beam is made to strike a different position. To resolve this
issue, the sample is dissolved or suspended in a non-volatile viscous liquid so that following
sample ablation the liquid matrix will flow across and restore the lost sample. The liquid matrix
also assists in dissipating the energy from the beam to prevent damage to the sample. However,
the generated spectra are associated with a characteristic high background in the low to modest
m/z range due to the generation of secondary ions from the liquid matrix. This makes it difficult
to detect analyte ions with m/z < 500, particularly for low sample concentrations. Although
FAB ionisation is less practised today due to the development of laser-based and spray ionisation
methods, it remains an important technique for many applications, including the study of organic
and small biological compounds [Downard, 2004].
MALDI uses lasers operating with a ultraviolet (UV) or infrared (IR) wavelength to desorb and
ionise samples on solid surfaces by transferring enough energy to cause electronic excitement.
The analyte of interest is mixed with a large mole excess of matrix compounds that absorbs
efficiently at the laser’s wavelength. The matrix aids energy dissipation and assists ionisation
by electron or chemical processes. All MALDI matrices contain phenolic or carboxylic acid
groups as proton transfer from matrix to sample is important for efficient ionisation of many
compounds. Both solid and liquid matrices have been implemented, although solids have been
far more successful in applications. Electrostatic spraying of the sample-matrix solution is used
as opposed to dried droplets to achieve a uniform, thin layer for more reproducible mass spectra.
MALDI-MS is a firmly established method for studying polar, high molecular weight compounds,
such as proteins and nucleic acids [Downard, 2004].
A major disadvantage of MALDI and other ionisation methods that involve sample deposition
in its solid state is their incompatibility with high-throughput separations prior to MS analysis.
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Figure 5. Magnified schematic of an ESI source. Droplets emerging from the Taylor
cone contain positively charged molecular ions ([M+H] +). The solvent evaporates causing the
droplets to gradually shrink in size and the ions within the droplets to move closer together.
Eventually, Coulombic repulsive forces between like-charged ions overcome the counteracting
liquid surface tension to generate free ions that progress on to the mass analyser.
Although MS can be used to analyse sample mixtures directly, some compounds in complex mix-
tures, such as biological extracts, may not be mass resolved. Chromatography and electrophoresis
are widely used for the separation of components in complex mixtures. Solution-based spray
ionisation techniques have made it possible to use these technologies in conjunction with MS to
provide an additional dimension for separation. This reduces spectral congestion and the need
for peak deconvolution tools. Of relevance to the MS detailed in this thesis is the ESI mode of
generating ions. An electrolyte solution and capillary are used to produce a fine mist of droplets
with a net positive or negative charge, depending on the polarity of the needle. The droplets
emerge from what is known as a Taylor cone, formed by the elongation of electrolyte solution at
the needle tip as charged species are repelled from the needle (Fig. 5). The charged droplets
are attracted to the entrance of the mass analyser. A counter-current dry gas is applied to aid
the evaporation of these ESI droplets. As the droplets get smaller, the ions within them move
closer together until eventually Coulombic repulsive forces become strong enough to overcome
the counteracting forces of liquid surface tension. At this point ionic species are solvent-free and
progress on to the mass analyser.
APCI is also capable of ionising polar molecules directly from solution. However, this involves
vaporising the solution stream prior to ionisation and then using an electrical discharge to ionise
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the gaseous sample molecules. Ionisation takes place through chemical processes as described
for chemical ionisation. ESI and APCI ionisation are both employed widely in drug discovery
studies, including the study of metabolites. With both ionisation techniques being related and
having complementary applications, many MS instruments feature an interchangeable ESI and
APCI ion source [Downard, 2004].
1.2.2.2 Mass analysers
There are a number of different types of mass analysers that may even be employed in conjunction
to build hybrid instruments. Two types of mass analysers were used for this work: time-of-flight
(TOF) and quadrupoles. As the name implies, TOF mass analysers separate ions and measure
their m/z based on the time taken for them to travel from the ion source to the detector (Fig.
6). The ions are separated in a field-free region of the flight tube that is typically 1− 2 m in
length. Ions formed in the ion source are pushed out by a high accelerating potential that is
applied to a lens with the same polarity as the ions. Assuming that initially all like-charged ions
are given the same kinetic energy (KE), ions are separated according to the following equation:
t2 = m/z
(
l2
2eV
)
(3)
where t is time, l is flight tube length, and eV is the accelerating voltage. Since l and eV are
kept constant, the time taken to reach the detector is solely based on m/z. A flight tube with a
length of 1− 2 m is inadequate for separating ions with similar m/z. Furthermore, not all ions
receive the same initial KE due to the in-source spatial distribution of ions and their differential
proximities to the applied electrical field. This gives rise to poor mass resolutions and large
molecular weight measurement errors. Modern day instruments employ several features to correct
these issues. One of these features is reflectrons that are donut shaped lenses connected by a
series of resistors across which a high voltage is applied (Fig. 6). Ions entering the reflectron
are gradually repelled down the same flight tube or a second flight tube by the potential applied
across the lenses. Ions with higher KE will penetrate the reflectron more than those with lower
KE. This allows ions with lower KE to catch up to ions with higher KE. Employing reflectrons
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Figure 6. TOF mass analysers. A representation of a TOF mass analyser with TLF and a
reflectron to improve mass resolution by correcting for molecular ions with varying KE.
also effectively increases the flight path, thereby enhancing ion separations in this respect too.
Another feature that is employed to improve mass resolution is time-lag focusing (TLF). TLF
introduces a time delay after the ions are formed before applying the accelerating potential.
During the time delay, ions with higher initial KE will drift further away from the lens, or grid.
As a result these ions will receive less energy from the electrical field than those with lower initial
KE closer to the lens. Providing the time delay is correctly chosen, the ions with lower initial
KE will gain enough energy from the electrical field to catch up with those with higher initial
KE so that all ions reach the detector at the same time, thus improving mass resolution. TOF
instruments that employ both reflectrons and TLF are capable of achieving mass resolutions of
up to 30,000 (FWHM) [Downard, 2004].
Quadrupoles consist of four rods arranged in parallel, where opposite rods are electrically coupled
(Fig. 7a). A voltage of opposite polarity is applied to adjacent rods, which comprises a direct
current (DC) component and a radiofrequency (RF) component. Ions are accelerated along the
z -axis between the rods and experience forces in the x and y directions causing them to oscillate
towards and away from the rods. When these oscillations become too large, the ions strike
the rods and fail to reach the detector. The DC and RF components are held at a fixed ratio
to improve mass resolution. A complete mass spectrum is acquired by scanning the voltages
at this fixed ratio. Quadrupole mass analysers have fast scanning capabilities and can easily
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be coupled to gas and liquid chromatography instruments. However, they are associated with
considerably lower mass resolutions of ∼ 5000 (FWHM). Triple-quadrupole instruments employ
three quadrupoles (Q1, Q2, and Q3), where Q1 and Q3 are m/z selectors, whilst Q2 serves
as a collision chamber to fragment precursor ions that arrive from Q1 (Fig. 7b). During
collision-induced dissociation in Q2, ions collide with an unreactive monoatomic gas held at
high pressure converting some of their KE into internal energy. Low collision energies in the
order of up to a few hundred eV will activate vibrational states in the molecule with a narrow
range of internal energy distributions. However, where multiple collisions are involved, internal
energy can accumulate with each successive collision. Conversely, high energy collisions in the
order of several keV can induce a wide range of internal energies making most structurally viable
fragmentation processes possible. The voltages of Q1 are adjusted to only allow precursor ions
with defined m/z to be transmitted. Following collision-induced dissociation, fragment ions with
specified m/z are selected by Q3 to pass on to the detector. This instrumental layout makes
triple-quadrupole instruments useful for tandem mass spectrometry (MS/MS) applications. With
certain chemical bonds being more susceptible to cleavage and particular structural features in
molecules increasing the likelihood of fragmentation, MS/MS was originally developed to derive
structural information about analytes. However, it is also useful for highly sensitive, quantitative
analysis of a selective panel of metabolites [Downard, 2004].
Other available types of mass analysers include magnetic sectors, quadrupole ion traps, and
ion cyclotron resonance (ICR) mass analysers. Magnetic sector instruments contain a magnet
positioned over a region of the ion flight path. As ions of a particular charge and velocity traverse
the magnetic field, they experience a centrifugal force. When this is equal to the centripetal
force, the ions adopt a circular path with a radius that is dependent on its momentum. Ions of a
particular m/z require specific values of initial accelerating potential and magnetic field strength
to reach the detector by following the central trajectory. All other ions will collide with the
wall of the flight tube and go undetected. A series of slits are used to improve the focusing and
separation of ions. A complete mass spectrum is acquired by scanning voltages and magnetic
field strengths over time. As low accelerating voltages lead to insufficient ions leaving the ion
source and reaching the detector, it is usually only the magnetic field strength that is altered.
Scan rates with magnetic mass analysers are slower in comparison to quadrupole mass analysers
because additional time needs to be allowed for the magnetic field to settle between scans. A
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Figure 7. Quadrupole mass analysers. (a) Representation of a quadrupole mass analyser
showing the oscillation of ions under the influence of the variable fields. (b) Basic schematic of
a triple quadrupole instrument.
radial electrostatic field, created by two curved plates held at oppositely charged potentials, is
used in conjunction with the magnet to compensate for in-source spatial distribution of ions,
and consequently, the KE range of ions leaving the ion source. An ion will only traverse the
electrostatic field when its electrostatic force is equal to its centripetal force, and therefore
independent of m/z and only dependent on velocity. Such double focusing magnetic sector
instruments are capable of achieving high mass resolutions in the order of 100,000 (FWHM).
Reverse geometry instruments with a magnetic sector followed by an electric sector and a collision
cell between the two can be used for MS/MS experiments. The acquired MS/MS spectrum is
called a mass analysed ion kinetic spectrum (MIKES). However, since the electrostatic field only
separates ions on the basis of velocity and ions can lose velocity following collision, a MIKES is
associated with substantially broader fragment ion peaks in comparison to other tandem mass
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spectra. Linked scans, which scan both the electric and magnetic field strengths simultaneously
while maintaining a constant ratio of their magnitudes, are used to bring all the fragments of a
precursor ion with a particular m/z into focus on the detector. This helps to achieve MS/MS
spectra with drastically superior mass resolution in comparison to MIKES [Downard, 2004].
Quadrupole ion traps are constructed from two conical shaped lenses, or electrodes, and one
donut shaped ring lens. Ions are trapped in a small interior volume in the centre of the ring
electrode and between the conical lenses that form the caps of the ion trap. The flow of ions
into and out of the trap is controlled by altering the voltages at the caps. An oscillating
radiofrequency potential is applied to the ring electrode, which causes the trapped ions to exhibit
a complex sinusoidal motion. The storage of ions in the trap is dependent on a number of factors,
including the m/z, ring electrode radius, distance between the caps, oscillating frequency, and
amplitude of the voltages applied to the caps and the ring electrode. Only ions that have both
axial (between the caps) and radial (in the plane of the ring electrode) stability will remain
contained in the trap. An inert gas, such as helium, is used to lower the KE of trapped ions
by collision to assist in their storage. The ring electrode voltage is adjusted to store a range
of m/z values. The potential of the exit cap is then lowered and the ring electrode voltage is
linearly ramped to eject ions with increasingm/z in turn on to the detector. Storing ions until
they reach a sufficient density before releasing them on to the detector helps to achieve very
high sensitivities independent of ionisation efficiency. The density of ions stored in the trap is
dependent on space charge effects, where neighbouring ions can exert repulsive forces that can
perturb ion motion. This can cause a loss of mass resolution and mass shifts resulting in large
errors in mass measurements. In addition, the perturbed ion motion may even result in ions
leaving the trap without passing on to the detector, thereby reducing sensitivity. To achieve an
equilibrium between density and repulsion, an automatic gain control (AGC) is used [Downard,
2004].
ICR mass analysers comprise of a cubic, rectangular, or cylindrical box with entrance and exit
slits on opposite plates. When a magnetic field is applied, ions will adopt a circular motion with
a radius that is perpendicular to the field direction when the centripetal and centrifugal forces
are balanced. The ion’s cyclotron frequency is dependent on its m/z and independent of velocity.
Ions with a higher m/z will have low cyclotron frequencies relative to ions with lower m/z.
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Ions in stable orbit within the magnetic field can be stored for hours providing that pressure is
kept minimal. To generate an electrical signal, ions are excited through the application of an
oscillating electrical field. If the frequency of the electrical field is the same as the cyclotron
frequency, the ions will absorb energy increasing their velocity and orbital radius; however, their
cyclotron frequency will remain constant. At this point, the ion’s circular motion comes into
close proximity with the detector plates at the top and bottom of the cell to generate an image
current. The amplitude of the current is proportional to the number of excited ions at this
cyclotron frequency. In an ideal vacuum, excited ions will maintain their trajectories indefinitely;
however, in practice their energy is dampened and they return to their original energy producing
a decaying waveform in the time domain. FT is applied to convert the time domain spectrum
into a frequency domain spectrum for interpretation. In FT-ICR, a wide range of excitation
energies is applied at once to excite all ions in the cell simultaneously. This is kept very brief to
ensure that ion orbits do not exceed the dimensions of the cell. Increasing the magnetic field
strength increases mass resolution in a proportionate manner and confers other benefits, such as
increasing the number of contained ions and the speed of data acquisition [Downard, 2004].
1.2.2.3 Ion detectors
Ions that leave the mass analyser, except in the case of ICR mass analysers, pass on to an ion
detector and generate an image current. The simplest detector employed by mass spectrometers
is the Faraday cup. This comprises of a long, thin rectangular box with a resolving slit at the
front, and a collector plate at the rear to emit secondary electrons when struck by ions. The
plate is usually angled steeply relative to the direction of the incoming ion beam to prevent
ion reflection and the escape of secondary electrons. A second box is used to surround the
collector box, which is held at ground to shield the detector from electrical noise. Positively
charged ions that strike the collector plate are neutralised by electrons drawn from ground across
a resistor. The ion-induced current is then amplified and recorded. This type of detector is
unsuitable for scanning instruments where the population of ions transmitted to the detector
vary in m/z [Downard, 2004].
Electron multipliers achieve very high detection efficiencies in comparison to Faraday cups by
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Figure 8. Representation of a continuous dynode electron multiplier. The ion beam
strikes the detector and causes the emission of secondary electrons, which are then amplified as
they accelerate to the tip.
amplifying the secondary electrons emitted from the detector surface. There are two types
of electron multipliers: discrete dynode and continuous dynode. Discrete dynode electron
multipliers consist of a series of discrete plates with incrementing voltages linked by a chain of
resistors. The secondary electrons emitted after ions strike the first detector plate are amplified
at each successive plate by a cascading effect, thereby amplifying the ion-induced current. In
contrast, continuous dynodes have an internal surface that acts as a resistor for an electrical
gradient to be applied across the detector (Fig. 8). The secondary electrons emitted from the
detector surface are accelerated to the tip of the detector which amplifies the current. Electron
multipliers are commonly implemented in scanning quadrupole and magnetic sector instruments.
However, one disadvantage of these detectors is that they do not detect ions across the m/z
scale with equal efficiency as high m/z ions are detected less readily than low m/z ions. This
non-linear detector response means that ion signals cannot be used to determine the levels of
one component relative to another in a sample mixture [Downard, 2004].
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Figure 9. Schematic of a microchannel plate detector. Ions arriving over a large area
enter multiple angled channels and strike the detector to emit electrons. The secondary electrons
are amplified by a cascading effect to magnify the ion-induced current.
A microchannel plate detector has a thin, flat plate containing a series of small channels that
are typically angled several degrees relative to the direction of the ion beam (Fig. 9). Ions
entering the channels strike the wall and emit electrons that deflect back and forth repetitiously,
which amplifies the ion-induced current. A stack of several plates can be used to achieve
greater gains. This type of detector is commonly used in TOF instruments because ions from
the TOF mass analyser are unfocused and arrive at the detector over a large area. They are
also implemented in array detectors in scanning instruments, of which the photodiode array is
most commonly employed. In a photodiode array, a microchannel plate detector is coupled to
fibre optic channels via a phosphorescent screen. Electron impact causes light to be emitted
from the phosphorescent screen in the form of photons, which are in turn transmitted down
fibre optic channels on to a charge- or plasma-coupled device. Array detectors constructed for
magnetic sector instruments are able to detect ions across approximately 5% of the full m/z
range. However, those constructed for quadrupole instruments can achieve detection ranges
of approximately 25%, although there will be preferential detection of ions at one end of the
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m/z range over the other. All array detectors are associated with some compromise in mass
resolution as even a well focused ion beam will enter several channels. Mass resolution can be
improved across most of the m/z range at the expense of some sensitivity [Downard, 2004].
Detector response data is acquired in an analogue format and is converted to a digital format.
A mass calibration is performed prior to the experiment, which involves the assignment of
theoretical mass values to a well characterised sample or sample mixture. During the experiment,
the ion current produced at the detector is amplified and filtered to remove high frequency noise.
The amplified current is recorded over time and plotted on am/z scale by comparing the data
to that which was obtained during mass calibration [Downard, 2004].
1.2.2.4 Coupling liquid chromatography to mass spectrometry (LC-MS)
MS coupled with high performance liquid chromatography (HPLC) is a widely employed technique
for exploratory untargeted analysis and targeted MS/MS analysis in metabonomics [Nicholson
and Lindon, 2008,Plumb et al., 2002]. Liquid chromatography is an effective tool for separating
complex mixtures over time and can provide an additional dimension of separation prior to MS
analysis for more specific, sensitive, and accurate downstream detection of analytes. In brief, a
sample is injected into a loop and delivered to a chromatographic column (stationary phase) as
a band of solutes by a solvent (mobile phase) pumped from the reservoirs of an autosampler.
Components are separated on the column and passed one by one or as simple mixtures into the
ion source, depending on their column retention time (RT), and emerge as chromatographic peaks
at the end. The RT of an analyte is dependent on its affinity for the stationary and mobile phases.
Those with higher affinity for the stationary phase are retained, while those with higher affinity
for the mobile phase are eluted. Preferred mobile phases are those which contain a significant
portion of volatile organic solvent for efficient vaporisation before ions enter the mass analyser
for efficient sampling and maintenance of pressure. Examples of such solvents are acetonitrile
and methanol, both of which are widely employed in chromatography [Downard, 2004]. However,
mobile phases with high compositions of these solvents are not feasible for the analysis of aqueous
compounds. The distribution, width, and shape of the resulting chromatographic peaks are
related to chromatographic separation performance.
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Chromatographic columns are cylinders packed with particles, typically silica or polymer. The
surface properties of these particles can be varied to manufacture different column types.
In recent years, HPLC techniques have been improved substantially, primarily through the
development of more robust column chemistries that allow separations to be conducted at very
high pressures using standard laboratory instrumentation. Short columns and rapid gradients
may be employed for high-throughput analysis, consistent with the current metabonomics
workflow, while maintaining good resolution and sensitivity. Termed ultra performance liquid
chromatography (UPLC), or ultra high pressure liquid chromatography (UHPLC), the conditions
are tailored to exploit very small column particles and high flow rates, which in combination give
rise to vastly improved separations when compared to HPLC [Swartz, 2005,Plumb et al., 2002].
Chromatographic resolution (Rs) is often thought about in the most basic sense:
Rs =
2(t1 − t2)
w1 + w2
(4)
where t1 and t2 represent the retention times of two peaks, and w1 and w2 represent their
respective peak widths. However, resolution can be expressed mathematically in more relevant
terms using the fundamental resolution equation:
Rs =
√
N
4︸︷︷︸
efficiency
(
α− 1
α
)
︸ ︷︷ ︸
selectivity
(
k
k + 1
)
︸ ︷︷ ︸
retentivity
(5)
where N is efficiency, α is selectivity, and k is retentivity. N is a measure of intra-column band
spreading and is characterised by theoretical plates. Theoretical plates are adjacent imaginary
segments along the column (Fig. 10) and is a concept derived from distillation theory. Within
each theoretical plate, analytes are in equilibrium between the stationary and mobile phases.
The greater the number of theoretical plates, the less band spreading there is, and therefore
the greater the efficiency of separations. Selectivity and retentivity are chemical parameters
that move peaks relative to one another and are measures of the interaction of analytes with
the stationary and mobile phases. They are subject to the influences of variables such as
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Figure 10. Intra-column diffusion processes. A cross-sectional representation of a chro-
matographic column illustrating the various diffusion processes (eddy diffusion, longitudinal
diffusion, and mass transfer) that determine intra-column band spreading and resolution.
temperature, elution solvent, mobile phase composition, and column chemistry. Historically,
chemical parameters have been easier to manipulate in order to improve resolution. Increasing
retentivity can improve resolution, but this comes with the cost of longer retention times, wider
peaks, and a loss of sensitivity. Increasing selectivity can improve resolution; however, the
elution order may change. Efficiency on the other hand, is a physical parameter that is more
difficult to alter for the purpose of achieving better resolution due to the square root influence.
However, reducing particle size to below 2 µm can significantly improve efficiency, and hence
resolution without affecting inter-peak distances. UPLC systems aim to increase N to achieve
higher chromatographic efficiency, while selectivity and retentivity remain the same as those for
HPLC systems [Waters, 2016].
Separation efficiency is inversely proportional to particle size (dp):
N ∝ 1
dp
(6)
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Therefore, a decrease in dp by a factor of 3 would, in theory, increase efficiency by 3 fold and
improve resolution by
√
3 fold. Improved resolution translates to enhanced peak capacity, which
means capturing more information per unit of time for a given sample. Well resolved peaks
also promote more accurate quantification of sample analytes without excessive need for peak
deconvolution. In order to achieve the resolution gains predicted by theory, the optimal flow
rate (Fopt) must be implemented for the specific particle size used. Fopt is inversely proportional
to dp:
Fopt ∝ 1
dp
(7)
Therefore, a reduction in dp by a factor of 3 equates to an increase in Fopt by a factor of 3. This
will reduce analytical run time by the same degree, thereby increasing sample throughput. Since:
N ∝ 1
w2
(8)
increasing Fopt also reduces peak width and increases peak height proportionally. Taller peaks are
easier to distinguish from baseline noise (increased S/N), thereby increasing sensitivity [Waters,
2016].
To further understand the factors that influence intra-column band spreading and peak width, it
is necessary to look at how analyte molecules interact with the stationary and mobile phases on
a molecular scale. The van Deemter equation is an empirical formula comprised of three terms
that can be used to explore the diffusion related factors that influence band spreading:
HETP = a(dp)︸ ︷︷ ︸
A term
+
b
u︸︷︷︸
B term
+ c(dp)
2u︸ ︷︷ ︸
C term
(9)
where HETP is the height equivalent to a theoretical plate, u is the linear velocity of the mobile
phase, and a, b, and c are diffusion coefficients. The A term represents eddy diffusion, that
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Figure 11. Van Deemter plots. (a) The effect of diffusion processes described by the van
Deemter equation (A term, eddy diffusion; B term, longitudinal diffusion; C term, mass transfer)
on HETP when increasing linear velocity (u). (b) Increase in optimal efficiency with smaller
particle sizes at high mobile phase speeds.
which occurs to the surface of and around particles. It is mainly related to particle size, which in
turn also determines how well the chromatographic bed is packed. It is also associated with the
uniformity of flow to and around the particles. The B term represents longitudinal diffusion back
and forth within the bulk mobile phase and is linked to linear velocity. The C term represents
mass transfer, which is the diffusion of analyte molecules in and out of chromatographic pores.
It is related to both linear velocity and particle size. The lower the HETP, the more theoretical
plates there are in the chromatographic column. This can be expressed mathematically as:
N =
L
HETP
(10)
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where L is the chromatographic column length. The effect of A, B, and C terms on HETP can be
illustrated using a graph of HETP vs. linear velocity (Fig. 11a). The A term is independent of
linear velocity; therefore, it is plotted as a horizontal line. Its position on the y-axis is dependent
on dp, where the smaller the dp, the smaller the HETP. The B term is plotted as a downward
sloping curve with increasing linear velocity. This term is independent of dp and indicates that
at lower linear velocities, the analyte molecules remain in the column for longer increasing the
opportunity for intra-column band spreading. The C term is plotted as an increasing linear
relationship between HETP and u. It takes time for analyte molecules to move into and out of
stationary phase pores. Molecules that migrate further into the pores of particles will take longer
to progress through the column relative to molecules that do not penetrate the pores as much.
In addition, analyte molecules carried in the centre of the mobile phase stream will progress
faster than those around the chromatographic bed. This spatial distribution dependent variation
in column progression between different populations of analyte molecules results in analyte
band broadening. This dispersion effect is amplified by higher linear velocities that expand the
distance between mobile and immobilised molecules in the mobile phase stream. Therefore, lower
linear velocities are required in order to keep the population of analyte molecules together and
produce narrower peaks. The interplay between longitudinal diffusion and mass transfer creates
a tunable flow rate to obtain optimum resolution for a given analytical run time [Waters, 2016].
UPLC uses smaller particle sizes in comparison to HPLC in the column packing, which reduces
eddy diffusion by decreasing the travel distance of analyte molecules to the surface of particles from
the bulk mobile phase and around particles. The paths of analyte molecules are encouraged to be
more similar in length by reducing the number of available longer, indirect paths. Consequently,
the analyte band is narrowed translating to smaller peak widths. Although particle size does
not directly influence longitudinal diffusion, it promotes higher optimum linear velocities, which
reduces the opportunity for intra-column band spreading to occur by longitudinal diffusion.
Particle size also has a direct effect on mass transfer. For smaller particles, it takes less time for
molecules to enter pores, interact with the bonded surface (such as C18 and C8), and detach to
re-enter the bulk mobile phase. On the van Deemter plot this decreases the slope of the C term.
Overall, the van Deemter plot for a smaller particle column shows lower HETP values for higher
mobile phase speeds, but also a broader optimum operating range (Fig. 11b). This means that
higher efficiency and resolution can be achieved in less time making UPLC technology favourable
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for high-throughput analysis, a key feature of a metabonomics workflow [Waters, 2016].
1.3 Multivariate analysis
Biological samples are complex milieus of metabolites that generate high volume spectral data
sets that are ultimately processed and transformed into huge, complex data tables (X matrix).
Each row constitutes an observation, or sample, and each column represents a measured variable,
such as a chemical shift or chromatographic peak. Such large, multivariate datasets can be
difficult to digest in the absence of appropriate tools. Computation-based pattern recognition
(PR) tools and expert system approaches, similar to those employed in other -omics platforms,
may be used to cut through this data complexity and extract useful information. PR is a
generic term used to describe the generation of scientific hypotheses or testing of hypotheses by
mathematically reducing the number of multiple parameters that normally conceal and make
inaccessible valuable information [Lindon et al., 2000]. Such multivariate approaches are excellent
at detecting correlations among metabolites that may reveal the regulation of entire biochemical
pathways or networks.
Principal component analysis (PCA) and partial least squares (PLS) regression represent some of
the most useful and easily applied PR techniques. PCA, for example, is a projection-based method
that provides a summary, or overview, of all observations in the data table by transforming
the existing combination of variables into new variables called principal components to reveal
any systematic variation. This summary is useful for detecting trends, correlated variables, and
outliers [Trygg et al., 2007,Lindon et al., 2000]. The properties of principal components are
such that each is linearly orthogonal or uncorrelated to others, and the first of these principal
components explains the largest variance in the dataset followed by the next in sequential order.
Therefore, a plot of just two or three principal components is sufficient to highlight both subtle
and gross differences between samples in a 2- or 3-dimensional scatter plot (Fig. 1) [Lindon
et al., 2000]. The relative positions of data points in the scatter plot are used to relate samples
to one other, where samples that lie in close proximity have similar multivariate profiles and
those that are far apart have dissimilar profiles [Trygg et al., 2007]. The process of distinguishing
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clusters of data points is intrinsic to unsupervised methods (no prior independent knowledge)
of identifying class separations, such as between individuals treated and not treated with a
particular drug [Lindon et al., 2000].
The PCA model is generated based on the direction of data showing the greatest variation,
which is not necessarily aligned with the direction of separating classes. Therefore, PCA is
rarely sufficient for elucidating subtle differences between classes [Bylesjö et al., 2006]. Where
there is additional knowledge of samples, whether the information be quantitative (e.g. dose
concentration and age) or qualitative (e.g. treatment group and gender), supervised methods can
be employed for more focused data analysis to extract additional information. The additional
knowledge constitutes an extra data table, a Y matrix. PLS is the first of such supervised
methods for modelling the relationship between the X and Y matrices. However, PLS models
are negatively affected by any systematic variation in the X matrix that is not related to the
Y matrix, that is, not part of the X-Y correlation structure. Orthogonal PLS (OPLS) is
an extension of PLS that separates the systematic variation in X into two parts in order to
facilitate model interpretation, one correlated toY (predictive variation) and one uncorrelated,
or orthogonal, to Y [Trygg et al., 2007,Bylesjö et al., 2006]. While PLS and OPLS regressions
are used for quantitative Y matrix data, discrimination analysis (PLS-DA and OPLS-DA,
respectively) is used for qualitative data structures. Discrimination analysis pinpoints the
optimum position at which to place the discriminant surface to maximise the separation of
classes [Lindon et al., 2003]. Mathematical models constructed using a "training set" can be
used to predict the classes of each sample in a "test set" and evaluate the model’s robustness.
These computer-based models are sometimes called expert systems [Lindon et al., 2000].
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1.4 Molecular chirality
1.4.1 Nomenclature
The term chiral is derived from the Greek word for hand, as hands are a prime example of
chirality. Although very similar, the right hand cannot be superimposed on the left hand and
each hand interacts with surrounding objects in a distinctive manner. Chirality is also widely
apparent at a molecular level. Molecular chirality was discovered by Louis Pasteur in 1848
during his crystallography studies on the sodium ammonium salt of paratartaric acid. During
microscopic examination, he found that the salt crystallised as a mixture of two forms that were
non-superimposable mirror images of each other. When separating the two crystal forms and
measuring their optical activity, he found the rotation to be equal in magnitude, but in opposite
directions [Gal, 2013]. Chirality is achieved through the geometric rearrangement of atoms and
functional groups around a chiral centre, or stereocentre, that results in the formation of two
optically symmetrical molecules called enantiomers (Fig. 12).
Several nomenclature systems have been developed to describe enantiomers. The first is based on
the optical activity of the isomer. If the enantiomer rotates a plane of polarised light clockwise,
it is labelled as the dextrorotary (+) form. In contrast, if the plane of polarised light is rotated
anti-clockwise, the enantiomer is labelled as the levorotary (−) form.
Other nomenclatures for denoting enantiomers are dependent on configuration. In chemistry, the
R/S nomenclature system is most commonly used, where each chiral centre is designated as R or
S according to the Cahn-Ingold-Prelog (CIP) priority rules (Fig. 13b). The CIP priority rules
assign rankings to functional groups or atoms around the chiral centre using the atomic number.
Rankings are designated starting with atoms at a distance of one bond from the chiral centre.
Where there are ties between groups, the atoms at a distance of two bonds from the chiral centre
are considered, and so on until the tie breaks and a ranking can be assigned. The stereocentre
is then viewed with the lowest priority group pointing away from the observer. If the priority
order descends clockwise, the enantiomer is labelled R for Rectus (Latin for straight), and if
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Figure 12. Summary of the different types of isomers and their associated nomen-
clature.
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it decreases anti-clockwise, the enantiomer is labelled S for Sinister (Latin for left). The R/S
system has no fixed relation to the (+)/(−) system. One advantage of using R/S nomenclature
is that it allows one to systematically name compounds based on chemical structure. Another
advantage is that it can be used to describe each chiral centre for compounds with more than
one stereocentre.
In biochemistry, the D/L nomenclature system is generally used for naming biomolecules, such
as amino acids and carbohydrates. It has no reference to the optical activity of the molecule in
question, but rather the optical activity of glyceraldehyde that is used as a reference. The D
Figure 13. Nomenclature for enantiomers. (a) Fisher projections showing the assignment
of D/L nomenclature to biomolecules relative to the enantiomers of glyceraldehyde. In Fisher
projections the main carbon chain is drawn with the lowest numbered carbon at the top. The
horizontal and vertical lines in the Fisher projection indicate that the bonds are pointing towards
or away from the observer, respectively. (b) Cahn-Ingold-Prelog (CIP) priority rules and CO-R-N
rule for describing the stereocentre configuration of enantiomers. The CIP priority rules can
be applied to all chiral compounds as they describe them according to the priority order of
substituents around the chiral centre using the atomic number. The CO-R-N rule is used to
specifically determine the correct D/L configuration of the central chiral carbon of amino acids.
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or L labelling indicates the compound’s stereochemistry relative to that of the dextrorotary or
levorotary enantiomer of glyceraldehyde (Fig. 13a). Although more logical, the R/S system
is not usually adopted in biochemistry. This is to ensure that the molecule’s labelling is not
affected by substitution reactions that could potentially alter the CIP priority order. All amino
acids, with the exception of glycine, comprise of four different functional groups around a central
chiral carbon atom. A simple way to determine theD/L configuration of the chiral carbon is to
apply the so-called CO-R-N rule (-COOH, -R, -NH2) as shown in Fig. 13b. The chiral carbon
is viewed with the hydrogen atom (lowest priority group) pointing away from the observer. The
other three groups will ’spell out’ CO-R-N. If spelt clockwise, the amino acid is labelledD, and
if spelt anti-clockwise, the amino acid is labelled L.
1.4.2 Chirality in biology
Chirality is a property underlying all biological systems and plays a fundamental role in the
activity of biological molecules. Although several elements have the capacity to become a
chiral centre, a carbon atom bonded to four different atoms or functional groups forms the
most common basis of chirality in biological molecules. Almost a decade after Louis Pasteur
discovered molecular chirality, he also discovered the enantioselective microbial metabolism of
tartaric acid in 1857 after switching fields from chemistry and crystallography to microbiological
studies. This was the first observation of enantioselectivity in a biological process [Gal, 2008].
Although enantiomers share similar physical and chemical properties, they frequently have
different biological effects. For this reason, chirality is an important factor in many marketed
compounds, such as drugs, agrochemicals, and food additives. Differences in the biological
activity of these compounds may arise due to enantiomeric inequality in terms of protein binding
and transport, rates of metabolism, clearance rates, and mechanism of action. This is because
most enzymes and receptors display stringent substrate selectivity.
During evolution, L-amino acids and D-sugars were selected for protein synthesis and energy
metabolism in mammals, respectively. Homochirality amongst organic compounds is considered
crucial to the existence of life on Earth as it determines the spatial architecture of biological
polymers for molecular recognition and replication processes through enzyme specificity and
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structural interactions [Fuchs et al., 2005,Mason, 1984]. It is this highly stereospecific environment
that gives rise to differences in the efficacy and toxicology of external enantiomeric substances. A
classic example that highlights the importance of enantiospecificity is thalidomide. Thalidomide
contains a single chiral centre, and was made and marketed as a racemic mixture of (R)-
thalidomide and (S )-thalidomide. It was introduced as a sedative for pregnant women to treat
morning sickness in the late 1950s, but later withdrawn for its teratogenic side effects. Although
(R)-thalidomide is therapeutic, (S )-thalidomide is associated with teratogenicity due to its ability
to intercalate with DNA at guanine-cytosine (GC) rich regions in the promoters of genes, such as
those encoding insulin-like growth factors 1 and 2 (IGF1 and IGF2, respectively). Such genes are
crucial for foetal development, and as a result, thalidomide use during pregnancy was associated
with birth defects [Stephens et al., 2000].
Although there is a large enantiomeric excess of L-amino acids in mammals, D-amino acids can
also be detected at considerable concentrations and perform essential operations, typically as
signalling molecules. For example, D-serine and D-aspartate reach considerable concentrations in
the central nervous system (CNS), where they act as endogenous coagonists of the excitatory
N -methyl-D-aspartate (NMDA) receptor that binds to the neurotransmitter L-glutamate [Fuchs
et al., 2005,Morikawa et al., 2001]. D-serine is detected constantly at high concentrations,
and D-aspartate periodically, during embryonic development. This suggests that they play
a pivotal role in the regulation of cerebral development [Hashimoto et al., 1993,Kim et al.,
2010]. Deviations in the normal systemic profiles of D-amino acids can give rise to pathological
conditions. In amyotrophic lateral sclerosis (ALS), a severe motor neuron disease, elevated levels
of extracellular D-serine in the spinal cord can cause excitotoxicity in motor neurons via NMDA
receptors, thus aggravating motor neuronal loss [Sasabe et al., 2007]. In contrast, schizophrenia,
a mental disorder characterised by abnormal social behaviour and hallucinations, is associated
with excess degradation of D-serine. This is mediated by the enzyme D-amino acid oxidase and
causes hypofunction by NMDA receptors in the brain [Madeira et al., 2008].
Chirality can also contribute towards inborn errors of metabolism. L-2-hydroxyglutaric aciduria
is an inherited chronic neurometabolic disorder characterised by progressive neurological dys-
function, ataxia, psychomotor regression, intellectual decline, weak muscle tone (hypotonia), and
seizures [Latini et al., 2003a,Sühs et al., 2012]. It is caused by an autosomal recessive mutation
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leading to a deficiency of L-2-hydroxygluterate dehydrogenase, a mitochondrial membrane-bound
enzyme that is prominently expressed in the brain and converts L-2-hydroxyglutaric acid to
2-ketogluterate [Sühs et al., 2012,Rzem et al., 2006]. Similarly, D-2-hydroxyglutaric aciduria is a
less common neurometabolic disorder caused by recessive mutations in the D-2-hydroxyglutarate
dehydrogenase gene. D-2-hydroxyglutarate dehydrogenase is a mitochondrial flavin adenine
dinucleotide (FAD) binding enzyme that is most active in the liver and kidneys, but also active
in the heart and brain. It is responsible for converting D-2-hydroxyglutarate to 2-ketoglutarate.
D-2-hydroxyglutaric aciduria is characterised by abnormal brain development, epilepsy, enlarged
heart (cardiomyopathy), and hypotonia [Kranendijk et al., 2010,Struys et al., 2005]. The main
pathogenic mechanism that causes tissue injury in both forms of 2-hydroxyglutaric aciduria
is thought to be impaired mitochondrial energy metabolism leading to energy deprivation,
excitotoxicity via the NMDA receptor, and accumulation of reactive oxygen species (ROS)
leading to oxidative stress [Latini et al., 2003a, Latini et al., 2003b]. Given the presence of
such diseases with chiral mechanisms, measuring the levels of free chiral compounds in biofluids
can potentially be used to clinically identify and monitor underlying pathological conditions.
Furthermore, therapeutic strategies that revolve around the modulation of enzymatic activity
to alter the levels of pathophysiologically related chiral metabolites may help to mitigate the
effects of disease.
D-amino acids are also utilised abundantly by microbial species, such as Lactobacilli and
Streptococci. D-amino acids are incorporated into the stem peptides of peptidoglycans that
cross-link linear polymer strands and contribute towards its net-like architecture and resistance
to most proteases [Vollmer et al., 2008]. In Gram-positive bacteria, many layers of peptidoglycans
constitute the cell wall providing structure, strength, and resilience to osmotic pressure. Gram-
negative bacteria have a single layer of peptidoglycan between the inner and outer cell membranes,
which is sufficient for maintaining the cell’s mechanical stability. Peptidoglycans also serve as a
supporting scaffold for other cell envelope components [Cava et al., 2011]. Another example of
D-amino acid use among bacteria is regulating bacterial spore germination through endocrine
and paracrine signalling pathways. In many Bacillus species, L-alanine reactivates metabolism
for spore germination; however, D-alanine is a potent inhibitor that antagonises the L-alanine
nutrient receptor [Atluri et al., 2006]. D-alanine mediated autoinhibition is activated under
adverse conditions, such as high population density and low nutrient availability, to prevent
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premature spore germination that would otherwise lead to starvation and cell death. The ability
of bacterial species to produce D-amino acids is attributed to their broad spectrum of enzymes
called racemases. Amino acid racemases are capable of converting L-amino acids to D-amino
acids or vice versa depending on cellular requirements [Cava et al., 2011]. Indeed the endogenous
microbiome is thought to be a key mammalian source of D-amino acids in addition to dietary
intake, spontaneous racemisation of liberated L-amino acids from polypeptides, and the restricted
host collection of amino acid racemases [Wang et al., 2012]. Therefore, profiling D-amino acids in
biofluids using chiral analytical methods may be used to probe the host-gut microbiome interface
to characterise gut microbial composition and their contributions to host metabolism.
1.5 Hypotheses and aims
1.5.1 Hypotheses
1. Current analytical platforms can be used to develop assays that generate untargeted or
semi-targeted metabolic profiles encompassing stereospecific measures of the metabolome,
while fulfilling the necessary criteria for routine metabonomics workflow integration.
2. An established enantioselective metabolic profiling assay can be applied to biological sample
sets to provide quantitative and/or semi-quantitative information on endogenous chiral
metabolites to complement parallel achiral methods.
1.5.2 Aims
1. Evaluate the potential of chiral solvating agents (CSAs) for chiral metabolic profiling using
1H NMR spectroscopy for the recognition and quantification of enantiomers in biological
fluids.
2. Explore the effect of CSAs on the stability of internal reference compounds in aqueous
samples.
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3. Evaluate the potential of an existing enantioselective UPLC-MS assay for the recognition
and quantification of enantiomers in biological fluids.
4. Select and optimise the enantioselective assay for relative/absolute quantification of enan-
tiomers in complex matrices.
5. Explore the applicability of the optimised enantioselective assay using exemplar biological
sample sets.
6. Critically evaluate the practical utility of the optimised assay in the context of a typical
metabonomics workflow.
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Chapter2
Chiral profiling using 1H NMR spectroscopy
2.1 Overview
NMR spectroscopy is a powerful analytical tool that finds widespread use across multiple research
and clinical environments due to its ability to report on many aspects of sample composition,
including chemical structure, dynamics, interactions, and compartmentalisation. Importantly
for the field of metabonomics, the 1H nucleus is amenable to analysis by this method, and the
ubiquity of hydrogen in biomolecules means it can often provide an excellent probe through which
to gain understanding of biological phenomena. As described above, 1H NMR spectroscopy has
proven to be a very useful platform for metabonomic studies as even the simplest experiments
conducted on biofluids and tissues yield rich spectral sets that report on all sample components
with an appropriate hydrogen atom in their chemical structure. This wide chemical class capture,
coupled with the quantitative nature of NMR spectra mean profiles generated in this way are
excellent inputs for chemometric analysis in the context of metabonomic studies. However, in
aqueous solutions without the presence of specific chiral additives or use of chiral matrices,
NMR experiments do not allow enantiomers to be distinguished as the nuclei in these molecules
have equivalent chemical environments (note it is possible to distinguish diasteroisomers for
this reason); therefore, this information is not recovered in NMR-based metabonomic methods
at present. The use of chiral agents to allow enantiodifferentiation is possible, but may be
accompanied by practical problems that limit their utility in a metaobnomics context. This
chapter describes existing methods that are potentially available to the analyst for developing a
chiral metabonomics-compatible assay, and evaluates both the use of a selection of agents and
their influence on chiral amino acids in urine and common internal standards used in NMR
spectroscopy to reference changes in chemical shift.
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2.2 Aim and objectives
2.2.1 Aim
Explore the effect of CSAs on the stability of internal reference compounds in aqueous samples
and their potential for chiral metabolic profiling using 1H NMR spectroscopy.
2.2.2 Objectives
• Evaluate the stability of existing deuterated reference compounds that are commonly
used in NMR spectroscopic studies to determine their suitability as internal references in
aqueous samples in the presence of CSAs.
• Assess the stabilities of tert-butanol (t-BuOH) and formate when co-solvated with CSAs
as potential novel internal referencing candidates.
• Characterise the nature of any CSA-substrate interactions on the basis of chemical shift
observations.
• Devise a reliable referencing strategy for aqueous samples containing CSAs for accurate
chemical shift determinations of endogenous metabolites.
• Investigate any potential interactions of DL-amino acids with β-cyclodextrin (β-CD) in
aqueous solution and identify any changes in chemical shifts that may differentiate D- and
L-enantiomers.
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2.3 Introduction
2.3.1 Chiral approaches using NMR spectroscopy
There are various approaches to stereochemical differentiation using NMR spectroscopy, most of
which have only been tested in standard solutions. Each is associated with different metabolite
coverage and chemical shift anisotropy (the change in chemical shift associated with shielding
effects by the local electronic environment or substrate orientation). These methods include chiral
derivatizing agents (CDAs), metal complexes, chiral liquid crystals (CLCs), and CSAs [Wenzel
and Chisholm, 2011].
Derivatizing a pair of enantiomers using an enantiomerically pure CDA, such as α-methoxy-
α-trifluoromethylphenylacetic acid (MTPA) and α-cyano-α-fluoro-ρ-tolylacetic acid (CFTA),
converts an enantiomeric mix into a diastereomeric mix. Unlike the original enantiomers, these
diastereomers exhibit differences in their nuclear shielding properties that manifest as different
chemical shifts in the NMR spectrum. The areas under the diastereomer peaks can subsequently
be deduced by integration and used to determine the enantiomeric ratio in a given sample [Wenzel
and Chisholm, 2011]. This was first demonstrated by Jacobus et al., 1968, where optically pure
1-(1-naphthyl)ethylamine was derivatized using a racemic mixture of O-methylmandelic acid and
then analysed by NMR spectroscopy in order to determine the amine’s optical purity [Jacobus
et al., 1968]. CDAs can be classed according to the functional group that they target, such
as aryl-containing carboxylic acid reagents that are commonly employed for the analysis of
secondary alcohols. In order to accurately discern the enantiomeric purity of a compound using
a CDA, no racemisation nor kinetic resolution (one enantiomer reacting faster than the other)
must take place during the derivatization step. Under these conditions, a 50 : 50 racemic mixture
should yield two diastereomer peaks with equal integrals [Wenzel and Chisholm, 2011]. One of
the main advantages of NMR spectroscopy is that samples can be kept intact in their natural
state without the need for derivatization. As such, they can easily be recovered after the NMR
experiment for further analysis. Therefore, CDAs are better utilised in combination with MS
protocols where the sample is essentially obliterated during analysis, although used in much
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smaller quantities relative to NMR spectroscopy.
A diverse range of metal complexes have been used to determine the absolute configuration
of chiral compounds and enantiomeric purity, such as lanthanide, palladium, and platinum
complexes. The principle mechanism of enantiodifferentiation involves the formation of donor-
acceptor complexes (or Lewis adducts) between a Lewis acidic metal (electron pair acceptor)
and a Lewis organic base (electron pair donor). Lanthanide (III) agents have been studied
extensively and are described as hard Lewis acids, unlike palladium (II) and platinum (II), that
primarily form complexes with oxygen and nitrogen containing donors. This means a wide array
of substrates can be studied encompassing virtually any nitrogen or oxygen bearing compound.
Lanthanide ions have paramagnetic properties that enable them to cause a large change in
chemical shift of a bound donor molecule. However, a limitation is that the ions also reduce
the relaxation times of nuclei in the substrate molecule, which gives rise to a degree of line
broadening. Exchange broadening can also occur due to intermediate exchange rates between
bound and unbound states of the donor molecule, which can further impede on the ability to
discriminate enantiomers. Line broadening effects are most pronounced for the ions and set of
conditions that cause the largest perturbations in chemical shift and at higher field strengths.
However, there are several strategies to circumvent this issue without having to compromise on
field strength. One way is to record proton decoupled 13C NMR spectra, as the effect of exchange
broadening on 13C nuclei is less in comparison to 1H nuclei at similar field strengths. However,
this is associated with a considerable loss of sensitivity due to the low natural abundance of 13C
nuclei. Other ways of restricting line broadening include the use of a more polar solvent, such
as acetonitrile-d3, in order to reduce the substrate’s association with the lanthanide ion, and
elevating sample temperatures to increase the exchange rate. Such solutions have been used
previously to successfully attain chiral discrimination when using lanthanide species at high field
strengths [Wenzel and Chisholm, 2011].
Methods of enantiomeric discrimination using CLCs, such as poly(γ-benzyl-L-glutamate), have
only been developed recently. CLCs do not directly interact with the substrate, but rather
partially align themselves relative to the magnetic field along with the substrate. The enantiomers
will usually align with different orientations relative to the applied magnetic field due to the
restrictions imposed by the liquid crystals. The advantage of employing CLCs is that there are no
67
specific interactions involved, which means that they are compatible for the analysis of virtually
any class of chiral compounds. However, chemical shift differences are usually quite small
between enantiomers and can prove unsatisfactory for chiral discrimination and quantification.
Differentially aligned enantiomers may also exhibit different dipolar coupling constants between
1H−1H and 1H−13C nuclei, which can provide an alternative mode of discrimination [Wenzel
and Chisholm, 2011]. However, the presence of different dipolar coupling constants can cause
spectral overcrowding. Homonuclear or heteronuclear selective refocusing (SERF) experiments
may be used to simplify spectral acquisition and overcome spectral complexity by measuring
only one coupling constant [Farjon et al., 2007]. However, the most commonly employed method
for chiral discrimination with CLCs involves acquiring spectra of a quadrupolar nucleus, such
as deuterium. Unlike in free solution where there is rapid isotropic tumbling, the application
of a CLC creates an anisotropic tumbling environment that evokes quadrupolar splitting. The
magnitude of quadrupolar splitting is dependent on the C−D bond orientations relative to the
applied magnetic field. For a pair of enantiomers with different orientations, two doublets are
generated in the spectrum which can then be integrated to determine enantiomeric purity. An
obvious complication of this method is the low natural isotopic abundance of deuterium in
the untreated sample. The other is that quadrupolar splitting can often lead to complicated
spectra with overlapping resonances, as there is potential for two doublets to form for every
intramolecular deuterium environment [Wenzel and Chisholm, 2011].
CSAs, such as cyclodextrins and crown ethers, interact with the enantiomers through non-covalent
bonds, such as hydrogen bonds and van der Waals forces, to form CSA-substrate complexes.
The nature of these non-covalent interactions is unique for each enantiomer, which leads to the
formation of diastereomer complexes that can then be resolved using NMR spectroscopy to
ascertain the relative proportions of each enantiomer in the sample. The R- and S -substrates
each have separate association constants for their equilibria between bound and unbound states
(kR and kS, respectively). Usually these equilibria are associated with fast exchange on the
NMR time scale, and the NMR spectrum represents a time average of the bound and unbound
states [Wenzel and Chisholm, 2011]. There is substantial evidence to show that the use of
lanthanides in conjugation with CSAs can enhance perturbations in the NMR spectrum via a
dipolar mechanism, and as a result, improve enantiomeric resolution [Wenzel et al., 1997,Wenzel
and Brogan, 1999,Wenzel et al., 2000]. If the physical association between the CSA and substrate
68
is the only discriminating factor, then it is favourable to have the CSA at high concentrations
in solution relative to the substrate to adjust the equilibria in favour of the bound state. A
second mechanism by which CSAs may achieve enantiomeric discrimination is through differing
kR and kS constants, which results in one enantiomer remaining bound to the CSA for longer
than the other. Differences in the average time spent complexed with the CSA may also give
rise to differences in chemical shifts between the two enantiomers. Usually both discriminating
mechanisms are in operation to some degree, and when both are significant, the spectra can
show complicated patterns of behaviour. Under these circumstances, a series of spectra with a
fixed substrate concentration and a gradually incrementing CSA concentration may need to be
recorded to interpret the spectrum accurately. Although unlikely in NMR spectroscopy, one
possible observation depending on the magnitude of the chemical shift differences induced by
the CSA is the gradual splitting, fusion, and reversal of the relative positions of enantiomeric
peaks. Given this possibility, recording a single spectrum for any given sample with an unknown
CSA to substrate ratio may lead to a false conclusion of no discernible enantiomeric separation
or incorrect peak assignment [Wenzel and Chisholm, 2011].
2.3.2 Chiral solvating agents
An advantage of using CSAs over CDAs is that to determine the enantiomeric purity of a
substrate the CSA itself does not have to be of high enantiomeric purity. Although higher CSA
enantiomeric purity does equate to better enantiomeric differentiation, given any discernible
enantiomeric separation, the integration of resonances will accurately represent the enantiomeric
purity of the substrate. Another advantage of using CSAs is that there is no concern over kinetic
resolution [Wenzel and Chisholm, 2011]. In terms of practicality, CSAs can be directly mixed
into a sample without pre-treatment, which essentially keeps all metabolites in their natural
endogenous state. Given these advantages, we opted to use CSAs to evaluate the potential of
chiral metabonomics using NMR spectroscopy.
Previous work has shown that using CSAs in conjunction with 1H NMR spectroscopy has much
promise in achieving chiral discrimination of isomers in biofluids. Pérez-Trujillo et al., 2012
demonstrated that β-CD can be used to enantiodifferentiate the well known anti-inflammatory
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Figure 14. CSA structures and interactions. (a) Chemical structure of β-CD and
representations of its superimposition with one D-glucose subunit and inclusion complex with
D-tryptophan. (b) Chemical structure of (18-crown-6)-tetracarboxylic acid and a representation
of its interaction with D-tryptophan.
drug ibuprofen in human urine with no prior treatment. Although they observed some overlap
between the peaks that corresponded to R- and S -ibuprofen, fast exchange resulted in well defined
peaks in the 1D 1H spectrum to accurately determine enantiomeric purity. Furthermore,β-CD
was also found to enhance the differentiation of ibuprofen derivatives in intact urine samples.
Additional interactions were observed between β-CD and endogenous urinary metabolites, such
as phenylalanine and tryptophan, which consequently resulted in chemical shift changes [Pérez-
Trujillo et al., 2012]. Similarly, Matthews et al., 1997 used β-CD to differentiate the enantiomers
of ρ-trifluoromethylmandelic acid and Mosher’s acid (α-methoxy-α-(trifluoromethyl)-phenylacetic
acid) using 19F NMR spectroscopy in untreated rat urine [Matthews et al., 1997]. In a previous
study, proton decoupled 13C NMR spectroscopy was used to study the human urinary excretion
of diastereomeric acylglucoronides following oral administration of 13C labelled ketoprofen. The
resonances produced by the diastereomers were separated by introducing methyl-β-CD to form
inclusion complexes [Akira and Shinohara, 1996]. Although chiral 13C and 19F NMR analysis are
useful in the context of pharmacological studies, they are less applicable to metabolic profiling
of endogenous metabolites due to the absence or limited presence of these nuclei in biological
systems and the restricted opportunity to routinely employ labelled substrates.
All enantioselective chiral mechanisms require a minimum of three interactions, where the
strongest is not necessarily the most important. In a three point interaction model, a pair of
enantiomers can only share a maximum of two interaction sites on the chiral selector leaving the
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third site responsible for chiral differentiation. These interactions may be attractive or repulsive,
and can take the form of hydrogen bonding, steric hindrance, pi-pi interactions (mainly in aromatic
compounds), dipolar interactions (ion-dipole, dipole-dipole, and dipole-induced-dipole), van der
Waals forces, and the hydrophobic effect. The interactions involved are not just dependent
on the CSA and substrate, but also the sample conditions, such as the type of solvent, pH,
temperature, and the presence of other interfering molecules [Berthod, 2006]. Hence, it is critical
that efforts are made to adjust the sample conditions to optimise CSA-substrate interactions. In
instances where sample conditions cannot be altered, the choice of CSA is made by taking into
account the environment in which the interactions are set to occur.
Cyclodextrins and crown ethers are two major classes of CSAs that have been expansively
studied. Cyclodextrins are small cyclic polypeptides comprised of D-glucose monomers attached
via α-1,4-glycosidic linkages to form a truncated cone shaped cavity. There are three native
cyclodextrins, α-CD, β-CD, and γ-CD, that comprise of 6, 7, and 8 glucose units, respectively.
Usually, the best interaction and chiral differentiation occurs when the size of the substrate
complements that of the cyclodextrin’s cavity. The variation in cavity size across the native
cyclodextrins broadens the range of substrates they can interact with. Cyclodextrins were
initially thought to be rigid structures; however, this assumption is incompatible with more
recent observations, primarily through NMR studies, such as the ease of forming inclusion
complexes with various molecular shapes. The inside of the cavity is hydrophobic and lined
with the non-bonding electron lone pairs of the glycosidic oxygen bridges and glucose hydrogens
H3 and H5 which protrude inwards to form two planar rings. Therefore, the cavity is capable
of forming inclusion complexes with substrates that have a hydrophobic group or an aromatic
ring (Fig. 14a) [Dodziuk, 2006, Szejtli, 1998]. Meanwhile, the smaller rim of the cavity is
lined with hydroxyl (-OH) groups at the 6-position of the glucose ring and the larger rim is
lined with -OH groups at the 2- and 3-positions, both of which can form hydrogen bonds with
polar substrates. Chiral discrimination of enantiomeric pairs often involves differences in their
interaction with secondary -OH groups at the larger rim. One or more of these -OH groups
may be modified to produce a wide spectrum of cyclodextrin species, including methylated,
carbomoylated, carboxymethylated, and amino-modified cyclodextrins. The native cyclodextrins
can therefore serve as scaffolds on to which additional functional groups and other substituents
may be assembled to further improve molecular recognition and chiral separations. However,
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Figure 15. Internal reference compounds for 1H NMR spectroscopy. Chemical struc-
tures of (a) TSP-d4, (b) DSS-d4, (c) DSA-d6, (d) t-BuOH, and (e) sodium formate.
unlike the native cyclodextrins, only a limited number of these modified cyclodextrin species
are water soluble. This renders many of them inapplicable for chiral discrimination in aqueous
solutions [Wenzel et al., 2000,Wenzel and Chisholm, 2011,Berthod, 2006].
Previous studies have most commonly evaluated crown ethers with a planar 18-crown-6-unit,
which can interact with protonated primary amines. Enantiomers can associate with different
orientations relative to the crown ether by interacting with different groups on the plane to yield
two different diastereomeric configurations (Fig. 14b). 18-Crown-6-tetracarboxylic acid (TCA),
a derivative of tartaric acid, has been the most extensively studied crown ether for chiral analysis
of primary amines in both NMR spectroscopic and liquid chromatographic studies owing to
its ability to produce larger enantiomeric discriminations. Another reason for TCA’s extensive
evaluation is its versatility in terms of application. For example, TCA can be mixed directly
with a neutral amine to induce a neutralisation reaction and produce protonated ammonium
ions that are required for complexation to occur between the two species. It is also compatible
with numerous solvents, including methanol-d4, deuterium oxide, and acetonitrile-d3 [Wenzel
and Chisholm, 2011].
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2.3.3 Internal reference compound stability with CSAs
One of the challenges of employing CSAs in NMR spectroscopy for chiral discrimination is
the choice of a stable reference compound that is not subject to peak broadening or a change
in chemical shift when co-solvated [Pérez-Trujillo et al., 2012]. This is the result of chemical
groups on the CSA interacting in one or more ways with those of the reference compound. For
example, Li et al., 1993 reported the interaction of β-CD with tetramethylsilane (TMS) and
sodium 2,2-dimethyl-2-silapentane-5-sulphonate (DSS), two recommended reference compounds
for NMR measurements in organic solvents and water, respectively. This called into question
the suitability of these compounds as internal references when co-solvated with cyclodextrins [Li
et al., 1993]. A stable reference is fundamental to the correct analysis of NMR spectra. In the
context of chiral profiling, it is important for accurately determining the smallest of differences
in chemical shifts that may resolve enantiomeric resonances, and hence, should be one of the
first questions to be addressed.
2.4 Experimental methods
2.4.1 Materials
Sodium 3-(trimethylsilyl)propionate (TSP-d4), DSS-d4, and 4,4-dimethyl-4-silapentane-1-amm-
onium trifluoroacetate (DSA-d6) were purchased from GOSS Scientific Instruments, Isotec,
and Sigma-Aldrich, respectively. t-BuOH, sodium formate, TCA ((+)-(18-crown-6)-2,3,11,12-
tetracarboxylic acid), and all DL-amino acids were purchased from Sigma-Aldrich. α-CD, β-CD
hydrate, and γ-CD were obtained from Fluka, Sigma-Aldrich, and Molekula, respectively. 5 mm
Ultra Precision NMR tubes were obtained from GPE Scientific, and coaxial inserts for 5 mm
NMR sample tubes were obtained from Wilmad-LabGlass.
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2.4.2 Sample preparation
TSP, DSS, DSA, t-BuOH, and formate were evaluated for their chemical shift stability in
phosphate buffer (0.2 M Na2HPO4, 0.043 M NaH2PO4, 3 mM NaN3, 80% H2O, and 20% D2O)
and urine in the presence of native cyclodextrins (α-CD, β-CD, and γ-CD) and the crown ether
TCA. Human urine samples were collected from a previous nutritional intervention study. In
brief, midstream urine samples were collected from 10 healthy individuals, male and female, at
14 time points over a course of 3.5 days. All participants were 18-50 years of age, non-smokers,
not on any form of regular medication, and had a BMI of 18-30 kg/m2. The urine samples were
subsequently filtered through 20 µm filters and stored in 15 ml tubes at -40 ◦C.
Figure 16. CSA sample preparation for 1H NMR spectroscopy. A schematic of the
experimental method used for evaluating internal reference compound stability in the presence
of CSAs in aqueous solution.
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Urine samples from 3 randomly selected participants at 3 randomly selected time points (total
of 9 samples) were used to evaluate the reference compounds (Fig. 16). The frozen samples
were allowed to defrost at room temperature for no longer than 20 min, and then centrifuged at
4,500 rpm for 5 min. The collected supernatants were pooled to create a representative complex
matrix. The urine samples were prepped in 1.5 ml tubes by adding 200 µl of phosphate buffer
and 400 µl of urine on ice to prevent excessive degradation as described by Beckonert et al,
2007 [Beckonert et al., 2007]. The concentration of each reference compound was kept constant
at 0.5 mM in both phosphate buffer and urine, while the CSA concentration was incremented
from 0 mM to 8 mM for the cyclodextrins and 0 mM to 6 mM for TCA. 510 µl of sample was
transferred into a 5 mm NMR tube, and an external reference (3 mM TSP-d4 in a coaxial insert)
was used to monitor any change in chemical shift of the internal reference compound. For the
DL-amino acids, with the exception of DL-tyrosine and DL-tryptophan, 20 mM stock solutions
were prepared in phosphate buffer. DL-tyrosine and DL-tryptophan were prepared in phosphate
buffer at a concentration of 2.5 mM due to their low solubility. The total concentration of
DL-amino acid in the sample was kept at 1 mM, while the β-CD concentration was increased
from 0 mM to 5 mM. 550 µl of each sample was transferred to a 5 mm NMR tube, sealed, and
stored at 4 ◦C until NMR spectroscopic analysis.
This methodological development analysis was approved by the Imperial College Research Ethics
Committee (ICREC_11_2_5). Informed consent was obtained for all participants, and samples
were collected according to the approved study protocol.
2.4.3 1H NMR spectroscopy
High resolution 1D 1H NMR spectra were acquired at a field strength of 14.1 T (600.29 MHz 1H
resonance frequency) using a Bruker DRX600 spectrometer fitted with a 5 mm broadband inverse
tube probehead (Bruker Biospin, Rheinstetten, Germany) at a temperature of 300 K. The probe
was matched and tuned automatically in the 1H channel during setup. A BACS 60 automated
sample changer was used to introduce each sample into the instrument, and acquisitions were
controlled using Xwin-NMR and Icon-NMR (Bruker Biospin) software. Gradient shimming was
performed to improve magnetic field homogeneity as well as receiver gain adjustment to control
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the amplitude of the FID for each sample by incorporating the commands into the automated
program.
Standard 1D 1H spectra were acquired using a NOESYPR1D pulse program (RD - 90◦ - t1 - 90◦ -
tm - 90◦ - AQ). The 90◦ pulse length (P1) and the irradiation (carrier) frequency offset (O1) were
adjusted to optimise signal strength and suppress the central water peak, respectively. The
relaxation delay (RD) was set to 3 s to ensure complete relaxation of nuclei between scans. The
FID was recorded into 6.4× 104 data points in the time domain with a spectral width of 20 ppm
during the acquisition period (AQ = 2.73 s). The spectra were acquired using 64 scans following
8 dummy scans.
2.4.4 Data analysis
The recorded 1H NMR spectra were imported into Bruker TopSpin 3.1 (Bruker Biospin) where
they were manually phased, baseline corrected using a polynomial function, and calibrated
using the external TSP reference. For reference compound stability evaluation, the chemical
shift of the reference compound was measured relative to the external TSP peak for increasing
concentrations of CSA. This was subsequently used to determine the change in chemical shift of
the reference compound using the equation:
∆δ = δobs − δA (1)
where ∆δ is the change in chemical shift, δobs is the observed chemical shift, and δA is the
chemical shift of the free substrate (unbound reference compound).
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2.5 Results
2.5.1 Reference compound stability with α-CD
To evaluate the stability of internal reference compounds in the presence of CSAs we calculated
∆δ using Eq. 1. Chemical shifts were determined using an external reference (3 mM TSP in a
coaxial insert). The concentric position of the insert within the NMR tube ensured good line
shape and the best accuracy for measuring ∆δ [Rana et al., 1991].
TSP, DSS, DSA, and t-BuOH were all associated with a downfield change in chemical shift
when co-solvated with β-CD in both phosphate buffer and urine as indicated by positive ∆δ
values (Fig. 17). This was most pronounced for TSP with a ∆δ of 101.8 Hz in phosphate
buffer and 90.9 Hz in urine at a molar ratio (CSA to substrate) of 16. T-BuOH had the most
stable chemical shift with a minimal ∆δ of 1.9 Hz and 1.0 Hz in phosphate buffer and urine,
respectively, at a molar ratio of 16. A downfield change in chemical shift is indicative of a
deshielding effect, where the magnetic field generated by the electrons in the s-orbital of the
hydrogen atoms in the methyl (-CH3) groups is weakened. This presents less opposition to the
applied magnetic field and allows the 1H nuclei to absorb at their Larmor frequency at lower
magnetic field strengths, the Larmor frequency being the precession frequency of the magnetic
moment of the proton around the external magnetic field. In contrast, formate experienced a
slight upfield change in chemical shift with a ∆δ of -1.8 Hz in phosphate buffer at a molar ratio
of 16. This suggests a small shielding effect on the 1H nucleus of formate in the presence of
α-CD; however, this was unapparent in urine. Due to the endogenous presence of formate in
urine, the concentration of formate in the urine sample was first determined using 1 mM TSP as
an internal standard with the assistance of Chenomx NMR Suite 7.5 software. An appropriate
volume of sodium formate stock solution was then added to each urine sample to adjust its
concentration to 0.5 mM. In doing so, the results for formate were directly comparable to all the
other reference compounds. Based on these results, both formate and t-BuOH had fairly stable
chemical shifts making them the most appropriate internal references for NMR spectroscopic
analysis of aqueous samples that contain α-CD.
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Chemical exchange is the dynamic process by which a nucleus exchanges between two or more
environments. The presence of only one peak for all interacting reference compounds is indicative
of fast chemical exchange. This means that by the time the NMR pulse sequence came to an
end, the reference compound had already swapped between the α-CSA-bound and -unbound
environments, perhaps even multiple times depending on the rate of exchange. Therefore, the
single peak is a representation of the population weighted average of α-CD-bound and -unbound
species. The differences between environments with respect to their magnetic properties can give
rise to a wide variety of changes in NMR spectra [Bain, 2003]. In this instance, where chemical
exchange occurred between two environments via an intermolecular process, the interaction may
be represented by the equilibrium:
A + B
ka

kd
AB
where A is the free substrate, B is the free CSA, AB is the CSA-substrate complex, ka is the
association constant, and kd is the dissociation constant. In fast chemical exchange, the rate of
chemical exchange exceeds the difference between the chemical shifts of A (δA) and AB (δAB)
on the NMR time scale, and the nuclear spins effectively experience a local field which is the
observed average of the two states (δobs):
δobs = PAδA + PABδAB (2)
where PA and PAB represent the population of free and CSA-bound substrates, respectively
[Williamson, 2013]. PA and PAB are fractions, therefore:
PA + PAB = 1 (3)
allowing us to express the fraction of CSA-substrate complexes as:
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PAB = (δobs − δA)/(δAB − δA) (4)
Fast chemical exchange may occur due to weak interactions between the CSA and substrate
permitting rapid association/dissociation kinetics and interchange of resonance frequencies
between δA and δAB. Increasing the molar ratio increases PAB relative to PA and causes δobs to
smoothly shift towards δAB, thereby increasing ∆δ [Roberts, 1993,Bain, 2003,Williamson, 2013].
Substantial line broadening was observed for both TSP and DSS with increasing molar ratio
(Fig. 17a). This is called homogeneous broadening and occurs due to faster spin-spin relaxation.
T 2 is the transverse component of the magnetisation vector which decays exponentially towards
its equilibrium value zero as a result of the redistribution of excess potential energy associated
with the electrons in the magnetic field amongst the spins. In other words, it is the loss of
phase coherence of nuclei spinning perpendicular to the main field of magnetisation because of
complex forces developing between dipoles moving in close proximity and altering local magnetic
profiles. For fast chemical exchange where the spectrum is coalesced into a single peak, T 2
measurements can be used to extract the rate of chemical exchange. Although line width is an
indicator of T 2, on its own it is unreliable due to the presence of magnetic field inhomogeneity,
which will have the net effect of making NMR resonances broader than that expected from
T 2 alone. However, T 2 can be reliably determined using Carr-Purcell-Meiboom-Gill (CPMG)
spin echo pulse sequence experiments that suppress inhomogeneous broadening allowing only
homogeneous broadening to evolve [Loria et al., 1999,Bain, 2003].
An increase in T 2 relaxation for both TSP and DSS may be an indication of slower chemical
exchange. Once the system is out of the limits of fast exchange, peaks become broader when in
equilibrium between A and AB, and δobs will no longer simply be a weighted average of δA and
δAB. Although slower exchange leads to a change in the appearance of the spectra, the position
of δmax will remain the same. Further reduction in chemical exchange to the point where the
exchange rate is slower than the difference in chemical shifts on the NMR time scale would lead to
the decomposition of δobs into two individual transitions, δA and δAB, where the intensities reflect
the concentrations of A and AB, respectively. However, signal broadening is not necessarily
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Figure 17. Internal reference compound stability with CSAs. (a) Expanded regions
of 1D 1H NMR spectra of 0.5 mM TSP, DSS, DSA, t-BuOH, and formate with increasing
concentrations of α-CD, β-CD, γ-CD, and TCA. The chemical shifts were determined relative
to an external reference (3 mM TSP), and ∆δ was calculated relative to the internal reference
compound’s spectral position in the absence of CSA as indicated by the dotted line. (b) Change
in ∆δ with increasing molar ratio (CSA to substrate) for all reference compounds in phosphate
buffer and urine.
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caused by slower chemical exchange. Another feasible explanation for signal broadening is slow
tumbling, which may occur when there is some form of aggregation [Williamson, 2013].
The interaction of TSP, DSS, and DSA with α-CD involves the formation of inclusion complexes,
whereby the non-polar trimethylsilyl (-Si(CH3)3) group is incorporated into the hydrophobic
cavity. This is apparent in the 1H NMR spectrum of α-CD, where changes in the glucose H5
resonance were clearly evident for TSP (Fig. 18a). Although, a spectrum of α-CD on its own
was not acquired during the experiment, the spectrum of α-CD co-solvated with formate may
be used as a substitute due to the lack of interaction between these compounds. Unlike TSP,
changes in the H5 resonance for DSS and DSA are much more subtle, but slight deviations are
noticeable upon close inspection. This suggests that TSP has better size complementarity with
α-CD than DSA and DSS for a stronger association. This is also evidenced by differences in ∆δ of
the -CH3 resonance across the three reference compounds, where larger ∆δ values were observed
for TSP with increasing molar ratio relative to DSS and DSA (Fig. 17). Cyclodextrins usually
form 1:1 complexes with substrates in aqueous solutions. However, other ratios have also been
observed in previous studies and may coexist with the simple 1:1 stoichiometry [Szejtli, 1998].
One way to confirm the stoichiometry of interaction is to use the Job’s method of continuous
variation, where ∆δ is plotted against molar fraction by keeping the total concentration of CSA
and substrate constant [Lis-Cieplak et al., 2014]. The direction from which the guest molecule
enters the cavity, via the smaller or larger rim, is also ambiguous and can only be ascertained by
performing Nuclear Overhauser effect (NOE) experiments. NOE is the change in intensity of
an NMR resonance due to saturation of another and results from dipole-dipole cross relaxation
between nuclei through space. The strength of the NOE enhancement provides an approximation
to internuclear separation, and thus, can be used to derive information regarding the spatial
proximity of protons [Neuhaus, 2000]. Previous cyclodextrin chemistry studies have indicated
the non-participance of the -OH group at the 6-position in intramolecular hydrogen bonding,
which enables it to rotate and partially obstruct the cavity at the smaller rim [Schneider et al.,
1998]. Based on this evidence, substrate entry is most likely to occur via the larger rim.
In contrast, the interaction of t-BuOH with α-CD is unlikely to take the form of an inclusion
complex due to the close proximity of its -OH group to its -CH3 groups. In support, no changes
were observed for both H3 and H5 resonances of α-CD (Fig. 18a). Instead, the interaction is
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Figure 18. 1H NMR spectra of cyclodextrins when co-solvated with internal ref-
erence compounds. Expanded regions of 1D 1H NMR spectra of (a) α-CD, (b) β-CD,
and (c) γ-CD co-solvated with 0.5 mM formate, TSP, DSS, DSA, and t-BuOH with assigned
1H resonances. The spectrum for each cyclodextrin co-solvated with formate was used as the
reference spectrum to determine the presence or absence of interaction with the other compounds.
Changes in cyclodextrin 1H resonances evidencing the presence of interaction are highlighted.
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most likely based on the formation of hydrogen bonds between the -OH groups on both species.
Due to fast intermolecular exchange on the NMR time scale between solute and solvent, the
observation of separate -OH signals is not possible in protic solvents, such as water. Therefore,
the only way to confirm the presence of hydrogen bonding is by using non-protic solvents, such
as DMSO, where separate -OH signals as well as their couplings to adjacent C-H protons can
be well analysed [Schneider et al., 1998]. In doing so, a change in chemical shift downfield as a
result of deshielding effects may be observed for protons involved in hydrogen bonding relative
to uninvolved protons.
Generally, co-solvation of all the evaluated reference compounds with α-CD produced smaller
changes in chemical shift in urine relative to phosphate buffer (Fig. 17b). This is due to the
presence of numerous other substrates in urine that have the potential to interfere with the
formation of α-CD-reference compound inclusion complexes. This may be accomplished in two
ways. The first is direct competition for the hydrophobic cavity, where one or more molecules
may occupy the cavity space at one time. The second involves interactions with the -OH groups
on the rims of the cavity, which may lead to steric hindrance or repulsion preventing entry into
the cavity. Both mechanisms will increase PA relative to PAB, thus reducing ∆δ.
2.5.2 Reference compound stability with β-CD
As with α-CD, the co-solvation of TSP, DSS, DSA, and t-BuOH with β-CD caused a downfield
shift, indicating a deshielding effect on the 1H nuclei of the -CH3 groups (Fig. 17). The presence
of a single peak representing A and AB is demonstrative of fast chemical exchange. However,
this time the changes in chemical shift were most pronounced for DSS with a ∆δ of 79.1 Hz
and 77.6 Hz in phosphate buffer and urine, respectively, when co-solvated with β-CD at a molar
ratio of 16. This is more than twice the ∆δ values observed when DSS was co-solvated with
α-CD at an equivalent molar ratio (38.4 Hz in phosphate buffer and 33.5 Hz in urine). This
suggests better size complementarity with β-CD than α-CD for stronger complexation. This
was also reflected in the 1H NMR resonances of β-CD, where a considerable upfield shift of
the H5 resonance was clearly apparent in comparison to the reference spectrum causing almost
complete deconvolution of the overlapping H5 and H6 resonances (Fig. 18b). An upfield shift
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Figure 19. Effect of total molar concentration on ∆δ of t-BuOH when co-solvated
with β-CD. The change in ∆δ of t-BuOH was quantified following an increase in the global
concentration of both β-CD and t-BuOH while maintaining a molar ratio of 1.
of the H3 resonance was also observed. This suggests that the -Si(CH3)3 group of DSS is able to
embed itself deeply within the hydrophobic pocket allowing it to cause significant shielding of
H3 and H5 nuclei.
In contrast, the ∆δ values for TSP were smaller for β-CD than for α-CD at equivalent molar
ratios (78.4 Hz in phosphate buffer and 67.0 Hz in urine at a molar ratio of 16). This suggests that
TSP has better size complementarity with α-CD relative to β-CD. Changes in the glucose H5/H6
cluster and H3 for β-CD were also notable for TSP, although these were not as pronounced as
those seen for DSS (Fig. 18b). The changes in ∆δ for DSA when co-solvated with β-CD at an
increasing molar ratio were very similar to those of TSP in both phosphate buffer and urine
(Fig. 17b), which may suggest that they have similar ka constants. The stronger association of
DSS with β-CD relative to TSP and DSA may be explained by the bulkier sulphonate (-SO−3 )
group offering a more advantageous substrate position within the cavity.
As with α-CD, formate remained the most stable with very little deviation in chemical shift
in the presence of β-CD (Fig. 17). Although t-BuOH experienced much lower changes in
chemical shift relative to TSP, DSS, and DSA, they were still quite significant (12.4 Hz in
phosphate buffer and 7.9 Hz in urine at a molar ratio of 16). No changes were observed for any
of the β-CD resonances when co-solvated with t-BuOH as seen for α-CD (Fig. 18b); however,
the interaction is again likely to involve hydrogen bonding between the -OH groups of both
species. The larger downfield shifts of t-BuOH withβ-CD relative to α-CD suggests a stronger
interaction with β-CD. In addition to altering the molar ratio, the effect of changing global
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concentration of the sample, while maintaining a constant molar ratio of 1, was also monitored
for the interaction of t-BuOH with β-CD (Fig. 19). A 1:1 stoichiometry is expected to result
in no change in ∆δ since PA and PAB will remain the same. However, an increase in global
concentration resulted in an increase in ∆δ. Furthermore, the curve does not have a linear
gradient, as is expected of a fixed stoichiometry, which provides evidence of a more complex
stoichiometry. One factor that may contribute to this complex stoichiometry is the ability of
cyclodextrins to self assemble in aqueous solution to form small aggregates, which contribute
towards their solubilisation. Although insignificant at low concentrations, the tendency to self
assemble becomes much more significant with increasing cyclodextrin concentration, which may
therefore affect its availability to the substrate [McAlpine and Garcia-Garibay, 1998,Jansook
et al., 2010,Messner et al., 2010,Loftsson et al., 2004].
For TSP, DSS, and DSA there was stabilisation or near stabilisation of ∆δ at ∆δmax at high molar
ratios (Fig. 17). For t-BuOH, although there was no stabilisation, there was a gradual decrease
in slope. Therefore, t-BuOH may require higher molar ratios to achieve ∆δmax. Stabilisation at
∆δmax is an indication of saturation kinetics, where the proportion of CSA to substrate is so high
that almost all, if not all, of the substrate is complexed with the CSA (δobs = δAB). Since we
know δAB for TSP, DSS, and DSA, we can use Eq. 4 to calculate PAB, and thus, PA using Eq.
3 for any given δobs. Saturation kinetics can be exploited for referencing in aqueous samples
containing high concentrations of β-CD by stabilising δobs at δmax. DSS had the lowest molar
ratio threshold for stabilisation; therefore, DSS is the most suitable candidate when opting for
this strategy of referencing. As with α-CD, ∆δ was generally lower in urine relative to phosphate
buffer for all reference compounds at corresponding molar ratios due to matrix effects.
2.5.3 Reference compound stability with γ-CD
In distinction to α-CD and β-CD, no change in ∆δ was observed for TSP when co-solvated with
γ-CD at an increasing molar ratio, suggesting no interaction between the two species (Fig. 17).
The chemical shift stability of TSP most likely originates from its lack of size complementarity
for the hydrophobic cavity, thus preventing the formation of inclusion complexes. Previous
studies have suggested that using an external reference may be unreliable for the purposes of
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measuring ∆δ in samples containing cyclodextrin species as they may cause changes in the
magnetic susceptibilities of water through the formation of hydrogen bonds with cyclodextrin
glucose units [Schneider et al., 1998,Li et al., 1993]. However, the fact that there was no difference
between the internal and external TSP resonances despite an increase in γ-CD concentration
suggests that the external TSP signal remained stable for the concentration range used in this
study. Given that the chemical shift of TSP remained virtually unchanged in both phosphate
buffer and urine, irrespective of molar ratio, it may be employed reliably as an internal reference
for NMR studies that involve using γ-CD in aqueous solution.
In contrast to TSP, DSS and DSA both experienced small downfield shifts in phosphate buffer
of 2.6 Hz and 0.9 Hz at a molar ratio of 16, respectively (Fig. 17). Minor changes in the 1H
resonances of the H5/H6 cluster for γ-CD were apparent for DSS, but not DSA (Fig. 18c).
This suggests loosely formed inclusion complexes between γ-CD and DSS, but not DSA. This
may again be due to the bulkier -SO−3 group on DSS offering better size complementarity relative
to DSA and TSP. However, this interaction was significantly reduced by competing substrates in
urine as indicated by up to a 70% reduction in ∆δ relative to phosphate buffer (Fig. 17b). The
small changes in ∆δ of DSA may be due to hydrogen bonding between its ammonium (-NH +3 )
group and the -OH groups on γ-CD. Interestingly, in contradiction to the co-solvation of DSA
and γ-CD in phosphate buffer, co-solvation in urine produced upfield shifts. This suggests that
in the presence of urinary matrix effects, the nature of DSA’s interaction withγ-CD undergoes
a change that leads to the 1H nuclei of the -CH3 groups experiencing an increase in nuclear
shielding. This may be due to other competing substrates in urine with higher binding affinities
displacing DSA and making the primary site of interaction unavailable. DSA may, therefore, be
forced to interact more weakly with γ-CD at a less preferential secondary site.
The co-solvation of both t-BuOH and formate with varying concentrations of γ-CD resulted
in slight upfield changes in chemical shift in both phosphate buffer and urine ( Fig. 17). This
differentiates from their interaction with both α-CD and β-CD that produced downfield changes
in chemical shift, suggesting a different mode of interaction that is unaffected by the choice of
matrix.
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2.5.4 Reference compound stability with TCA
The presence of TCA with all reference compounds in aqueous solution was associated with a
downfield change in chemical shift with fast chemical exchange kinetics (Fig. 17). In phosphate
buffer, the trajectories for the change in ∆δ were linear with relatively similar gradients for TSP,
DSS, DSA, and t-BuOH (8.8 Hz, 8.1 Hz, 8.5 Hz, and 7.9 Hz at a molar ratio of 12, respectively).
The constant gradient suggests that ∆δ is proportional to the molar ratio for the range that
was investigated. The relatively low ∆δ suggests a weak association, which most probably takes
the form of hydrogen bonding between the -OH groups of both species. However, formate does
not follow the same trend. Small downfield changes in chemical shift were observed for formate
with no correlation to TCA concentration (0.7 Hz in phosphate buffer at a molar ratio of 12).
These changes were not observed in urine making formate a suitable internal reference for NMR
spectroscopic analysis of urine samples substituted with TCA.
In urine, we found ∆δ to be higher for TSP at corresponding molar ratios, particularly at higher
molar ratios (Fig. 17b). In contrast, DSS and DSA generated similar ∆δ values to those of
phosphate buffer. This difference may be due to the influence of urinary pH, which can vary
between 4.5 and 8 for healthy adults [Simerville et al., 2005]. As TSP is a weak acid, it is more
prone to the effects of sample pH than DSS and DSA, which are much more resilient to changes
in sample pH [Alum et al., 2008,Wishart et al., 1995]. Although we did not measure the pH of
the urine sample used for this experiment, a high pH above the pKa of TSP and TCA will result
in the loss of H+ ions from their carboxylic acid (-COOH) groups. The presence of charged
species will open up the opportunity for stronger interactions between molecules increasing ka,
and consequently ∆δ. For t-BuOH, ∆δ values decreased in urine relative to phosphate buffer at
equivalent molar ratios, presumably due to competitive inhibition from urinary substrates.
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2.5.5 D/L-amino acids with β-CD
To determine whether D- and L-amino acids can be chirally discriminated using CSAs in
aqueous solution, we mixed 50:50 racemic solutions of each amino acid with incrementing
concentrations of the chiral selector β-CD. β-CD was used as the cyclodextrin of choice because
of its general extensive use for chiral selection across analytical platforms, including NMR
spectroscopy, presumably due to the complementarity of its hydrophobic cavity for a broad
range of biomolecules. Furthermore, previous studies have provided evidence of its interaction
with endogenous metabolites, including amino acids [Linde et al., 2010,Pérez-Trujillo et al.,
2012,Kahle and Holzgrabe, 2004,Terekhova and Kulikov, 2002]. Despite these previous reports,
we did not observe any discernible chiral separations to allow for enantiomeric quantification.
We did not employ any form of referencing in order to quantify∆δ for each of the amino acids,
as we had done for the internal reference compounds, as this was not our objective.
2.6 Discussion
CSAs have been successfully employed in previous studies for chiral discrimination using NMR
spectroscopy [Pérez-Trujillo et al., 2012,Wenzel and Chisholm, 2011,Redondo et al., 1999,Lovely
and Wenzel, 2006]. The principal theory behind these chiral separations involves differences in
non-covalent interactions between the pair of enantiomers with the CSA to generate reversible
diastereomeric complexes. These diastereomeric complexes may exhibit different nuclear shielding
properties, giving rise to differences in their spectral chemical shifts. Subsequent integration of
the peaks assigned to each diastereomeric complex will allow the enantiomeric purity of the chiral
substrate to be determined. One of the issues surrounding the use of CSAs in NMR spectroscopy
is the choice of a stable internal reference compound, which is fundamental to accurate analysis
of NMR spectra. It is particularly important in the context of chiral metabolic profiling which
involves determining minute changes in chemical shift imposed by any CSA interaction.
We evaluated three internal reference compounds that are widely used in NMR spectroscopic
studies (TSP, DSS, and DSA) in conjunction with two major CSA classes (cyclodextrins and
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crown ethers) using 1H NMR spectroscopy. In addition, we also evaluated the potential of
t-BuOH and formate as novel candidates for internal referencing in the presence of CSAs,
despite the inadequate spectral position of t-BuOH (1.25 ppm) and formate being an endogenous
metabolite. Based on our observations, the most suitable internal reference candidates were
determined for each CSA that was evaluated (Table 1). Our findings indicate that most internal
references interact with CSAs in aqueous solution to some extent or another, which mostly
manifests in the NMR spectrum as a positional change of their chemical shift. Most interactions
were characterised as fast chemical exchange on the NMR time scale as the distribution of
CSA-bound and -unbound states was represented by a population weighted average resonance
frequency. Chemical exchange is generally fast in the context of CSA-substrate interactions
according to previous NMR spectroscopic investigations [Sompornpisut et al., 2002,Bernatowicz
et al., 2006,Lovely and Wenzel, 2006,Bardelang et al., 2007].
Internal references may interact with the native cyclodextrins through the formation of inclusion
complexes, but also through weaker dipole-dipole mechanisms to varying degrees. Whether or
not an inclusion complex is formed is governed mainly by the substrate’s size complementarity
for the cyclodextrin’s hydrophobic cavity. Following inclusion of the substrate, the strength of
the association is determined by a number of factors, including the substrate’s position and
orientation within the cavity. The exact nature of each interaction can be determined using
NOE experiments as described by Guerro-Martinez et al., 2006 [Guerrero-Martínez et al., 2006].
Despite interaction, high chemical shift stability can occur at high molar ratios due to saturation
kinetics, as seen for DSS in the presence of β-CD. In addition to changes in chemical shift, CSA
interactions may also cause line broadening effects due to faster T 2 relaxation, such as that seen
for TSP and DSS when co-solvated with α-CD.
Li et al., 1993 conducted a similar study that examined the suitability of TMS and DSS as
NMR references in aqueous solution in the presence of all three native cyclodextrin species [Li
et al., 1993]. They recorded 1H and 13C NMR spectra using DSS as an external reference. In
contradiction to what we found, they reported no interaction for DSS with α-CD. Our results
clearly showed an interaction between these two species, evidenced by substantial downfield
changes in chemical shift accompanied by an increase in linewidth. The presence of interaction
is also illustrated in the β-CD resonances, where an upfield shift in the glucose H5 resonance
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Table 1: Summary of suitable internal reference compounds
for aqueous samples containing CSAs.
CSA Internal reference compound
α-CD formate, t-BuOH
β-CD formate
γ-CD TSP
TCA formate
was observed. This is indicative of inclusion complex formation due to the presence of H5 in the
lining of the hydrophobic cavity. Similar observations were made for both TSP and DSA in the
presence of α-CD, which is to be expected considering the similarities in their chemical structure.
Li et al., 1993 also reported the inclusion of DSS by β-CD and γ-CD which is consistent with
our findings.
In urine, which is considered a complex matrix, ∆δ values for the internal reference compounds
tested were generally smaller than those seen in phosphate buffer at corresponding molar ratios.
This is likely due to the presence of numerous other molecules that have the potential to compete
for the same interaction sites on the CSA. Consequently, there is reduced availability of the
CSA, and therefore, a reduction in the population of CSA-substrate complexes.
External referencing may also be employed in place of an internal referencing when dealing
with CSAs, particularly when there are known problems associated with the internal reference,
such as pH sensitivity, biomolecular interactions, and poor solubility. External referencing is
best achieved using a concentrically positioned coaxial insert so that its position remains fixed
inside the NMR tube and remains the same across all samples. Concentricity is important in
maintaining magnetic field homogeneity in order to obtain good line shape and preserve chemical
shift accuracy for individual samples. In addition, a high degree of consistency is sustained
across samples for automated NMR experiments, thus preserving spectral quality throughout the
run. However, external referencing is susceptible to the effects of bulk magnetic susceptibility.
One effect of bulk susceptibility, which we at times observed for resonances originating from
the sample in the annular region between the tubes, is splitting at the peak tip. This has been
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observed in previous studies as well [Douglass and Fratiello, 1963]. This can lead to minor
inaccuracies in determining the chemical shifts of metabolites in the sample. Spinning the coaxial
system has been demonstrated to overcome any differences in bulk susceptibility between the
sample and external reference solutions. This is because rotating the system allows all particles
in both tubes to experience the same average field [Zimmerman and Foster, 1957,Douglass
and Fratiello, 1963,Williams and Gutowsky, 1956]. Alternatively, bulk susceptibility may be
measured using various methods for chemical shift correction to be applied post-acquisition [Frei
and Bernstein, 1962,Douglass and Fratiello, 1963,Live and Chan, 1970,Homer and Whitney,
1972].
We did not observe any discernible peak separations for any of the DL-amino acids when co-
solvated with β-CD in aqueous solution, although studies have previously shown evidence of
interactions [Terekhova et al., 2005,Linde et al., 2010,Pérez-Trujillo et al., 2012]. For example,
Linde et al., 2010 demonstrated the formation of amino acid complexes with β-CD using advanced
2D NMR techniques, rotating frame Overhauser effect spectroscopy (ROESY) and diffusion
ordered spectroscopy (DOSY). ROESY was used to provide structural information regarding the
complex, while DOSY was used to estimate the complexed population percentage in equimolar
mixtures of the CSA and substrate in D2O which indicates the affinity for complexation [Linde
et al., 2010]. Due to their hydrophobic cavity, cyclodextrins are particularly well suited to
forming inclusion complexes with any water soluble compound that is in possession of an
aromatic ring or a hydrophobic group. Phenyl rings have complementary sizes to both α-CD
and β-CD [Wenzel and Chisholm, 2011]. This makes α-CD and β-CD particularly well suited
to forming inclusion complexes with the aromatic amino acids: DL-phenylalanine, DL-tyrosine,
and DL-tryptophan. Despite the interaction of DL-amino acids with native cyclodextrins, to our
knowledge, no enantioseparations have been reported using NMR spectroscopy when the two
species are freely solubilised in aqueous solution.
Past studies have coupled cyclodextrins to paramagnetic species, such as lanthanide (III) ions, to
induce perturbations in the NMR spectrum via a dipolar mechanism [Wenzel and Chisholm, 2011].
This strategy may prove useful in ascertaining enantioseparations for DL-amino acids. Chen et
al., 2011 employed β-CD functionalised Fe3O4 nanospheres as their chiral selecting system for
the enantioseparation of DL-amino acids using 1H NMR spectroscopy. The enantioselectivity of
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the chiral selector system originates from more efficient complexation of β-CD with the L-amino
acid isomers. The combination of chiral selection provided by β-CD and magnetic separation
provided by the ferrimagnetic Fe3O4 nanoparticles made this a particularly efficacious chiral
selection system [Chen et al., 2011].
Cyclodextrins have had more success as chiral selectors for amino acids on other analytical
platforms besides NMR spectroscopy, such as LC-MS, GC-MS, and capillary electrophoresis
(CE). In LC-MS, cyclodextrins have been employed in chiral stationary phases (CSPs) for the
enantioseparation of amino acid derivatives in the mobile phase [Hinze et al., 1985,Fujimura
et al., 1990,Rizzi et al., 1995,Tang et al., 1996]. GC-MS is also a viable option, because amino
acid inclusion complexes with cyclodextrins in solution are preserved in the gas phase following
electrospray. In GC-MS, chiral analysis of amino acids is performed using the enantiomeric
differences in host-guest exchange reaction kinetics, whereby protonated amino acid guests are
exchanged in the gas phase in the presence of neutral alkyl amines. During the exchange process,
there is a net reaction involving the transfer of protons from the amino acids to the alkyl amines,
and the rate of transfer is sensitive to chirality [Ramirez et al., 2000, Ahn et al., 2001]. In
CE, cyclodextrins are dissolved in the separation buffer. As with LC-MS, chiral separation
of DL-amino acids with cyclodextrins using CE has usually required pre-column amino acid
derivatization in order to increase sensitivity, as most amino acids lack strong UV absorbance,
and improve selectivity [Valkó et al., 1996, Lu and Chen, 2002]. Most derivatizing reagents
provide the opportunity to use laser-induced fluorescence (LIF) to increase sensitivity through
fluorescence detection [Wan and Blomberg, 2000].
Although the ability of TCA to chirally differentiate DL-amino acids in aqueous solution using
NMR spectroscopy was not evaluated in this study, previous studies have investigated TCA
extensively in both NMR and liquid chromatographic applications with primary amines [Wenzel
and Thurston, 2000b,Wenzel et al., 2009,Berkecz et al., 2006]. TCA can be mixed directly
with unprotonated amines where a neutralisation reaction with the carboxylic acid moiety of
TCA produces ammonium ions which are needed for association. TCA has been shown to
be an effective CSA for underivatized DL-amino acids; however, enantiomeric discrimination
is more pronounced in solvents such as methanol-d4 and acetonitrile-d3 relative to deuterium
oxide [Wenzel and Thurston, 2000b,Wenzel et al., 2009]. Therefore, in order to use TCA for
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chiral metabolic profiling of biofluids and achieve appreciable separations, sample preparation
may require drying down and then reconstituting the sample in methanol-d4 or acetonitrile-d3.
Deuterium chloride may need to be added to achieve solubilisation of some amino acids [Wenzel
and Thurston, 2000b]. As with cyclodextrins, the addition of lanthanide ions to the mixture,
such as ytterbium(III), can enhance enantiomeric discrimination [Wenzel and Thurston, 2000a].
Practically, it is extremely difficult to employ CSAs for complex matrices using NMR spectroscopy
where the spectrum is already fraught with high complexity, where hundreds of metabolites at
varying abundances produce highly overlapping peaks. Although there are currently sophisticated
and automated methods of peak deconvolution available to increase the reliability of metabolite
identification and quantification, this predicament is only likely to worsen in the presence of CSAs.
One way CSAs may complicate this scenario is by causing significant deviation of the chemical
shifts of interacting metabolites. This can increase the uncertainty of metabolite identification,
which is most commonly done using a library of reference spectra or with the assistance of
sophisticated peak deconvolving software. In addition, CSAs can occupy a sizeable region of the
spectrum and mask metabolite peaks within the same ppm region ( Supplementary Fig. 1).
This can lead to the loss of a wealth of potentially valuable information.
In conclusion, many of the commonly used internal references in NMR spectroscopy were found
to be unsuitable for referencing in the presence of CSAs in aqueous samples. This is due to a
dynamic chemical exchange process involving rapid association-dissociation kinetics through
various types of interactions, including inclusion complexes and dipolar mechanisms. Given these
circumstances, we have devised a suitable internal referencing strategy for some of the most
commonly employed CSAs in NMR spectroscopy. This is critical for the accurate determination
of chemical shifts and subsequent peak assignment, particularly in metabolic profiling. With
respect to the chiral discriminatory abilities of CSAs in aqueous solutions, we did not observe any
discernible chiral separations in the NMR spectra when co-solvating the proteinogenic DL-amino
acids with β-CD. Changes in chemical shift patterns in the absence of chiral separations, together
with the immense complexity of NMR spectra for biofluids, draws into question the usefulness of
employing CSAs in NMR spectroscopy for the purpose of chiral metabolic profiling. Further
work using other promising CSAs and sample preparatory procedures need to be evaluated to
confirm this notion.
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Chapter3
An enantioselective UPLC-MS assay for
quantification of amino acid enantiomers
3.1 Overview
MS methods are equipped with the capability to perform robust, selective quantification of
endogenous metabolites with sensitivities in the nanomolar to micromolar range. Therefore, MS
is a desirable analytical technique for the trace analysis of D-amino acids that are generally in
low abundance in biofluids, but fulfil biologically important functions that are not currently
well understood. The mass analysis capabilities of MS can be used in conjugation with the
physical separation capabilities of liquid chromatography. UPLC-MS, in particular, is a powerful
technique for the separation and detection of individual components in a complex mixture.
UPLC takes advantage of the technological strides made in particle chemistry performance for
increased system efficiency (number of peaks resolved per unit time). Therefore, it achieves
superior selectivity and sensitivity in comparison to HPLC, and as a result, has many applications
both within and beyond metabonomics, including pharmacokinetics, toxicology screening and
confirmation, forensics, and contaminant detection. This chapter describes the development of
an existing indirect chiral analytical approach for the relative quantification of enantiomers of a
small targeted panel of amino acids in complex matrices.
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3.2 Aim and objectives
3.2.1 Aim
Evaluate the potential of an existing UPLC-MS assay for chiral recognition and quantification of
D- and L-amino acids, and perform initial optimisation to increase assay sensitivity in complex
matrices.
3.2.2 Objectives
• Conduct an initial assessment of enantioseparations on a TOF instrument to determine
proteinogenic amino acid panel coverage and resolution.
• Investigate assay performance in complex matrices and the magnitude of any potential
matrix effects.
• Optimise the sensitivity of the assay by systematically investigating sources of analyte loss
during sample preparation and analysis.
3.3 Introduction
3.3.1 Chiral analysis with HPLC
Chiral separations are most commonly performed by HPLC, representing over half of all
publications in this area [Ward and Ward, 2011]. There are two main strategies for separating
enantiomers using HPLC. The first is a direct approach based on the formation of reversible
diastereomeric complexes on a chiral stationary phase, or with a chiral selector in the mobile
phase followed by separation on an achiral stationary phase. The second is an indirect method,
which entails the formation of irreversible diastereomers using a homochiral CDA with subsequent
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separation of diastereomeric derivatives using an achiral stationary phase [Ilisz et al., 2008,
Bhushan and Brückner, 2004].
A considerable advantage of using CSPs is the ability to perform direct analysis of samples in
the absence of derivatization, although sometimes derivatization using an achiral reagent may
be required to improve enantioseparations or enhance sensitivity [Ilisz et al., 2008]. Macrocyclic
antibiotics interact with molecules through non-covalent interactions, very much like cyclodextrins.
Furthermore, akin to cyclodextrin modifications, reworking the antibiotic structure can broaden
substrate selectivity. CSPs based on glycopeptide antibiotics, such as teicoplanin, possess ionic
groups and are compatible with both organic and aqueous mobile phases. This makes them
suitable for the separation of polar and ionic compounds, such as amino acids. For example,
following evaluation of a CSP comprised of the macrocyclic antibiotic A-40,926 in relation to a
teicoplanin CSP, the two CSPs were found to complement one another with good resolution
of chiral compounds, including α- and β-amino acids [Berthod et al., 2000,D’Acquarica et al.,
2000].
The indirect method is associated with a number of advantages over the direct method. First
and foremost, CDAs convert enantiomers into irreversible diastereomeric products, which
eliminates the opportunity for spontaneous racemisation to occur during the sample preparatory
steps that ensue derivatization and during analysis. This is critical for reliable and accurate
enantiomeric quantification in biofluids during metabolic profiling studies. There is also an
expansive collection of commercially available homochiral CDAs with well established reactions
that yield diastereomeric products that can be well resolved. Another major advantage is
the wide choice of chromatographic conditions for better chromatographic optimisation and
improved resolution. Also, the ability to perform separations on inexpensive achiral columns is
an important factor to consider, particularly during routine method application for large scale
metabolic profiling studies [Ilisz et al., 2008,Bhushan and Brückner, 2004].
There are several important considerations to take into account when selecting a suitable CDA
for a targeted panel of analytes. The CDA and chiral molecule must contain compatible and
readily reacting functional groups for derivatization to occur. The reaction should proceed
quantitatively for both enantiomers and quickly in a single step to ensure there is no kinetic
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resolution as a result of differences in reaction rate. Furthermore, the reaction should take
place under mild conditions to avoid racemisation of both reactants. The employment of high
CDA enantiomeric purity is essential for precise quantification of amino acid enantiomers. The
chromatographic separation of diastereomeric derivatives is usually improved when there are
bulky groups attached to the chiral centre and the chiral centres of both the CDA and analyte
are in close proximity in the resulting diastereomers [Ilisz et al., 2008,Bhushan and Brückner,
2004].
3.3.2 (S)-NIFE derivatization of DL-amino acids
Several CDAs are commercially available for chiral discrimination of proteinogenic amino acids;
however, many suffer from inherent problems, including inadequate amino acid panel coverage,
unstable diastereomeric derivatives, low reaction yields, and poor detectability of amino acid
derivatives. Visser et al., 2011 investigated the performance of seven different CDAs in quantifying
D-amino acids using UPLC-MS and found that the reagent (S )-N -(4-nitrophenoxycarbonyl)-L-
phenylalanine methoxyethyl ester ((S )-NIFE) resolved all nineteen chiral proteinogenic amino
acids with superior sensitivity. The reaction was carried out under mild conditions in the absence
of spontaneous racemisation during sample preparation and proceeded quickly, which reduced
the opportunity for kinetic resolution. Following the initial investigation, (S )-NIFE was used
to devise a UPLC-MS assay protocol to simultaneously quantify all D-amino acids in human
biofluids, including blood plasma, urine, and cerebrospinal fluid (CSF). The assay was sensitive
enough to detect nanomolar concentrations of D-amino acids in these complex matrices with
excellent accuracy and intra- and inter-assay precision [Visser et al., 2011]. We thus sought to
replicate this method for the purpose of later applying it to various metabolic profiling studies
where D-amino acids are of particular interest.
(S )-NIFE (1) reacts with the amino group on the L- and D-amino acid enantiomers (2 and
3, respectively) to generate their corresponding diastereomeric derivatives (4 and 5, respec-
tively) (Fig. 20a). The formation of diastereomeric products is accompanied by an equimolar
concentration of 4-nitrophenol (6) [Péter et al., 2002]. This is an example of a nucleophilic
substitution reaction. Previously, it was shown that the yield of derivatization at ambient
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Figure 20. (S)-NIFE derivatization and decomposition. (a) Reaction schematic for the
(S )-NIFE derivatization of D- and L-amino acids. (b) Schematic of (S )-NIFE decomposition
under basic conditions. (1) (S )-NIFE, (2) L-amino acid, (3) D-amino acid, (4) L-amino acid
derivative, (5) D-amino acid derivative, (6) 4-nitrophenol, (7) phenylalanine methoxyethyl ester,
(8) N, N ’-bis(3-phenylpropionic acid methoxyethyl ester 2-yl)urea. ∗, chiral centre.
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temperatures reaches a maximum in aqueous solution at pH > 11 [Péter et al., 2000]. Basic
conditions are a prerequisite to keep the amino group in an unprotonated state for it to behave as
a nucleophile and displace 4-nitrophenol from the (S )-NIFE carbamate. Under basic conditions,
excess (S )-NIFE in aqueous-organic solutions decomposes to form 4-nitrophenol along with
phenylalanine methoxethyl ester (7) and N,N ’-bis(3-phenylpropionic acid methoxyethyl ester
2-yl)urea (8) from an unstable carbamic acid intermediate (Fig. 20b) [Péter et al., 2002].
3.4 Experimental methods
3.4.1 Materials
(S )-NIFE was obtained from Santa Cruz Biotechnology Inc., all unlabelled DL-amino acids from
Sigma-Aldrich, and L-serine-d3 from Cambridge Isotope Laboratories. LC-MS grade acetonitrile
and ammonium hydrogencarbonate were obtained from Fluka Analytical, Sigma-Aldrich. Optima
LC-MS grade water and 0.1% formic acid in water were attained from Fischer Scientific. Analar
hydrochloric acid (HCl) was purchased from BDH Prolabo, VWR and sodium tetraborate-10-
hydrate from Reidel-de-Haën, Sigma-Aldrich. 10K Nanosep centrifugal devices with an OMEGA
membrane were acquired from Pall, and screw neck LC-MS total recovery glass vials were
purchased from Waters. Gibco Dulbecco’s Modified Eagle Medium (DMEM) and fetal bovine
serum (FBS) were obtained from ThermoFisher Scientific.
3.4.2 Sample preparation
A subset of human urine samples were obtained from healthy participants of a nutritional
intervention study and pooled together to create a representative urine sample as described in
the previous chapter (Section 2.4.2). Frozen urine samples were thawed at room temperature,
vortexed, and centrifuged for 10 min at 20,817 g at 4 ◦C to remove any salt precipitates. The
samples were then prepared using the method described by Visser et al., 2011 [Visser et al.,
2011] (Fig. 21). However, sample vaporisation was performed using a centrifugal evaporator set
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Figure 21. UPLC-MS sample preparation for the separation of (S)-NIFE deriva-
tized amino acids enantiomers. A schematic of the UPLC-MS protocol for the separation
and quantification of D- and L-amino acid derivatives in urine and cell culture media.
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to room temperature instead of a nitrogen stream on a heating block, and derivatized samples
were filtered using 10K centrifugal devices instead of 0.2 µm filters.
For cell media supplemented with FBS, initially 100 µl of media was mixed with isotopically
labelled internal standard (IS) solution and protein precipitated using acetonitrile as described
by Visser et al., 2011 (Fig. 21) [Visser et al., 2011]. Later, the volume of cell media was reduced
to 30 µl and mixed with 12 µl of IS (25 µM L-serine-d3) and 90 µl of ice cold methanol. The
mixtures were incubated at -80 ◦C for 1 h, and then centrifuged for 10 min at 20,817 g at
4 ◦C to remove any protein precipitation. The recovered supernatants were dried down using a
centrifugal evaporator set to room temperature. The dry residues were reconstituted in 50 µl
of H2O and 35 µl of 0.15 M sodium tetraborate, and left to incubate at room temperature for
10 min. For the derivatization step, 50 µl of 12.5 mg/ml (S )-NIFE in acetonitrile (initially 2.5
mg/ml) was added, and the mixtures were incubated at room temperature for 20 min. The
reactions were terminated by adding 15 µl of 4 M HCl to bring the total sample volume up to 150
µl. The mixtures were left to incubate at -20 ◦C for 10 min for salt precipitation to occur, and
then passed through 10K centrifugal devices at 6,797 g at 4 ◦C. The filtrates were transferred to
total recovery LC-MS glass vials and stored at -80 ◦C until chromatographic analysis.
3.4.3 Instrumental parameters
The diastereomers were separated by injecting 5 µl of each sample on to a 100 mm × 2.1 mm
Aquity 1.7 µm UPLC BEH C18 column using an Aquity UPLC system coupled to a Q-Tof
Ultima API mass spectrometer (Waters). The column was maintained at a temperature of 60 ◦C
and the flow rate was kept constant at 0.6 ml/min. Detection was carried out with positive
electrospray ionisation (+ESI) using MS scan mode. The electrospray capillary voltage was set
to 2.7 kV, cone voltage (CV) to 17 V, and collision energy (Ecoll) to 5 eV. The desolvation gas
flow was maintained at 900 L/hr and cone gas flow at 40 L/hr. The desolvation temperature
was set at 500 ◦C. With the exception of glutamic acid, all D- and L-amino acid derivatives were
separated using a basic mobile phase gradient elution profile comprised of 10 mM ammonium
bicarbonate and acetonitrile (Table 2). D- and L-glutamic acid derivatives were resolved using
an alternate acidic mobile phase gradient elution profile comprised of 0.1% formic acid in water
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Table 2: Basic gradient elution
profile for the separation of di-
astereomer products after (S)-NIFE
derivatization.
Time (min) Mobile phase
%A %B
0 96 4
5 96 4
9 90 10
11 88.5 11.5
16 72 28
19 70 30
21 65 35
22.5 10 90
23.5 10 90
25 96 4
27 96 4
Solvents A and B are 10 mM ammonium bi-
carbonate and acetonitrile, respectively. The
flow rate was kept constant at 0.6 ml/min.
Table 3: Acidic gradient elution pro-
file for the separation of (S)-NIFE
derivatized D- and L-glutamate.
Time (min) Mobile phase
%A %B
0 88 12
2 85 15
5 80 20
8 75 25
11 70 30
14 60 40
16 50 50
17 5 95
18 5 95
19 88 12
20 88 12
Solvents A and B are 0.1% formic acid in water
and acetonitrile, respectively. The flow rate
was kept constant at 0.6 ml/min.
and acetonitrile (Table 3). Spectral acquisitions were performed using the Waters MassLynx
v4.1 software.
3.4.4 Data analysis
Smoothing and peak integration of extracted chromatograms were performed using Waters
MassLynx v4.1 software. Resolutions (Rs) for enantiomeric separations were calculated using
the equation:
Rs = 2(tD − tL)/(wD + wL)
where tD and tL are the retention times of the D- and L-amino acid derivatives, respectively, and
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wD and wL are their corresponding peak widths. The limit of detection (LOD) and limit of
quantification (LOQ) were determined using the S/N method, where the LOD and LOQ are
equivalent to 3× and 10× the noise, respectively [Shrivastava et al., 2011]. S/N was calculated
using the MassLynx software’s auto-integrating functionality.
3.5 Results
3.5.1 Enantioselectivity and resolution
When quantifying D-amino acids in the presence of high concentrations of the L-enantiomer, it is
critical for their corresponding diastereomers ((S )-NIFE-D-AA and (S )-NIFE-L-AA, respectively)
to be well resolved. Initial evaluation of the amino acid standard mixtures using the UPLC-MS
assay on the Q-Tof Ultima API revealed that all amino acids but one (DL-glutamic acid) can
be chirally resolved using a basic mobile phase comprised of 10 mM ammonium bicarbonate
(solvent A) and acetonitrile (solvent B) and a gradient elution profile (Fig. 22a). The sample
injection volume was reduced from 10 µl (used by Visser et al., 2011) to 5 µl to prevent sample
overload and loss of resolution. All amino acids, except DL-aspartic acid, were associated with
Rs > 1, which indicates baseline separation of the diastereomers (Table 4). The (S )-NIFE-L-AA
was always found to elute before its corresponding (S )-NIFE-D-AA. Although the derivatized
enantiomeric pairs of leucine and isoleucine were well resolved, the derivatized D-enantiomers of
both amino acids were not baseline resolved (Rs = 0.82). Since we used a relatively old existing
column for these separations (500+ injections) that had previously been used for other assays,
these Rs values are likely to be underestimated relative to those achievable on a new well primed
column. Rs deterioration can result from strongly adsorbed contaminants from previous uses or
mechanical destabilisation of the packed bed due to rough handling or manufacturing defects.
Good separations were also achieved in urine and cell media supplemented with FBS, although
the retention times of some analytes, and hence their resolution, were subject to small deviations.
Although (S )-NIFE-D-Glu and (S )-NIFE-L-Glu could not be resolved using the basic mobile
phase, they were resolved using an acidic mobile phase comprised of 0.1% formic acid (solvent
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Figure 22. Extracted chromatograms of amino acids derivatized by (S)-NIFE. (a)
Stack plot of chromatograms showing the chiral resolution of D- and L-amino acids following
(S )-NIFE derivatization when using a basic mobile phase elution gradient profile on the Q-Tof
Ultima. (b) Enantioseparations of (S )-NIFE-DL-Asp and (S )-NIFE-DL-Glu using an acidic
mobile phase gradient elution profile on the Q-Tof Ultima.
A) and acetonitrile (solvent B) (Fig. 22b and Table 4). When using the acidic mobile phase,
the derivatives of DL-aspartic acid were also fully resolved (Rs = 1.09). This is of particular
importance in the context of absolute quantification by accurate peak integration. However, the
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Table 4: Fragment ions and resolutions (S)-NIFE derivatized amino acids.
Amino acid Fragment ion(m/z )
Retention time
(min)
Peak width
(min) Rs
tL tD wL wD
Alanine 339.15 10.92 12.35 0.25 0.18 6.65
Serine 355.15 10.27 10.78 0.18 0.20 2.68
Proline 365.15 12.13 12.73 0.24 0.20 2.73
Valine 367.18 13.17 14.36 0.16 0.15 7.68
Threonine 369.17 10.69 12.21 0.25 0.17 7.24
Leucine 381.20 14.51 15.45 0.14 0.11 7.52
Isoleucine 381.20 14.26 15.36 0.13 0.11 9.17
Asparagine 382.16 9.89 10.46 0.20 0.19 2.92
Aspartic acid 383.15 6.48 6.77 0.40 0.35 0.77
Aspartic acid a 383.15 3.93 4.17 0.22 0.22 1.09
Glutamine 396.21 10.96 11.51 0.22 0.16 2.89
Glutamic acid a 397.45 4.21 4.45 0.21 0.20 1.17
Methionine 399.15 13.73 14.63 0.17 0.15 5.63
Histidine 405.16 10.74 11.40 0.23 0.19 3.14
Arginine 424.21 11.94 12.48 0.27 0.23 2.16
Tryptophan 454.18 15.47 16.14 0.14 0.12 5.15
Cysteine 620.23 18.39 19.01 0.17 0.19 3.44
Lysine 645.28 17.56 18.05 0.13 0.15 3.50
Tyrosine 680.27 20.39 21.27 0.18 0.15 5.33
Rs is resolution, tL and tD represent the retention times of (S )-NIFE-L-AAs and (S )-NIFE-D-AAs,
respectively, and wL and wD represent their corresponding peak widths at baseline.
a Eluted using the acidic mobile phase elution gradient profile.
low pH mobile phase is associated with considerably lower sensitivity in comparison to the high
pH mobile phase making it unfavourable for trace analysis.
The employment of a high pH mobile phase for analysis, well above the pKa values of basic
compounds, seems somewhat counter-intuitive as it creates an environment which should
theoretically suppress analyte ionisation in ESI+ mode. This is expected to decrease sensitivity
during MS detection. Therefore, our observation suggests that, contrary to common expectations,
high pH mobile phases do not necessarily suppress the ionisation of basic compounds and that
positive ions are formed abundantly. Previous studies have also shown high detection of
basic compounds in ESI+ mode by employing high pH buffers in mobile phases [Kelly et al.,
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Figure 23. Chromatogram and mass spectra of (S)-NIFE derivatization by-
products. Peaks 1 (RT = 13.77) and 4 (RT = 22.22) in the method blank represent the
[M+H]+ of phenylalanine methoxyethyl ester (m/z 224.12) and N, N ’-bis(3-phenylpropionic
acid methoxyethyl ester 2-yl)urea (m/z 473.21), respectively. The remaining ions are fragments
of these two by-products. Peaks 2 (RT = 15.21) and 3 (RT = 16.01) in the chromatogram
correspond to (S )-NIFE-L-Phe and (S )-NIFE-D-Phe, respectively, and are derived from the urea
dimer by-product during collision-induced dissociation. m/z 495.20 and 437.16 represent the
sodium adducts ([M+Na]+) of the urea dimer and (S )-NIFE-L-Phe, respectively.
1992,Mansoori et al., 1997,Mallet et al., 2004].
(S )-NIFE-L-Phe with m/z 415.18 was identified in large quantities in the method blank (Fig.
23). Indeed as the name ((S)-N -(4-nitrophenoxycarbonyl)-L-phenylalanine methoxyethyl ester)
implies, L-phenylalanine is an integral part of the (S )-NIFE chemical structure. This suggests that
the urea dimer byproduct (m/z 473.21) that is formed during excess (S )-NIFE decomposition
(Fig. 20b) is fragmented by the ionisation process to form L-Phe-(S )-NIFE (Fig. 24). We also
detected a small amount of D-Phe-(S )-NIFE in the method blank (Fig. 23). D-Phe-(S )-NIFE
may originate from spontaneous racemisation of the urea dimer byproduct (Fig. 24). If this
is the case, it may also suggest that all (S )-NIFE derivatized amino acids have the potential
to spontaneously racemise. Sizeable spontaneous racemisation has the propensity to affect the
accuracy of quantification of D-amino acids in biofluids more than L-amino acids, in terms of
% error, due to their naturally low abundance. In any case, the detection of both D-Phe-(S )-
NIFE and L-Phe-(S )-NIFE in the method blank, due to the very nature of (S )-NIFE, clearly
implies that it will not be possible to quantify the levels of D- and L-phenylalanine in biofluids
in future studies using this assay. Of the other byproducts formed through excess (S )-NIFE
decomposition, only phenylalanine methoxyethyl ester (m/z 224.12) was detected in the method
blank (Fig. 23). This suggests that the 4-nitrophenol side product is lost in the solvent front
during chromatography.
In the context of this assay, the presence of (R)-NIFE can be highly detrimental to the analysis
of all D-amino acids, particularly in biofluids that contain large amounts of L-amino acids. This is
because derivatization of L-amino acids by (R)-NIFE results in the formation of (R)-NIFE-L-AA,
which is the enantiomer of (S )-NIFE-D-AA. Therefore, (R)-NIFE-L-AA is expected to have
the same RT as (S )-NIFE-D-AA when performing chromatography using achiral conditions
(Fig. 25). To verify that the commercial (S )-NIFE reagent we obtained was chirally pure, we
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Figure 24. Racemisation and fragmentation of the (S)-NIFE urea dimer by-product.
NIFE decomposes under basic conditions to form its corresponding urea dimer. The urea dimers
can potentially undergo spontaneous racemisation at one or both of its chiral centres. Bond
cleavage after the carboxylic acid group on the urea dimer due to collision-induced
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dissociation produces its corresponding Phe-NIFE fragment. Phe-NIFE can also potentially
undergo spontaneous racemisation. L-Phe-(S )-NIFE and D-Phe-(R)-NIFE are enantiomers, and
likewise, D-Phe-(S )-NIFE and L-Phe-(R)-NIFE are also enantiomers. ∗, chiral centre; red arrow,
decomposition of NIFE; blue arrow, dissociation of urea dimer; green arrow, racemisation.
derivatized 100 µM of the pure L-enantiomer for a representative panel of amino acids (L-alanine,
L-isoleucine, L-threonine, and L-glutamine). No detectable peak was observed at the expected
RT of the (S )-NIFE-D-AA for all evaluated amino acids, which suggests undetectable levels
of (R)-NIFE in the commercial (S )-NIFE reagent, and also D-amino acid in the L-amino acid
solutions. The evaluated amino acids were associated with LODs less than 100 nM on the Q-Tof
Ultima in aqueous-organic solvent. The LOD is the lowest concentration of analyte that can
be reliably detected using the assay, but not necessarily quantified. Therefore, based on these
detection limits it was deduced that the commercial (S )-NIFE reagent had an enantiomeric
purity exceeding 99.9%. The absence of any detectable (S )-NIFE-D-AA peaks also suggests
that there is negligible spontaneous racemisation of (S )-NIFE-L-AA under the assay conditions.
These results demonstrate that this assay is suitable for the trace analysis of D-amino acids.
As a consequence of enantiomers sharing the same RT on an achiral column, the approach we
used to assessing enantiomeric purity of the CDA would have led to ambiguous results given the
presence of detectable levels of (R)-NIFE in the commercial (S )-NIFE product or D-amino acid
in the prepared L-amino acid solutions. In a scenario where the chiral impurity arises from one
or both reagents, a single peak corresponding to either (R)-NIFE-L-AA, (S )-NIFE-D-AA, or
both would have been observed during the test. If both reagents were chirally impure, (R)-NIFE-
Figure 25. Theoretical chromatogram of derivatives formed from racemic mixtures
of both NIFE and the amino acid. (S )-NIFE-L-AA and (R)-NIFE-D-AA are enantiomers,
and therefore, co-elute. Similarly, (S )-NIFE-D-AA and (R)-NIFE-L-AA are enantiomers and
also co-elute.
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D-AA would also be produced, although at lower concentrations relative to (R)-NIFE-L-AA
and (S )-NIFE-D-AA given the large excess of (S )-NIFE and the L-amino acids relative to their
enantiomeric counterparts. (R)-NIFE-D-AA has the same RT as (S )-NIFE-L-AA, being its
corresponding enantiomer (Fig. 25), and will therefore go undetected. Therefore, although the
test we used would have been able to detect the presence of chiral impurity, it would have been
impossible to determine the source, which represents a major limitation. An alternative way
of assessing the enantiomeric purity of a CDA is to use a CSP that directly interacts with the
reagent itself rather than its derivatives. This is providing that this method is associated with
sufficiently high sensitivity to detect minute quantities of any chiral impurity.
Cysteine, tyrosine, and lysine were found to react with two molecules of (S )-NIFE. For cysteine
and lysine, only double conjugate products were observed indicating that their reactions proceed
to completion. However for tyrosine, products containing a single (S )-NIFE group were also
observed even in the presence of a many fold excess of the CDA, which suggests incomplete
derivatization (Fig. 26). Although the single conjugate only accounts for a small proportion of
the total product formed (< 10%), its quantification may be corrected for by the inclusion of an
appropriate stable isotopically labelled standard. The exclusive formation of double conjugate
derivatives for cysteine indicates that (S )-NIFE is also capable of reacting with thiols (-SH) as
well as primary and secondary amines. -SH groups, like -NH2 groups, are nucleophilic because
they have two lone pairs of electrons. The formation of bis (S )-NIFE derivatives of tyrosine,
although not exclusive, suggests that (S )-NIFE is also capable of reacting with -OH groups.
Figure 26. Single and double conjugate (S)-NIFE derivatives of tyrosine. Extracted
chromatogram overlay of tyrosine derivatives with one and two ( S )-NIFE groups (m/z 431.18
and 680.27, respectively) and its corresponding mass spectrum. m/z 702.26 represents [M+Na]+
of the more abundant bis derivative.
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However, other amino acids, namely serine and threonine, also have an -OH group in their side
chain, yet do not form bis derivatives like tyrosine. This is because although -OH groups are
associated with two lone pairs of electrons, oxygen is highly electronegative (the measure of an
atom’s ability to attract a bonding pair of electrons) which makes the electrons less available for
nucleophilic attack. The -R group of tyrosine is associated with a pKa of 10.5, whereas the -R
groups for both serine and threonine have a pKa of 13. So under the weak alkaline conditions for
derivatization (0.04 M sodium tetraborate), the -OH group of the tyrosine side chain is ionised
to -O− which is a better nucleophile than -OH. The lower pKa for tyrosine relative to serine and
threonine is most likely to stem from the electron withdrawing capability of its benzene ring.
3.5.2 Matrix effects
D-serine was used as a methodological exemplar to further assess the UPLC-MS assay’s per-
formance. Calibration curves of D-serine were produced using the standard addition method
in sample solvent, cell media, and urine to determine the linear range of quantification and
assess the extent of any matrix effects (Fig. 27). A fixed concentration of L-serine-d3, which
co-elutes with L-serine, was used as an internal standard for each calibration sample. Due to the
significant presence of [M+Na]+, signal intensities were quantified by selecting the masses of both
Figure 27. Calibration curves of D-serine. Calibration curves were performed in aqueous-
organic solvent, urine, and cell media supplemented with FBS. Background subtraction was
performed for both urine and cell media to give only the signal intensity that is attributed to the
D-serine that was added. A fixed concentration of L-serine-d3 was used as an internal standard
for all calibration samples (represented by the hashed lines).
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[M+H]+ and [M+Na]+. As expected, combining the two species provided additional sensitivity.
For urine and cell media, the signal originating from endogenous D-serine was subtracted to
give the intensity of only that which was added. Both complex matrices were associated with a
marked reduction in the calibration curve gradient in relation to the solvent. Consequently, their
linear response ranges were considerably greater. Likewise, although the response for L-serine-d3
remained constant for all calibration curves, its response was severely diminished for the complex
matrices relative to the solvent with recovery rates of 42.1% and 14.6% for urine and cell media,
respectively. These observations suggest the presence of a substantial matrix effect on analyte
recovery.
In contrast to LOD, LOQ is defined as the lowest concentration of analyte that can be quantified
using the assay with acceptable precision and accuracy. The LOD and LOQ for D-serine in solvent
were 24 nM and 81 nM, respectively. The LOD and LOQ for D-serine in urine were 254 nM
and 847 nM, respectively, and for cell media they were 792 nM and 2,641 nM, respectively.
The LOD and LOQ calculations in urine and cell media were performed using the signal of
endogenous D-serine, for which it was necessary to determine the endogenous concentration
using the calibration curve.
3.5.3 Investigating analyte loss
To check for the presence of ion suppression, a racemic mixture of pre-derivatized serine ((S )-
NIFE-DL-Ser) was added to the sample solvent and cell media at fixed concentrations within the
linear response defined by its calibration curve. Ion suppression is a matrix effect phenomenon
where a co-eluting molecule influences the ionisation of the analyte which results in an attenuated
response. Although an increase in the desired analyte response (ion enhancement) is also a
possibility, this happens far less frequently [Jessome and Volmer, 2006]. The aqueous-organic
solvent provides the best conditions for zero ion suppression, while the sample matrix will
demonstrate the effect of matrix-induced ion suppression on the detector response. As ion
suppression is a phenomenon that occurs specifically during sample analysis, the analyte must
be introduced to the sample just prior to analysis in order to prohibit any confounding influences
on the analyte response from preceding steps. For this reason, equimolar concentrations of
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pre-derivatized serine was added to each sample from a common batch instead of adding non-
derivatized serine to each sample and then derivatizing each one independently. This allows us
to distinguish ion suppression from any analyte signal loss due to under-recovery during sample
preparation, such as poor derivatization efficiency or analyte decomposition.
The observed signal intensities for (S )-NIFE-D-Ser were lower in cell media relative to the solvent
by an average of 20% across all concentrations, suggesting the presence of ion suppression (Fig.
28a). However, since we added pre-derivatized serine to underivatized cell media, only the ion
suppression that is attributed to underivatized matrix components was assessed. During normal
sample preparation, other (S )-NIFE derivatives besides (S )-NIFE-DL-Ser would form which could
also contribute to ion suppression [Péter et al., 2000,Péter et al., 2002,Hess et al., 2004,Roux
et al., 2012,Bouatra et al., 2013]. Therefore, the magnitude of ion suppression measured here is
likely to be an underestimate of the total ion suppression that would normally be encountered
for routinely prepared samples. A more comprehensive way of assessing ion suppression is to
perform post-column infusion, where the (S )-NIFE derivatized cell media sample is injected
into the UPLC-MS system and (S )-NIFE-DL-Ser is continuously infused downstream of the
column using a syringe pump and "tee union" to mix with the column eﬄuent. Introducing
(S )-NIFE-DL-Ser directly into the mass spectrometer at a constant rate should produce a stable
ESI response. Where there is ionisation interference from components of the injected sample,
the ESI response will drop and allow us to pinpoint the exact chromatographic region or regions
of ion suppression. The chromatographic conditions can then be adjusted accordingly to ensure
that (S )-NIFE-DL-Ser does not elute within those ion suppressed segments.
Urine contains high concentrations of urea, which has two -NH2 groups that can potentially react
with (S )-NIFE, and therefore, provide a source of strong competitive inhibition to derivatization.
Therefore, we derivatized DL-serine in the absence and presence of large quantities of urea
to check for analyte recovery. There were no effect on the relative signal intensities of both
(S )-NIFE-D-Ser and (S )-NIFE-L-Ser in the presence of urea (data not shown). Furthermore, we
were not able to detect any urea derivatives, suggesting that urea is not derivatized by (S )-NIFE
despite its possession of -NH2 groups. The is presumably due to partial sharing of the -NH2
electron lone pairs with the carbonyl (-CO) group, which makes them chemically inert.
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Figure 28. Investigating potential sources of analyte loss. (a) The relative intensities
of (S )-NIFE-D-Ser in aqueous-organic solvent and cell media supplemented with FBS to check
for the presence of matrix-induced ion suppression (mean, n=2). (b) Change in signal intensity
of (S )-NIFE-L-Ser-d3 in solvent and cell media associated with each decrementing step of sample
preparation (mean ± s.d., n=3). S3 represents L-serine-d3 being added after sample evaporation,
whereas S1 and S2 represent the addition of L-serine-d3 at the start of sample preparation and
after acetonitrile protein precipitation, respectively. (c) A comparison of (S )-NIFE-D-Ser signals
in cell media when protein precipitated using 2 different methods (mean ± s.d., n=3). ACN,
acetonitrile; MeOH, methanol. (d) Increase in (S )-NIFE-D-Ser signal intensity when performing
derivatization with increasing concentrations of (S )-NIFE (mean ± s.d., n=3).
To interrogate whether analyte loss was occurring during sample preparation, a fixed amount
of L-serine-d3 was spiked into the solvent and cell media at different stages. There was not
much difference between the amount of the analyte recovered when spiking L-serine-d3 after
acetonitrile precipitation (S2) and at the beginning of sample preparation (S1) (Fig. 28b).
However, there was a 4 fold increase in analyte recovery when adding L-serine-d3 after the sample
evaporation step (S3) that ensues protein precipitation. There are two main potential reasons
for analyte loss during sample evaporation. First, although the temperature of the centrifugal
evaporator was set to room temperature, a considerable amount of heat was still generated by
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the spinning rotor and could contribute to thermal decomposition of samples. Second, as the
sample is gradually vaporised, the analyte may adhere to the inside walls of the tube. As a result
the surface-adhered analyte may not get reconstituted and derivatized, thus lowering the overall
yield of derivatized product. This is highly likely considering the use of 7.5 sample volumes of
acetonitrile for protein precipitation in the method proposed by Visser et al., 2011, which brings
the total volume to 875 µl (100 µl sample + 25 µl IS + 750 µl acetonitrile) prior to sample
evaporation. This is then reconstituted in a total volume of 135 µl (50 µl H2O + 35 µl sodium
tetraborate + 50 µl (S )-NIFE) for derivatization. To test this hypothesis, an alternate protein
precipitation method using ice cold methanol, which requires only 3 sample volumes bringing the
total volume to 425 µl, was used for comparison (Fig. 28c). The results showed a significant
improvement in analyte yield when using a lower volume of organic solvent, thus confirming
our hypothesis. Thoroughly vortexing the reconstituted sample to collect any surface-adhered
analyte may also help to further minimise analyte loss during this step. Methanol also appeared
to be more effective than acetonitrile for extracting proteins in cell media (based on visual
inspection of protein pellet sizes). Therefore, methanol was used as the preferential solvent in
terms of both analyte recovery and protein extraction for further cell media sample preparations.
In order to prevent kinetic resolution and allow the reaction to proceed quantitatively, it is
important to use an excess amount of CDA. Previously, it has been shown that a (S )-NIFE to
amino acid molar ratio of at least 2 is required for the reaction to proceed to completion [Péter
et al., 2000]. However, this is only true for amino acids which react with one ( S )-NIFE group.
For those which form bis derivatives (cysteine, lysine, and tyrosine), it is recommended to use
a molar ratio of 3 to ascertain a complete reaction while keeping wasteful excess CDA to a
minimum. For biological fluids, where the concentration of the desired analyte as well as other
reacting substrates is unknown and likely to vary considerably between samples, it is difficult to
determine the amount of (S )-NIFE required to achieve an excess that would allow the reaction to
proceed to completion on the basis of molar ratio calculations. Instead, analyte signal intensity
stabilisation in the complex matrix may be used as an indication of reaction completion and CDA
excess. Excess CDA may be achieved in one of two ways: increasing the CDA concentration or
diluting the sample at the cost of losing sensitivity. Since the objective was to improve sensitivity
we opted for the former option.
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20 µM D-serine was added to aqueous-organic solvent and cell media and then derivatized using
an incrementing concentration of (S)-NIFE from 0 mg/ml to 25 mg/ml. In solvent, the D-serine
intensity stabilised after 5 mg/ml; however, in cell media the intensity failed to stabilise even
after adding 25 mg/ml. This suggests that even when using 10× the (S )-NIFE concentration
proposed by Visser et al., 2011 (2.5 mg/ml), the amount of CDA is still insufficient for achieving
complete derivatization in cell media. This is presumably due to its supplementation with large
amounts of L-amino acids. Since complete derivatization is critical for quantitative analysis,
the cell media sample volume was reduced from 100 µl to 30 µl, while increasing the (S )-NIFE
concentration to 12.5 mg/ml. The end volume of the derivatized sample was adjusted accordingly
to maintain the sample dilution factor (×5), thereby preserving sensitivity.
Following the identification and remediation of a number of sources of analyte loss, the L-serine-d3
response in cell media was still approximately 40% short of the response achieved in aqueous-
organic solvent at equivalent concentrations. Although this is a considerable improvement in
comparison to the responses achieved prior optimisation (≈15% of the solvent response), there
is still a considerable matrix effect. This is presumably due to signal suppression originating
from (S )-NIFE derivatized species in the sample matrix, which was unaccounted for during our
assessment of ion suppression.
3.6 Discussion
D-amino acids are emerging as important signalling molecules in mammals, particularly in
the CNS [Fuchs et al., 2005,Ohide et al., 2011]. Alterations in their concentrations have been
implicated in the pathogenesis of several human diseases, including ALS and schizophrenia [Sasabe
et al., 2007,Madeira et al., 2008]. Therefore, research into D-amino acids as potential diagnostic
markers or therapeutic targets is justified. D-amino acids are also utilised heavily by bacteria,
such as for peptidoglycan synthesis and the regulation of biofilms [Lam et al., 2009,Kolodkin-Gal
et al., 2010]. Chiral profiling of D-amino acids may be used in conjunction with conventional
achiral methods of metabolic profiling to provide some useful insight into commensal gut bacterial
behaviour during health and disease. Although several methods exist for the determination of
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D-amino acids, several limitations, including poor sensitivity and limited metabolite coverage,
inhibit their widespread applicability.
Here we employed an existing UPLC-MS method involving the use of the CDA (S )-NIFE, which
has previously been reported to differentiate all chiral proteinogenic amino acids in biofluids with
excellent sensitivity [Visser et al., 2011]. The method was adapted for use on the Q-Tof Ultima
API instrument. Upon initial evaluation, we found that 17 out of the 19 chiral proteinogenic
amino acids can be differentiated with baseline separation using a basic mobile phase gradient
elution profile. The remaining two amino acids, aspartate and glutamate, can be completely
resolved using an alternative acidic mobile phase gradient elution profile. Unfortunately, despite
complete separation of (S )-NIFE-D-Phe and (S )-NIFE-L-Phe, due to the formation of these
products during fragmentation of the urea dimer by-product that is produced during excess
(S)-NIFE decomposition under basic conditions, both compounds cannot be reliably quantified
in unknown biological samples. Visser et al., 2011 reported the % D-isomer relative to the DL
total for each amino acid in human biofluids, including phenylalanine [Visser et al., 2011]. This
suggests that they quantified (S )-NIFE-D-Phe and (S )-NIFE-L-Phe, despite their confounding
origination from the urea dimer by-product. Therefore, it is likely that their measurements of
these two compounds, and consequently, their calculation of % D-phenylalanine are inaccurate.
Mass spectral analysis revealed a sizeable formation of [M+Na]+ species. [M+Na]+ represent
the most commonly observed metal adduct ions in ESI+ analyses, followed by [M+K]+ [Kruve
et al., 2013]. By selecting the masses of both [M+H]+ and [M+Na]+ for the extraction of
chromatograms, we were able to substantially increase analyte signal intensity. The most
common source of metallic sample contamination is laboratory glassware, whereby various salts
are used during the manufacturing process and can leach out from the glass into the aqueous
sample [Goodhew and Gulley, 1974]. The other source of [M+Na]+ is from high endogenous
concentrations of salt in the biological samples themselves. One commonly employed strategy to
reduce the population of these ions is lowering the pH of the mobile phase to provide an excess of
protons relative to metal ions to predominantly form [M+H]+. However, for this particular assay
using an acidic mobile phase is associated with considerably lower sensitivity in comparison to a
basic mobile phase. [M+Na]+ and other metal adducts have been used for reliable quantification
of analytes in previous studies [Christians et al., 2000,Zhao et al., 2000,Frison-Norrie and Sporns,
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2002]. However, high variability in salt concentrations between clinical samples, such as urine,
may lead to quantifications based solely on metal adducts yielding inaccurate results. Therefore,
it is advisable to monitor all other relatively abundant product ion species in conjugation with
[M+Na]+ as well.
D-serine was used as our methodological exemplar to perform calibration curves in aqueous-
organic solvent, cell media, and urine. These revealed a considerable matrix effect which
drastically reduced assay sensitivity. Good assay sensitivity is essential for adequate detection,
particularly in the context of measuring D-amino acids in biofluids due to their low concentrations.
Therefore, we sought to improve sensitivity by investigating various potential sources of analyte
loss. These investigations were performed using cell media, since it was the matrix in which the
analyte signal was most diminished.
We first checked for the presence of ion suppression. After injecting the sample into the UPLC-
MS system, sample molecules are initially in solution in the mobile phase and the ESI source
produces charged droplets. There are a number of possible fates for the analyte thereafter. First,
the analyte may precipitate from solution and deposit as a solid compound or co-precipitate with
other non-volatile sample compounds. Second, if the analyte remains in the liquid stream, it may
collect on the interface plate of the mass spectrometer. Third, the analyte may be transferred
to the gas phase as a neutral gas molecule, which is then lost. Analytes that do enter the gas
phase as an ion or charged solvent cluster may lose their charge via neutralisation reactions,
charge stripping, or charge transfer to other gas phase species. Fourth, the ion or charged solvent
cluster may reach the declustering region of the API source, where the analyte may be observed
in the mass spectrometer. Any mechanism that inhibits the analyte’s pathway to reaching the
mass spectrometer can cause ion suppression [King et al., 2000]. ESI droplets have a finite
amount of space and can only hold a limited amount of charge on their surface. As biological
samples contain large amounts of endogenous compounds with potentially very high basicities
and surface activities to compete with the analyte for charge or space on the surface of ESI
droplets, ion suppression is common with these samples. Ion suppression in the gas phase is far
less common, but may occur to some extent as a result of deprotonating reactions with high
basicity molecules, akin to ion suppression with APCI. In general, the two most effective ways to
reduce ion suppression are improving chromatographic selectivity and sample preparation. The
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easiest of the two is adjusting the chromatographic conditions to prevent analyte peaks from
eluting in regions of ion suppression, which are identified by performing post-column infusion.
Other strategies for minimising ion suppression include using APCI (typically associated with
lower ion suppression than ESI), increasing sample dilution, and decreasing sample injection
volume [Jessome and Volmer, 2006]. However, sample dilution and reduced injection volume are
not viable options for trace analysis, such as that of D-amino acids in biofluids. Our investigation
did not reveal massive ion suppression of (S )-NIFE-D-Ser in cell media; therefore, no adjustments
were made to the chromatographic conditions. However, the extent of ion suppression may have
been underestimated as we only assessed the influence of the underivatized matrix on the analyte
signal and failed to assess that of the (S )-NIFE derivatized matrix.
An investigation of the sample preparation protocol revealed two main sources of analyte loss,
corresponding to the sample evaporation and (S)-NIFE derivatization steps. During sample
evaporation, there is a considerable amount of analyte adherance to the walls of the sample tube.
As a result, this portion of analytes is not reconstituted and derivatized. During derivatization,
a complete reaction is essential to prevent kinetic resolution and allow accurate quantification.
However, we found that the concentration of (S )-NIFE proposed by Visser et al., 2011 was
insufficient for complete derivatization of cell media samples, leading to suboptimal yields of
the diastereomeric derivatives. Consequently, the sample preparation protocol was amended to
counteract these issues and improve assay sensitivity. Although analyte recovery in cell media was
improved considerably following assay optimisation, absolute recoveries were still approximately
60%. However, according to FDA guidelines for the development of bioanlytical methods, poor
analyte recovery does not invalidate a method providing there is use of suitable internal standards
for the extraction of precise and reproducible measurements [Food and Administration, 2001].
In conclusion, an existing UPLC-MS assay for chiral differentiation and quantification of
proteinogenic amino acids was adapted for the Q-Tof Ultima API and optimised for chiral
profiling in cell media. The optimisation resulted in increased sensitivity making the assay
ideal for the trace analysis of D-amino acids in complex matrices. The method has several
advantages over existing chiral profiling methods for amino acids in terms of metabolite coverage,
simplicity of sample preparation, resolution, and sensitivity. Importantly, it does not suffer
from unreliability due to chiral impurity of the CDA or spontaneous racemisation of analytes.
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Therefore, this method may provide a useful tool for exploring chiral measures of the metabolome.
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Chapter4
Enantioselective analysis of amino acid
neurotransmitters in a amyotrophic lateral
sclerosis cell model
4.1 Overview
ALS, also known as motor neuron disease (MND), is characterised by the progressive loss of
motor neurons causing deterioration of motor functions. Mutations of the superoxide dismutase
1 (SOD1) gene have been linked to familial ALS; however, the underlying molecular mechanisms
by which SOD1 mutations cause disease remain unclear. Familial ALS is similar to sporadic ALS
in the pathological and clinical contexts; therefore, mutant SOD1-based animal and cell models
are commonly used in ALS studies. One of the predominating theories behind ALS pathogenesis
is overt stimulation of the NMDA receptor, which binds to the neurotransmitter L-glutamate
and is responsible for post-synaptic excitatory neurotransmission in motor neurons. D-serine and
glycine are coagonists of the NMDA receptor. D-serine, the more potent of the two coagonists,
has been implicated in increased glutamatergic neurotransmission, neuronal excitotoxicity, and
ultimately motor neuronal cell death. Previously, we optimised an existing enantioselective
UPLC-MS assay for the chiral analysis of a small panel of proteinogenic amino acids in cell
media. ALS is a pathological scenario where enantioselective analysis is imperative; therefore,
we sought to apply the assay to investigate the expression of stereospecific neurotransmitters by
mutant SOD1 expressing neural cell lines as part of an in vitro ALS study. This sample set was
used to assess the reliability of the assay to perform relative quantification of a targeted panel of
analytes and ability to provide insight to generate informed hypotheses.
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4.2 Aim and objectives
4.2.1 Aim
Evaluate the reliability of the optimised enantioselective UPLC-MS assay for relative quantifica-
tion of a targeted panel of amino acids in a biologically relevant sample set, and its potential to
provide useful information relating to stereospecific measures.
4.2.2 Objectives
• Apply the assay for relative quantification of stereospecific amino acid neurotransmitters
in cell media collected from an in vitro ALS pilot study.
• Evaluate the robustness and reliability of the UPLC-MS assay for chiral profiling in cell
media.
• Interpret the pilot study data to understand the relative contributions of neural cell types
to the extracellular amino acid pool and intercellular crosstalk.
• Determine the influence of SOD1 mutation on the extracellular concentrations of amino
acid neurotransmitters, particularly D-serine.
• Derive useful hypotheses to direct further in vitro studies into the pathophysiological
mechanisms driving ALS.
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4.3 Introduction
4.3.1 Mutant SOD1 expression and mechanisms of induced toxicity in ALS
ALS is a degenerative motor neuronal disease resulting in progressive muscular paralysis due to
a combination of voluntary muscle weakness, atrophy, and spasticity [Turner and Talbot, 2008].
Pathologically the disease is characterised by combined selective loss of upper and lower motor
neurons projecting from the spinal cord, brainstem, and cortex, the appearance of inclusion
bodies in remaining neuronal cells and astrocytes, and gliosis localised around dying neurons in
the ventral horns of the spinal cord [Sasabe et al., 2007,Turner and Talbot, 2008]. Approximately
90% of ALS cases are sporadic with unknown aetiology, while 10% are familial and for which 6
causative genes have been identified [Rosen et al., 1993,Gros-Louis et al., 2006]. As the cause
for most ALS cases are unknown and the clinical course is highly variable, a multitude of factors
are likely to contribute towards disease aetiology. Among the familial cases, 20% are caused
by a dominantly inherited mutation of SOD1 [Rosen et al., 1993]. SOD1 is an enzyme that
is primarily expressed in the cytosol, but also in the mitochondrial space. It catalyses the
conversion of superoxide, a toxic by-product of mitochondrial oxidative phosphorylation, to
water and hydrogen peroxide [Okado-Matsumoto and Fridovich, 2001,Bruijn et al., 2004]. Due
to similarities in the pathological and clinical scenarios of sporadic and familial ALS, animal and
cell models based on mutant SOD1 have been developed in an attempt to understand disease
mechanisms [Bruijn et al., 2004].
The mechanisms by which SOD1 leads to ALS remains unclear; however, it is well established that
SOD1-mediated toxicity is due to a toxic gain in function, which may result from mutation-induced
protein conformational changes that alter its biochemical and biophysical properties [Bruijn
et al., 2004,Gurney et al., 1994]. This is evidenced by the observation of an apparent lack of
motor abnormalities in SOD1 knockout mice [Reaume et al., 1996]. However, SOD1 knockout
mice have been associated with the occurrence of chronic peripheral axonopathy and denervation
muscular atrophy [Flood et al., 1999,Shefner et al., 1999]. Therefore, it seems that SOD1 loss of
function cannot be eliminated completely from the pathological mechanisms at play in SOD1
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mutants. The loss of function may have a part to play in relation to other additional functions of
SOD1, including peroxidation, nitration, copper buffering, phophatase activation, thiol oxidation,
zinc homeostasis, and immunomodulation [Yim et al., 1990,Turner and Talbot, 2008,Culotta
et al., 1995,Winterbourn et al., 2002,Wei et al., 2001,Marikovsky et al., 2003]. These functions
are not all routinely assessed across SOD1 mutants to completely rule out the contribution of
SOD1 loss of function towards ALS pathogenesis. Wild-type SOD1 over expressing mice are
also associated with some prolonged motor neuronal degeneration, but do not succumb to ALS.
Therefore, there seems to be a biphasic effect in SOD1 expression, whereby the low and high
extremes of expression are potentially pro-oxidative and neurotoxic, and intermediary expression
of SOD1 is essential for long-term sustenance of healthy motor neurons [Xing et al., 2002].
Although the biochemical reasons underlying selective mutant SOD1-induced toxicity in motor
neurons remain elusive, there are two prevailing theories. The first is copper-catalysed oxidative
stress, and the second is protein misfolding and oligomerisation-induced toxicity. The first
theory suggests that SOD1 mutations weaken catalytic copper binding and buffering; thus
resulting in oxidative stress. Previously, it was reported that transgenic mice over expressing
mutant SOD1G93A (conversion of glycine to alanine at codon 93) and the copper chaperone
for SOD1 (CCS) succumb to a considerably accelerated form of ALS in comparison to those
only over expressing the wild-type (SOD1WT) [Son et al., 2007]. Abnormal protein aggregation,
ubiquitination, and deposition in the CNS are obvious features of ALS. SOD1 positive inclusion
bodies have been identified selectively concentrated in affected neuromuscular tissues, which
has lead to the hypothesis of SOD1 aggregation-induced toxicity [Bruijn et al., 1997,Johnston
et al., 2000]. To date, there is currently a lack of evidence to suggest a direct contribution of
SOD1 protein aggregates to neurodegeneration in vivo. Consequently, there is currently much
speculation as to how these aggregates are formed, and whether they are causative factors or
simply a secondary pathological outcome of a primary insult.
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4.3.2 Glutamatergic excitotoxicity in ALS
The inability to identify a common biochemical feature for all SOD1 mutations using structure-
function studies has led to most transgenic animal model investigations being focused on
disease mechanisms which operate downstream of mutant SOD1-induced toxicity, including
glutamate-mediated excitotoxicity, axonal transport defects, dysfunctional mitochondria, and
apoptosis [van Cutsem et al., 2005]. Here we will focus on glutamate-mediated excitotoxicity, one
of the predominating theories behind ALS aetiology. During glutamatergic neurotransmission,
the pre-synaptic neuron releases L-glutamate, which activates ionotropic glutamate receptors on
the post-synaptic neuron. This triggers an influx of Na+ and Ca2+ ions into the post-synaptic cell,
which causes depolarisation and the generation of an action potential (Fig. 29). Excitotoxicity
is neuronal degeneration caused by over stimulation of glutamate receptors [Van Den Bosch
et al., 2006]. Mutant SOD1 expression is well correlated to an increase in glutamatergic
neurotransmission, leading to the proposal that impaired glutamate uptake is a principal cause
of motor neuronal cell death in ALS [van Cutsem et al., 2005,Bruijn et al., 2004]. Elevated
levels of glutamate were observed in the cortical extracellular fluid of transgenic mice expressing
human SODG93A and CSF of 40% of sporadic ALS patients in a large cohort [Alexander et al.,
2000,Spreux-Varoquaux et al., 2002]. Furthermore, transgenic mice over expressing SOD1G93A
experienced focal loss of excitatory amino acid transporter 2 (EAAT2, also known as GLT-1
for glutamate transporter-1), a glutamate transporter expressed by astrocytes, which coincided
with regions of gliosis [Howland et al., 2002]. These evidences suggest an important role for
glutamatergic neurotransmission in the pathogenesis of both inherited and sporadic ALS.
There are three classes of ionotropic glutamate receptors: NMDA receptors, α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) receptors, and kainate receptors [van Cutsem et al.,
2005]. Functionally, AMPA receptors are the most important for eliciting fast excitatory
neurotransmission. However, NMDA receptors are involved in the late component of excitatory
neurotransmission [Van Den Bosch et al., 2006]. Both are recognised to be important with
respect to excitotoxic neuronal cell death in ALS. AMPA receptors play a central role in the
mediation of glutamate excitotoxicity in sporadic ALS. This is due to a defect in the post-
transcriptional modification of messenger RNA (mRNA) encoding its GluR2 subunit [Kawahara
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et al., 2004]. The defect results in increased Ca2+ influx, which triggers the release of glutamate
into the synaptic cleft [Kwak and Kawahara, 2005]. With respect to NMDA receptor-mediated
cyctotoxicity, the use of a non-competitive NMDA receptor antagonist (memantine) has been
shown to delay the progression of disease and prolong survival in ALS mice over expressing
SOD1G93A [Wang and Zhang, 2005]. Irrespective of the post-synaptic glutamate receptor,
the principal cause of excitotoxicity is an increase in Ca2+ influx. How this results in the
induction of neuronal cell death is not yet fully understood, although there are several theories,
including activation of catabolic enzymes, such as proteases and endonucleases, and promotion
of mitochondrial dysfunction to cause the generation of reactive oxygen species (ROS) [Van
Den Bosch et al., 2006]. From here on, we divert our attention specifically towards NMDA
receptor-mediated glutamatergic excitotoxicity in ALS.
4.3.3 The role of D-serine in glutamatergic neurotransmission and ALS
NMDA receptors are heterotrimeric ion channels comprised of at least one NR1 and two NR2
subunits. The NR1 subunit is critical to form a functional receptor, whereas the NR2 subunits, of
which NR2A is the most commonly expressed in the adult brain, are responsible for modulating
the electrophysiological properties of the receptor, such as Ca2+ permeability [Paoletti and
Neyton, 2007,Simões et al., 2008]. The activation of NMDA receptors essentially requires binding
of a coagonist to the glycine modulatory site on the NR1 subunit, which is situated in close
proximity to the channel opening [Leeson and Iversen, 1994]. D-serine has been reported to be
a more potent coagonist at this site than glycine itself [Shleper et al., 2005]. Not only does
D-serine cause receptor activation, but also increased affinity of the receptor for L-glutamate,
reduced desensitisation, and increased receptor turnover through internalisation [Crow et al.,
2012]. D-serine is produced endogenously from L-serine by the enzyme serine racemase (SR).
This enzyme was primarily identified in glial cells [Wolosker et al., 1999], of which astrocytes are
the most abundant in the CNS and have the function of controlling extracellular homeostasis.
More recently, SR was also discovered in neuronal cells challenging the original notion that
astrocytes are the sole source of D-serine. In fact the levels of SR expression in neurons were
shown to be comparable, if not more, than the levels expressed in astrocytes [Kartvelishvily et al.,
2006,Yoshikawa et al., 2007,Benneyworth et al., 2012]. Despite this, D-serine is found enriched
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Figure 29. Astrocyte-neuron interactions during glutamatergic neurotransmission.
Astrocytes, but not neurons, express the enzyme 3-phosphoglycerate dehydrogenase, which
catalyses the production of L-serine from 3-phosphoglycerate (3-PG). L-serine is released from
astrocytes through ASCT1/2 and shuttled across to neurons, where it is taken up by ASCT1/2
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and asc-1 transporters. L-serine fuels the production of D-serine in neurons by serine racemase
(SR), which is then released at the pre-synaptic membrane through ASCT1/2 and asc-1 trans-
porters in response to depolarisation. Intracellular cytosolic concentrations ofD-serine are kept
low by SR and D-amino acid oxidase (DAAO), which catalyse its degradation into pyruvate and
ammonia. Astrocytes may also release D-serine by exocytosis in response to the activation of
receptors in its plasma membrane to cause an increase in cytosolic Ca2+ or through volume-
regulated anion channels (VRAC). In the synaptic cleft, D-serine binds to NMDA receptors with
GluN2A subunits on the post-synaptic neuron in conjunction with glutamate to cause receptor
activation, the influx of cations, and an action potential. Extracellular D-serine is then taken up
by astrocytes through ASCT1/2. NMDA receptors with the GluN2B subunit preferentially bind
to glycine. Glycine is produced from L-serine and released by neurons through asc-1 transporters.
It is then efficiently cleared from the synaptic cleft by glycine transporters (GlyT). L-Glutamate is
produced by aminotransferase or glutamate dehydrogenase from α-ketogluterate or glutaminase
from L-glutamine. It is accumulated inside vesicles and released from the pre-synaptic neuron by
exocytosis in response to depolarisation. L-Glutamate is then cleared from the synaptic cleft
by excitatory amino acid transporters (EAAT) 1/2 expressed by astrocytes, and EAAT1 and
excitatory amino acid carrier 1 (EAAC1) expressed by neurons. L-Glutamine is synthesised from
L-glutamate by glutamine synthetase, which is exclusively expressed in astrocytes. Glutamine is
then exported by system N (SN1)-mediated transport and transferred to neurons via system
A (sodium-coupled amino acid transporter/amino acid transporter A, SAT/ATA)-mediated
transport.
mainly in astrocytes [Schell et al., 1995,Kartvelishvily et al., 2006,Williams et al., 2006]. This
can be explained by the paradoxic function of SR to also catalyse the degradation of D-serine
through α,β-elimination of water to produce aminoacrylate, which then spontaneously hydrolyses
to produce pyruvate and ammonia. Furthermore, the efficiency of α,β-eliminase activity is
surprisingly high. Astrocytes are able to physically isolate D-serine from SR intracellularly by
vesicular compartmentalisation. However, neurons lack this capacity and resort to releasing
D-serine into the extracellular space. This unorthodox property of SR thus provides a mechanistic
explanation for the observation of low intracellular levels of D-serine in neurons in comparison
to astrocytes despite having higher SR expression [Wolosker, 2011]. The activation of SR
α,β-eliminase activity requires high intracellular levels of D-serine, suggesting that it provides
a mechanism for regulating intracellular D-serine levels [Foltyn et al., 2005]. The other well
established mode of D-serine degradation is via D-amino acid oxidase (DAAO), a peroxysomal
flavoprotein expressed in both neurons and astrocytes, which irreversibly deaminates D-serine to
form pyruvate [Shleper et al., 2005,Sacchi et al., 2012].
With respect to D-serine transport, its release from astrocytes is mainly dependent on Ca2+-
regulated exocytosis [Mothet et al., 2005] (Fig. 29). An increase in Ca2+ can be triggered through
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various molecular entities on the endoplasmic reticulum (ER) and plasma membrane [Martineau
et al., 2014]. Astrocytes can also release D-serine via non-exocytic means, including volume-
regulated anion channels (VRACs) and alanine-serine-cysteine transporters (ASCTs). The
activation of AMPA receptors by glutamate can cause astrocyte swelling due to the influx
of anions, such as Na+ and Ca2+, which can then activate VRACs to mediate the release of
D-serine [Rosenberg et al., 2010]. ASCT is a Na+-dependent antiporter, which couples the eﬄux
of D-serine to the influx of small neutral amino acids, such as L-serine and L-alanine [Ribeiro et al.,
2002]. ASCT1 and ASCT2 subtypes are expressed on both astrocytes and neurons [Yamamoto
et al., 2004, Shao et al., 2009]. They have stereoselectivity for L-amino acids over D-amino
acids with the highest affinity for L-alanine, L-serine, L-cysteine, and L-threonine. ASCT2 also
transports L-glutamine and L-asparagine with high affinity [Utsunomiya-Tate et al., 1996,Arriza
et al., 1993]. Despite their low affinity for D-serine, they also appear to be a predominant system
for the uptake of D-serine in astrocytes, thus regulating its extracellular concentration [Ribeiro
et al., 2002,Shao et al., 2009,Maucler et al., 2013]. The release of D-serine as a neurotransmitter
by pre-synaptic neurons is dependent on ASCT1, ASCT2, and the alanine-serine-cysteine-1
(asc-1) transporter. Asc-1 transporters are Na+-independent antiporters that have been shown
to mediate the release of both D-serine and glycine [Rosenberg et al., 2013,Rosenberg et al.,
2010]. Asc-1 transporters catalyse hetero-exchange of D-serine for glycine, L-alanine, L-serine,
L-cysetine, or L-threonine. Contrary to ASCTs, asc-1 transporters have low stereospecificity
and can transport D-serine with high affinity [Fukasawa et al., 2000,Matsuo et al., 2004,Safory
et al., 2015,Martineau et al., 2014]. Although asc-1 transporters can transport glycine, they
are predicted to play only a minor role in the modulation if extracellular glycine levels due to
the presence of more specific glycine transporters (GlyT). It is not yet clear how ASCTs and
asc-1 transporters work in conjunction to limit extracellularD-serine diffusion and constrain its
occupancy of NMDA receptors [Martineau et al., 2014].
There is considerable evidence implicating D-serine in NMDA receptor-mediated excitotoxicity
in ALS. Primary spinal cord neurons of ALS mice showed increased vulnerability to NMDA
receptor-mediated toxicity in a D-serine-dependent manner. Furthermore, the levels of D-serine
and SR expression in the spinal cords of ALS mice were progressively elevated with disease
progression, particularly in glial cells [Sasabe et al., 2007]. Therefore, a high extracellular
concentration of D-serine has been implicated as a novel mechanism underlying motor neuronal
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cell death in ALS. In the present study, we investigated the levels of D-serine along with other
mechanistically relevant amino acids in vitro using the UPLC-MS assay for enantioselective
amino acid quantification. Isolated cultures of the mouse motor neuron-like cell line NSC34 and
cocultures of NSC34 with astrocytes were used to determine the relative contributions of both
neural cell types to the extracellular pool of amino acid neurotransmitters.
4.4 Experimental methods
4.4.1 Materials
Cell media samples from isolated cultures of neuronal cells and cocultures of astrocytes and
neurons for the ALS in vitro work were kindly provided by H. Keun and C. Bendotti.
4.4.2 Cell culture
NSC34 is a hybrid cell line (a fusion of mouse neuroblastoma N18TG2 with mouse embryonic
spinal cord motor neurons) which exhibits motor neuronal features and is a well characterised
in vitro model for the study of motor neuron biology. Untransfected NSC34 and monoclonal
NSC34 cell lines stably expressing human SOD1WT and human SOD1G93A were grown in high
glucose DMEM supplemented with 5% heat inactivated FBS, 1 mM glutamine, 1 mM pyruvate,
and antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin) at 37 ◦C and 5% CO2. Cell
media samples were collected after 22 h of incubation. The SOD1WT and SOD1G93A expressing
cell lines were kept in selection by adding 0.5 mg/ml geneticin. All cell lines were cultured
simultaneously and had passage < 20 to limit any potential affects of senescence.
For the coculture experiments, different combinations of non-transgenic NSC34 and transgenic
SOD1WT and SOD1G93A expressing neuronal cells were cultured with mouse non-transgenic and
transgenic human SOD1WT and human SOD1G93A over expressing astrocytes. All cocultures
were performed in parallel in neurobasal medium supplemented with heat inactivated horse
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serum plus other supplements. Cell media samples were collected after 6 days of incubation at
37 ◦C and 5% CO2.
4.4.3 Sample preparation
All cell media samples were prepared using the protocol described previously (Section 3.3.3).
A method blank and calibration standards in aqueous-organic solvent were also prepared.
4.4.4 Data analysis
Smoothing and peak integration of extracted chromatograms were performed using Waters
MassLynx v4.1 software. All integrations were normalised to the IS (L-serine-d3). The mean ±
s.d. was calculated for each set of biological replicates. Statistical significance was tested using
one way ANOVA followed by Bonferroni corrected post-hoc two tailed t-tests assuming equal
variance and Bonferoni corrected linear regressions using a significance level of 5% (p < 0.05).
4.5 Results
A pilot study was performed using cell media samples collected from an ALS in vitro study to
test the performance of the optimised enantioselective UPLC-MS assay for relative quantification
of a selective panel of amino acids. A well characterised cell model of familial ALS, the mouse
motor neuron-like NSC34 cell line with stable overexpression of human SOD1WT or SOD1G93A
(WT and G93A, respectively), was studied in isolation and in coculture experiments with non-
transgenic (nTg) and transgenic astrocytes. WT cells were used in this experiment in conjunction
with nTg cells due to particular concerns regarding the effect of oncogenic transformation on
cellular metabolic profiles. The inclusion of a WT control helps to limit the impact of the
neuroblastoma phenotype during the interpretation of results. However, recent deep proteomic
analysis comparing NSC34 to primary motor neurons has indicated the conservation of proteins
and their relative abundance in common metabolic and house-keeping pathways. This suggests
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that the NSC34 cell line may prove a useful representative of motor neurons for metabolic
studies [Hornburg et al., 2014].
The cell media from these cell cultures were subjected to targeted MS analysis to investigate
the effect of SOD1G93A over expression on extracellular D-serine levels. In addition, we also
profiled other biologically relevant amino acids, namely L-serine, DL-glutamate, L-glutamine, and
glycine, to aid data interpretation. Since only the basic mobile phase gradient elution profile
was run for this sample set, the enantiomers of glutamate were not resolved, and therefore, not
quantified independently. However, based on the fact that mammals mainly synthesise L-amino
acids, changes in (S )-NIFE-Glu were interpreted as changes in extracellular L-glutamate on the
assumption that most, if not all, of the (S )-NIFE-Glu signal is attributed to (S )-NIFE-L-Glu.
A consistent internal calibration response was obtained across samples, which indicates there
was no fluctuation in instrumental performance during analysis. The response of less abundant
[M+Na]+ was measured for (S )-NIFE-L-Ser, (S )-NIFE-L-Gln, and (S )-NIFE-Gly instead of
[M+H]+ in an attempt to constrain the response to the linear range of detection given the presence
of large amounts of these amino acids in cell media. Following the selection of [M+Na]+, all
measured signal intensities of (S )-NIFE-L-Ser and (S )-NIFE-Gly were within the linear range of
quantification. However, (S )-NIFE-L-Gln signals still remained saturated, but only for cocultures
where the signal intensities were several folds higher than those observed for neuronal cells alone.
No other adducts were formed in sufficient abundance to prove useful for quantification. Despite
(S )-NIFE-L-Gln signal saturation, relative quantification of L-glutamine was still performed,
although it is likely to result in less data variability, and consequently, minimisation of any
differences between sample groups. The acquired UPLC-MS data representing DL-glutamate
and L-glutamine (despite the non-linearity of (S )-NIFE-L-Gln responses for cocultures) were
consistent with previously acquired 1H NMR data for the same sample set, thus confirming
reliability of the UPLC-MS data [Valbuena et al., 2015].
A major drawback of this present study is the lack of cell viability data to normalise measured
amino acid levels to cell numbers. To rule out cell viability as a causal factor for observed amino
acid profiles, relative metabolite ratios, which are independent of cell numbers, were calculated
to strengthen the reliability of data interpretation.
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4.5.1 Isolated cultures of neuronal cells
The isolated cultures of neuronal cells were associated with a small, non-significant concentrating
effect on the cell media during incubation due to evaporation, as evidenced by a general increase
in amino acid concentrations between collections at 0 h and 22 h in the absence of cells (Fig.
30). Therefore, net changes in amino acids will be described in relation to the 22 hr collection.
D-serine is produced in neuronal cells by the racemisation of L-serine catalysed by SR [Wolosker,
2011, Martineau et al., 2014]. We observed a net, albeit non-significant, decrease in (S )-
NIFE-D-Ser for all neuronal cell lines with no significant differences between cell lines (Fig.
30a). This apparent lack of D-serine production may be explained by the inherent neuronal
metabolic phenotype and SR regulation mechanisms. Unlike astrocytes, neuronal cells are
heavily reliant on an external source of L-serine because of their lack of 3-phosphoglycerate
dehydrogenase expression, which is one of the enzymes involved in the biosynthesis of L-serine
from 3-phosphoglycerate [Yamasaki et al., 2001]. Consistent with this notion, (S )-NIFE-L-Ser
signals were significantly diminished for all neuronal cell lines. With a lack of de novo L-serine
biosynthesis and a finite extracellular supply of it from the cell media, there may have been
an insufficient supply of L-serine to meet the demands of both high SR activity and normal
protein synthesis simultaneously. As protein synthesis is critical for cell survival, this will take
precedence over SR-mediated D-serine production.
Previous work on these neuronal cell lines by Valbuena et al., 2015 using 13C-labelled glucose
has shown that there is significant 13C enrichment of serine. This suggests de novo synthesis of L-
serine by NSC34 cells under serum deprived conditions [Valbuena et al., 2015]. As Valbuena et al.,
2015 intentionally used deprived conditions to subject the cells to oxidative and metabolic stress,
their findings cannot be used to draw deductions on the results we obtained. Nevertheless, their
results show that NSC34 cells do express 3-phosphoglycerate dehydrogenase to achieve de novo
L-serine synthesis, unlike primary neuronal cells. This may be attributed to the neuroblastoma
phenotypic traits of NSC34 cells, and may represent one of the ways in which these cells are a
misrepresentation of primary motor neurons. An alternative hypothesis for the low extracellular
D-serine concentrations we observed for the NSC34 cell cultures is low D-serine eﬄux due to
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limited hetero-exchange antiporter activity. As neuronal cells lack the ability to isolate D-serine
from the cytosol, the D-serine will be subjected to degradation by DAAO and SR. Another
hypothesis for low D-serine levels is negative SR regulation. SR is subject to a number of
regulatory mechanisms, including interacting proteins, translocation to the plasma membrane,
post-translational modifications, and degradation [Wolosker, 2011]. For instance, SR interacts
with protein interacting with C-kinase 1 (PICK1) which directs protein kinase C (PKC) to
specific targets for phosphorylation. SR phosphorylation is correlated with reduced L-serine
racemisation [Vargas-Lopes et al., 2011].
(S )-NIFE-L-Ser was significantly lower for NSC34 relative to WT and G93A (p = 0.028 and
p = 0.032, respectively), suggesting increased cellular uptake. The (S )-NIFE-D-Ser to (S )-NIFE-
L-Ser ratios were significantly higher for G93A relative to WT (p = 0.048). This may suggest
that SOD1 is involved in the regulation of extracellular serine, where SOD1G93A expression is in
favour of higher D-serine to L-serine ratios.
L-Glutamate synthesis in neurons can occur either via de novo synthesis from α-ketogluterate,
a product of the tricarboxylic acid (TCA) cycle, or the glutaminolytic pathway following the
influx of L-glutamine from the extracellular space. Its transport to and from neuronal cells is
regulated by the glutamate transporters EAAT1 (GLAST, glutamate/aspartate transporter) and
EAAC1 (EAAT3) and exocytosis, respectively. (S )-NIFE-Glu signals were found significantly
increased in the cell media for all neuronal cell lines, suggesting a net eﬄux of L-glutamate
(Fig. 30b). This was most prominent for NSC34, where signals were found to exceed those of
G93A and WT by 60.8% (p = 0.017) and 71.0% (p = 0.012), respectively. These differences
persisted after calculating the (S )-NIFE-Glu to (S )-NIFE-L-Gln ratios (p = 0.009 and p = 0.012,
respectively). This suggests that the overexpression of SOD1 is associated with reduced synthesis
and/or exocytosis or increased reuptake of glutamate. The overexpression of SOD1G93A was
associated with significantly higher (S )-NIFE-Glu signals (+26.1%, p = 0.005) and (S )-NIFE-Glu
to (S )-NIFE-L-Gln ratios (p=0.001) relative to SOD1WT overexpression. This suggests that
SOD1G93A overexpression promotes extracellular accumulation of glutamate.
As with L-serine, neuronal cells principally rely on the provision of L-glutamine from an external
source because of their inability to express glutamine synthetase, which converts L-glutamate
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Figure 30. Amino acid neurotransmitter profiles of neuronal cell culture media.
Relative data representing (a) (S )-NIFE-D-Ser, (S )-NIFE-L-Ser, and (S )-NIFE-D-Ser to (S )-
NIFE-L-Ser ratio, (b) (S )-NIFE-Glu, (S )-NIFE-L-Gln, and (S )-NIFE-Glu to (S )-NIFE-L-Gln
ratio, (c) (S )-NIFE-Gly and (S )-NIFE-Gly to (S )-NIFE-L-Ser ratio following derivatization
of cell media from mouse neuronal cells. The data was normalised to the IS (L-serine-d3) and
represents the mean of two biological replicates (n=2). Statistical significance was assessed for
each analyte by one way ANOVA and Bonferroni corrected post hoc t-tests. 0hrs, cell media
with no cells before incubation; 22hrs, cell media with no cells after 22hrs of incubation; NSC34,
non-transfected neural cell; WT, normal human SOD1 overexpressing neural cell; G93A, mutant
human SOD1 overexpressing neural cell. ∗, p < 0.05; ∗∗, p < 0.01; ∗ ∗ ∗, p < 0.001.
to L-glutamine [Bröer and Brookes, 2001]. Therefore, as expected (S )-NIFE-L-Gln signals
were significantly reduced in the cell media for all neuronal cell lines (Fig. 30b). Significant
differences were also observed between cell lines, where both WT and G93A were associated
with higher (S )-NIFE-L-Gln signal intensities than NSC34 by 5.33 fold (p = 0.023) and 2.12
fold (p = 0.015), respectively. Overall, (S )-NIFE-L-Gln was found to be inversely proportional
to (S )-NIFE-Glu (r = −0.768, adjusted R2 = 0.487, p = 0.011). This is expected due to
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their inherent metabolic linkage via the glutaminolytic pathway. These results suggest that
the overexpression of SOD1 is associated with reduced L-glutamine uptake and/or intracellular
glutaminolysis. The uptake of glutamine was more pronounced for SOD1G93A overexpressing
cells relative to those overexpressing SOD1WT (p = 0.039), which suggests that the association
of SOD1G93A with higher extracellular levels L-glutamate is driven by glutaminolysis.
Like D-serine, glycine is also a coagonist of NMDA receptors [Nong et al., 2003], albeit a less
potent one [Berger et al., 1998]. We observed non-significant increases in (S )-NIFE-Gly for all
neuronal cell lines (Fig. 30c). The extracellular availability of glycine is determined by highly
efficient glycine transporters (GlyT1 and GlyT2) and the asc-1 transporter which mediates the
hetero-exchange of glycine for small neutral amino acids, including L-serine [Eulenburg et al.,
2005,Rosenberg et al., 2013,Fukasawa et al., 2000]. Therefore, a decrease in extracellular L-serine
with a concomitant increase in extracellular glycine may be a sign of high asc-1 transporter
activity. The production of glycine is mainly catalysed by a one step reversible reaction from
L-serine by the enzyme serine hydroxymethyltransferase [Stover et al., 1997]. An increase in
extracellular glycine and a decrease in extracellularD-serine may suggest cellular preference for
L-serine metabolism to glycine under the given conditions. Although there were no apparent
differences in (S)-NIFE-Gly between cell lines, both WT and G93A were associated with lower
(S )-NIFE-Gly to (S )-NIFE-L-Ser ratios relative to NSC34, with the ratio for G93A being
slightly higher than WT. The metabolite ratios for glycine are consistent with those for D-serine
and DL-glutamate, and suggests that neuronal expression of SOD1G93A is associated with the
establishment of an extracellular environment that supports increased NMDA receptor activation.
4.5.2 Cocultures of neuronal cells and astrocytes
Neuronal cell lines were cultured with astrocytes to determine the effect of astrocytic presence
on extracellular amino acid neurotransmitter profiles and characterise any intercellular crosstalk.
In contrast to the isolated cultures of neuronal cells, the cocultures were associated an increase
in (S )-NIFE-D-Ser (Fig. 31a). This suggests that astrocytes have a profound impact on
extracellular D-serine levels. Astrocytes exclusively express 3-phosphoglycerate dehydrogenase
to allow de novo biosynthesis of L-serine. Therefore, they are able carry out in-house synthesis
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of D-serine using endogenously expressed SR. They can also shuttle L-serine to neuronal cells,
where it can subsequently be converted to D-serine by neuronal SR. This is in agreement with
previous literature that demonstrates the localisation of D-serine in the rat brain to discrete
populations of astrocytes in the grey matter, with a distribution that closely resembles that of
NMDA receptors [Schell et al., 1997].
The cocultures with SOD1G93A expressing astrocytes (G93A-nTg and G93A-G93A) were associ-
ated with significantly lower (S )-NIFE-D-Ser signals relative to their non-transgenic counterparts
(nTg-nTg and nTg-G93A) (p = 0.049 and p = 0.034, respectively). These differences were also
seen for the (S )-NIFE-D-Ser to (S )-NIFE-L-Ser ratios (p = 0.025 and p = 0.046, respectively).
This suggests that astrocyte expression of SOD1G93A is associated with lower extracellular
D-serine output. (S )-NIFE-D-Ser signals were also found to be higher in the cell media retrieved
from cocultures with SOD1G93A overexpressing neurons (nTg-G93A and G93A-G93A) relative
to their non-mutant SOD1 expressing counterparts (nTg-nTg and G93A-nTg) (p = 0.045 and
p = 0.034, respectively). This implies that, in contrast to astrocytes, SOD1G93A expression in
neuronal cells has a positive impact on extracellular D-serine output.
For (S )-NIFE-L-Ser, WT-WT and nTg-G93A were associated with net utilisation of L-serine,
whereas all other co-cultures were associated with a net release (Fig. 31a). Overall, (S )-NIFE-
L-Ser levels were inversely correlated to (S )-NIFE-D-Ser levels (r = −0.729, adjusted R2 = 0.441,
p < 0.001). This negative correlation may be explained by the counter transport of L-serine and
D-serine by ASCTs and asc-1 transporters [Ribeiro et al., 2002]. In other words, the extracellular
consumption of one enantiomer is counterbalanced by the elevation of the other. A previous
kinetic study demonstrated faster uptake of L-serine by primary neurons relative to primary
astrocytes, mediated mainly by ASCTs [Yamamoto et al., 2003]. This evidence suggests that
L-serine uptake is mainly governed by neuronal cells. However, this does not necessarily imply
that neuronal cells are the principal contributors to the extracellular D-serine pool, because firstly
ASCTs are non-specific which means that other neutral amino acids can also be exchanged for
D-serine, secondly SR may be regulated differentially in a cell type specific manner, and thirdly
astrocytes are able to carry out de novo biosynthesis of L-serine for subsequent endogenous
SR-mediated chiral conversion without shuttling to neurons.
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Figure 31. Amino acid neurotransmitter profiles in neuron-astrocyte coculture
media. Relative data representing (a) (S )-NIFE-D-Ser, (S )-NIFE-L-Ser, and (S )-NIFE-D-
Ser to (S )-NIFE-L-Ser ratio, (b) (S )-NIFE-Glu and (S )-NIFE-Glu to (S )-NIFE-L-Ser ratio,
(c) (S )-NIFE-L-Gln, (d) (S )-NIFE-Gly and (S )-NIFE-Gly to (S )-NIFE-L-Ser ratio following
derivatization of cell media from mouse neuronal cell-astrocyte cocultures. The first title
corresponds to the astrocyte and the second to the neuronal cell. The data was normalised
to the IS (L-serine-d3) and represents the mean of two biological replicates (n=2). Statistical
significance was assessed for each analyte by one way ANOVA and Bonferroni corrected post
hoc t-tests. media, cell media with no cells following 6 days of incubation; nTg, non-transfected
neural cell; WT, normal human SOD1 over expressing neural cell; G93A, mutant human SOD1
over expressing neural cell. ∗, p < 0.05; ∗∗, p < 0.01; ∗ ∗ ∗, p < 0.001.
In stark contrast to the isolated cultures of neuronal cells, all cocultures were associated with
a net uptake of glutamate from the cell media (Fig. 31b). This may be due to astrocytic
clearance of the extracellular L-glutamate pool by the glutamate transporters EAAT1 and
EAAT2. Efficient L-glutamate clearance is critical in preventing overstimulation of NMDA
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receptors [Anderson and Swanson, 2000]. (S )-NIFE-Glu signals were lower for cocultures
with SOD1G93A overexpressing astrocytes in comparison to their non-mutant SOD1 expressing
counterparts. Due to the saturated responses of (S )-NIFE-L-Gln, (S )-NIFE-L-Ser was used
as a substitute to determine the metabolite ratios for glutamate to avoid bias as a result of
any differences in cell numbers. L-Glutamate is used as an amino donor by phosphoserine
aminotransferase 1 during the conversion of 3-phosphoglycerate to L-serine [Jaeken et al., 1996],
thus their levels of both amino acids are somewhat negatively correlated. The (S )-NIFE-Glu to
(S )-NIFE-L-Ser ratios were also lower for cocultures with SOD1G93A overexpressing astrocytes.
Contrary to the results obtained for the isolated cultures of neuronal cells, an increase in
(S )-NIFE-L-Gln was seen for all cocultures (Fig. 31c). This is because astrocytes express
glutamine synthetase, which catalyses the synthesis of L-glutamine from L-glutamate produced
via the TCA cycle or taken up from the extracellular environment. In vivo, astrocytes are
known to shuttle L-glutamine to neurons, where it is subsequently converted to L-glutamate
by glutaminolysis [Bröer and Brookes, 2001]. L-glutamine is released by astrocytes via the
glutamine transporters ASCT2 and system N (SN1) transporter, and taken up by neurons
through sodium-coupled amino acid transporter/amino acid transporter A (SAT/ATA) [Bröer
and Brookes, 2001,Utsunomiya-Tate et al., 1996]. In the presence of astrocytes to provide an
external source of L-glutamine, there is increased opportunity for neuronal cells to produce L-
glutamate. SOD1G93A expressing astrocytes were associated with lower (S )-NIFE-L-Gln signals
relative to their non-mutant SOD1 expressing counterparts. This suggests that SOD1G93A
expressing astrocytes are related with lower L-glutamine synthesis and/or eﬄux. There was a
strong positive correlation between (S )-NIFE-L-Gln and (S )-NIFE-Glu (r = 0.960, adjusted
R2 = 0.910, p = 0.006), which can be explained by the inherent metabolic linkage of L-glutamine
and L-glutamate synthesis.
In contrast to the isolated cultures of neuronal cells, the cell media for all cocultures, with the
exception of G93A-nTg, had reduced levels of glycine relative to that in the absence of cells (Fig.
31d). This suggests a switch in preference of L-serine metabolism to D-serine instead of glycine,
presumably due to the increased availability of external L-serine. No significant differences were
observed for (S )-NIFE-Gly between different sets of cocultures.
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Overall, astrocytic expression of SOD1G93A appears to cause a general decrease in the extracellular
pool of amino acid neurotransmitters which have both astrocytic and neuronal origins (D-serine
and L-glutamate). Conversely, extracellular L-serine, derived specifically from astrocytes, is
elevated in the presence of SOD1G93A overexpressing astrocytes. These amino acid profile changes
may be suggestive of SOD1G93A expressing astrocyte-induced neuronal cell death, possibly by the
secretion of soluble neurotoxic factors. Whether these factors are also detrimental to astrocytes is
unknown and can only be ascertained by collecting additional cell viability data. This represents
a non-cell autonomous mechanism, whereby the genotypically mutant astrocyte causes neuronal
cells to exhibit the mutant phenotype irrespective of the neuronal genotype.
4.6 Discussion
A pilot study was performed to test the enantioselective UPLC-MS assay’s ability to perform
relative quantification of target analytes in a small biologically relevant sample set. The sample
set comprised of cell media collected from an ALS cell model to study the effects of SOD1G93A
overexpression on the extracellular levels of D-serine, a potent coagonist of the NMDA receptor
that has been implicated in the pathogenesis of ALS [Sasabe et al., 2007,Crow et al., 2012]. To
date, over 100 mutations of SOD1 have been reported in humans, most of which are associated
with autosomal dominant adult onset ALS (ALS1) [Turner and Talbot, 2008,Andersen, 2006]. Of
these, SOD1G93A is one which has been extensively characterised in transgenic ALS mouse models.
In these mice, SOD1G93A is ubiquitously expressed under the control of a human or mouse
SOD1 gene promoter at levels consistent with or greater than that of normal endogenous SOD1.
The pathology of ALS in these transgenic mouse models has close resemblance to the human
disease, making them desirable for the study of ALS biology [Gurney et al., 1994,Bruijn et al.,
2004]. Although we were primarily interested in the levels of D-serine, we also monitored L-serine,
DL-glutamate, L-glutamine, and glycine, which are all important components of glutamatergic
neurotransmission, in order to build a more comprehensive view.
We found that neuronal cells did not produce D-serine when cultured in isolation, despite reports
of abundant neuronal SR expression [Miya et al., 2008]. This is due to a lack of 3-phosphoglycerate
dehydrogenase expression, which prevents neuronal cells in vivo from synthesising L-serine de
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novo from 3-phosphoglycerate. Instead, neurons rely on an external supply of L-serine from
astrocytes [Ehmsen et al., 2013]. Although cell media provides an external source of L-serine, it
is a finite supply that may only be been sufficient to fulfil normal protein synthesis. This was
later confirmed by increases in extracellular D-serine when cocultured with astrocytes. However,
previous work with the hybrid NSC34 motor neuron-like cells used here has demonstrated that
these cells are capable of producing significant amounts ofL-serine when subjected to oxidative
and metabolic stress through serum deprivation [Valbuena et al., 2015]. This is presumably
due to their neuroblastoma characteristics that misrepresent primary neuronal cells. Although
the NSC34 cells in our experiments were not subject to stress, the absence of L-serine de novo
synthesis can only be confirmed by profiling cell extracts. Alternative hypotheses for a lack of
D-serine production, besides a nonreplenishable extracellular supply of L-serine, include negative
SR regulation and reduced eﬄux by antiporters (ASCT and asc-1 transporter). We also found
an increase in extracellular glycine levels, suggesting that these cells may have a preference for
L-serine metabolism to glycine over D-serine when cultured in isolation.
SOD1G93A overexpression in NSC34 cells was associated with increased extracellular D-serine to
L-serine ratios and glycine to L-serine ratios. SOD1G93A overexpression was also associated with
elevated levels of DL-glutamate. This is consistent with previous studies that have shown an
elevation of extracellular glutamate levels in both transgenic mouse models and sporadic ALS
patients [Alexander et al., 2000,Spreux-Varoquaux et al., 2002]. The DL-glutamate elevation
we observed is most likely due to increased glutaminolysis. This was shown by higher DL-
glutamate to L-glutamine ratios for SOD1G93A overexpressing cells. Other reasons for increased
extracellular DL-glutamate include increased glucose metabolism and increased L-glutamate eﬄux
via exocytosis perhaps in union with reduced L-glutamate uptake via glutamate transporters
(EAAT1 and EAAC1). Overall, high agonist and coagonist availability creates an environment
for increased NMDA receptor stimulation, thus implicating SOD1G93A in ALS. This is consistent
with previous studies that have shown that SOD1G93A expression in transgenic mice leads to
glutamate cytotoxicity [Rothstein et al., 2005,Bendotti et al., 2001,Sasabe et al., 2007].
For cocultures of astrocytes and NSC34 cells, although the numeric proportions of each cell
type were not determined, it is likely that the proliferating NSC34 cells were more prevalent.
Despite this, astrocytes were found to have a profound impact on extracellular amino acid
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Figure 32. Effect of SOD1G93A overexpression in astrocytes. A schematic to illustrate
the effect of SOD1G93A overexpression on neighbouring NSC34 cells and amino acid concentrations
in the cell medium.
profiles. Astrocytes are clearly implicated in extracellular homeostasis in the brain, where they
regulate the amount of ions, amino acid neurotransmitters, and water. They possess a wide array
of neurotransmitter receptors with considerable evidence linking them to secondary messenger
systems. This together with their star-shaped anatomy and network organisation enable them
to achieve integrated responses to multiple stimuli. Furthermore, their ability to synthesise
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neuroactive substances allow them to communicate amongst themselves and with neurons via
autocrine and paracrine signalling to coordinate a global response [Hansson and Rönnbäck, 1995].
In the cocultures of astrocytes and NSC34 cells, there was a general increase in extracellular
D-serine with concomitant decreases in extracellular L-serine and glycine. This suggests a general
switch in preference towards D-serine metabolism in the abundance of L-serine, and subsequent
increases in D-serine eﬄux via asc-1 transporters and ASCTs. A small change in D-serine can
translate into significant local changes in the vicinity of NMDA receptors. There was also a
reduction in extracellular DL-glutamate levels, despite an increase in extracellular L-glutamine,
presumably due to efficient uptake of L-glutamate by astrocytes through GLAST and GLT-1
transporters. This exists as a regulatory mechanism to prevent over stimulation of NMDA
receptors and cytotoxicity.
SOD1G93A overexpression in astrocytes was associated with a decrease in extracellularD-serine
and DL-glutamate. These amino acids have both astrocyte and neuronal cell origins. In contrast,
L-serine, which is only produced by astrocytes, was elevated in the extracellular environment.
This suggests that SOD1G93A overexpression in astrocytes can induce a neurotoxic effect on
neuronal cells, causing a depletion in cell numbers, and therefore, their contribution to the
extracellular amino acid pool (Fig. 32). Although L-glutamine, like L-serine, is exclusively
synthesised in astrocytes, SOD1G93A overexpression caused its levels to go down. If the hypothesis
that SOD1G93A overexpressing astrocytes have a neurotoxic effect on neighbouring neuronal cells
hold true, then just as neuronal L-glutamate synthesis is heavily dependent on astrocyte-derived
L-glutamine, L-glutamine synthesis in astrocytes is heavily dependent on the recycling of neuron-
derived L-glutamate. In other words, L-glutamine and L-glutamate synthesis are interdependent,
which highlights the inherent metabolic interrelationship between astrocytes and neurons.
Unfortunately we did not gather data regarding the numeric proportions of astrocytes and neurons
to confirm the notion of astrocyte-induced neurotoxicity, and whether toxicity is restricted to the
neuron subpopulation. However, previous studies have shown that mutations of the SOD1 gene
in astrocytes can cause motor neuronal cell death through a number of neurotoxic mechanisms.
Marchetto et al., 2008 demonstrated that primary astrocytes carrying SOD1G37R specifically
induce a decrease in the human embryonic stem cell-derived (hESC) motor neuron subpopulation
in cocultures by activating NOX2/gp91phox, a component of NADPH oxidase, to produce oxygen
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radicals [Marchetto et al., 2008]. Nagai et al., 2007 performed a number of neuronal-glial
cocultures that demonstrated that mutant SOD1 expressing rodent astrocytes cause cell death
of wild-type SOD1 expressing primary spinal and ESC-derived motor neurons. This was said to
be mediated by atrocyte specific soluble, neurotoxic factors that activate the Bax-dependent cell
death pathway. Furthermore, they also showed that out of a variety of non-neuronal cell types
carrying the mutant SOD1 gene, only astrocytes exhibit this potent toxic property, and that
among a variety of neuronal subtypes, motor neurons are the only subtype to succumb to this
astrocyte-induced toxicity [Nagai et al., 2007]. Wang et al., 2010 showed that knockdown of
SOD1G85R, but not SOD1G37R, in astrocytes delays the onset and progression of ALS disease
in transgenic mice. This suggests that different SOD1 mutants are associated with different
pathological mechanisms. Our data, together with the evidences gathered from previous studies,
point towards a non-cell autonomous mechanism for ALS pathogenesis.
As we analysed the levels of target analytes in cell media alone, which essentially only represents
one half the biological system, it was difficult to gauge the exact mechanisms involved for the
observed extracellular metabolic profile alterations, such as whether differences in extracellular
metabolite levels were a reflection of changes in cellular metabolism or transport. Rather this
type of study is useful for generating informed hypotheses to guide further experimental work,
which can then lead to more thorough comprehension of the biological system’s metabolic state.
Another major drawback of our study is the number of biological replicates analysed (n=2),
owing to the fact that it was intended to be a pilot study to test the performance of our optimised
enantioselective UPLC-MS assay for amino acid quantification. Therefore, further biological
replicates need to be tested to increase the reliability of our results.
The NSC34 cell line was used due to its suitability for high-throughput analysis and unlimited
propagation. However, since NSC34 is essentially a motor-neuron-like hybrid cell line with
some neuroblastoma characteristics, the results obtained here may vary in comparison to non-
proliferating primary motor neurons. Previously conducted deep proteomic analysis comparing
NSC34 cells to primary motor neurons has revealed some distinct differences in proteome
characteristics with respect to neuronal pathways that have relevance to ALS disease mechanisms.
This is due to the involvement of ALS associated proteins in a wide array of cellular processes.
Nevertheless, the expression of proteins and their relative abundances were conserved for common
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metabolic and house-keeping pathways, suggesting that the NSC34 cell line may still prove useful
for metabolic investigations [Hornburg et al., 2014].
Most ALS studies are conducted using transgenic mouse models in conjunction with cell models,
as these take into account the multitude of interacting factors which bring about the pathological
response. In contrast, cell culture experiments can only provide insight into one or, at most, a few
of these factors. ALS is a complex disease involving a number of putative disease mechanisms;
therefore, the use of ALS mouse models that bear close pathological resemblance to human ALS
is unavoidable.
In summary, the optimised enantioselective UPLC-MS assay was successfully implemented for
relative quantification of target amino acids in a pilot study based on an ALS cell model to
investigate the effects of SOD1G93A expression on extracellular D-serine output from transgenic
neural cell lines. Despite the limited number of replicates and low statistical power of this
study, we were able to gain useful insight into the pathological mechanisms involved in ALS and
generate a number of useful hypotheses to direct the course of further in vitro studies.
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Chapter5
Application of chiral profiling to a murine
bariatric surgery study
5.1 Overview
D-amino acids are heavily utilised by bacterial species to perform a wide variety of functions,
such as peptidoglycan synthesis and quorum sensing. The mammalian gut is home to hundreds
of bacterial species that are metabolically interfaced with the host and collectively constitute the
gut microbiome. Monitoring the levels of D-amino acids in excretory profiles may provide insight
into changes in indigenous gut microbial composition or behaviour in response to genetic and
environmental influences. In turn, this will also provide an indication of host status with respect
to gut mucosal integrity, immune system competence, dietary absorption, and metabolism. This
chapter describes the development of an MS/MS based approach for targeted chiral analysis of
proteinogenic amino acids in biofluids. The method was subsequently applied to a Roux-en-Y
gastric bypass (RYGB) animal study with pre-existing 16S rRNA pyrosequencing and metabolic
data, which revealed substantial shifts in endogenous gut floral populations and the host’s
metabolic status. This represents an ideal biological sample set for the investigation of potential
D-amino acid level alterations that may result from changes in gut microbial ecology.
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5.2 Aim and objectives
5.2.1 Aim
To integrate MS/MS analysis to develop the amino acid panel and then apply the enantioselective
UPLC-MS assay to an appropriate biological sample set to test the following hypothesis:
"significant shifts in the gut microbial ecosystem produces changes in the levels of D-amino acids
in biofluids".
5.2.2 Objectives
• Optimise MS/MS parameters for targeted analysis of D- and L-amino acids on a triple
quadrupole instrument in multiple reaction monitoring (MRM) mode.
• Characterise the suitability and limitations of acquired isotopically labelled amino acid
standards for internal calibration.
• Perform relative quantification of all detectableD- and L-amino acid enantiomers in urine
and plasma samples collected from RYGB- and sham-operated Wistar rats, and use
existing gut microbial data to identify the possible mechanisms underlying any significant
observations.
• Identify any additional caveats to enantiomeric quantification of amino acids in complex
matrices using the UPLC-MS assay, and attempt to resolve or circumvent these issues for
future applications.
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5.3 Introduction
5.3.1 The gut microbiome and its influence on host metabolic phenotypes
and the immune system in health and disease
The human microbiome is a dynamic, symbiotic consortium of microorganisms that reside in
various locations, including the gastrointestinal (GI) tract, skin, and oral mucosa [Consortium
et al., 2012]. The intestinal microbiota (gut flora) comprises of 300 - 500 different commensal
bacterial species [Guarner and Malagelada, 2003], and a total bacterial population in the range
of 1013 to 1014 cells [Prakash et al., 2011]. Most of these are located in the lumen of the large
intestine, with only a few species of bacteria colonising the epithelia of the stomach and small
intestine. The scarcity of bacteria in the upper tract is likely due to phasic propulsive motor
activity to prevent stable bacterial colonisation and harsh luminal medium conditions, owing to
acid, bile, and pancreatic secretions [Guarner and Malagelada, 2003,Prakash et al., 2011].
Colonisation of the GI tract begins immediately after birth [Guarner and Malagelada, 2003].
Initial colonisation is vital in determining the final adult composition of gut flora, because
pioneer bacteria can modulate host epithelial cell gene expression [Hooper et al., 2001], thus
creating a favourable environment for their long term survival, while preventing the growth of
other bacterial species introduced to the ecosystem at later stages [Guarner and Malagelada,
2003]. The adult microbial landscape is constructed through a series of complex and dynamic
interactions throughout life, including diet, lifestyle, disease, and antibiotic usage [Nicholson
et al., 2012]. Gut microbiota composition has also been reported to change with age, where
there is an increase in the total number of facultative anaerobes, shift in the Firmicutes to
Bacteroidetes ratio, and a significant decrease in Bifidobacteria at old age, which coincides with
depreciation of the immune system [Mariat et al., 2009]. Metabolic changes correlated with the
development of a mature gut microbial system may be identified in urinary or faecal profiles of
bacterial products [Nicholson et al., 2012]. The adult gut flora, once established, usually remains
relatively constant, although it may fluctuate under some circumstances, such as during acute
diarrhoeal illnesses, antibiotic therapy, and to a lesser extent dietary interventions [Moore and
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Moore, 1995,Guarner and Malagelada, 2003]. However, there is considerable inter-individual
variation with respect to the particular combination and population densities of predominant
bacterial species [Moore and Moore, 1995]. Bacteriological analysis of faecal flora has indicated
a predominance of anaerobic bacteria by a factor of 100 - 1000 relative to facultative anaer-
obes. The genera Bacteroides, Bifidobacterium, Eubacterium, Clostridium, Peptostreptococcus,
and Ruminococcus are all abundant anaerobes in humans, whereas Escherichia, Enterobacter,
Enterococcus, Klebsiella, Lactobacillus, and Proteus are examples of facultative anaerobes [Salmi-
nen et al., 1998,Guarner and Malagelada, 2003]. An understanding of the factors influencing
the colonisation of predominant gut bacterial species will inevitably help to explain normal
inter-individual variation in gut microbial composition.
Despite physical isolation, gut flora are intricately metabolically interfaced with the host. The
integration of microbes during the developmental trajectory of the microbiome modulates the
metabolic phenotype of the host, thus influencing the host’s biochemistry and susceptibility
to disease [Nicholson et al., 2012]. The collective genomes of gut microbes can express a wide
array of enzymes for biochemical pathways that are distinct from those of the host. The
overall outcomes of this complex metabolic activity is the recovery of metabolic energy and
generation of substrates from otherwise indigestible dietary residues for absorption by the host,
while simultaneously providing a supply of energy and nutrients to support bacterial colonial
growth [Guarner and Malagelada, 2003].
Gut flora carry out fermentation of indigestible carbohydrates, such as large polysaccharides,
some oligosaccharides that escape digestion, unabsorbed sugars, and alcohols. This generates
short-chain fatty acids (SCFAs), namely butyrate, propionate, and acetate [Cummings et al.,
1996,Cummings et al., 1987]. Bacterial proteolytic activity may also generate SCFAs; however,
it also accounts for the production of a number of potentially toxic molecules, such as ammonia,
amines, phenols, thiols, and indoles [Macfarlane et al., 1986,Guarner and Malagelada, 2003].
Protein sources include dietary elastin and collagen, secreted pancreatic enzymes, discarded
epithelial cells, and dead bacterial cells [Salminen et al., 1998]. SCFAs act as ligands for G
protein-coupled receptors (Gpr41 and Gpr43) expressed by a subset of enteroendocrine cells
in the gut epithelium. Ligand interaction increases the production of the hormone peptide
YY (PYY), which reduces intestinal transit rates for increased energy harvesting efficiency and
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host adipocity [Samuel et al., 2008]. Butyrate is utilised as an energy source by colonocytes,
propionate is largely taken up by the liver for gluconeogenesis, and acetate enters the peripheral
circulation where it is metabolised by peripheral tissues. Acetate is the principal SCFA produced
in the colon and is associated with increased cholesterol synthesis, whereas propionate inhibits
cholesterol synthesis. Therefore, decreasing the acetate to propionate ratio may reduce the
risk of cardiovascular disease [Wong et al., 2006]. SCFAs have also been implicated to regulate
the function of histone deactylases (HDACs), increase colonic mucosal serotonin release, and
stimulate the sympathetic nervous system [Nicholson et al., 2012]. Therefore, SCFAs influence a
diverse range of host functions making them one of the most important gut microbial metabolites.
Colonic bacteria may also contribute to vitamin synthesis, such as vitamins K and B12 [Hill,
1997], and the absorption of metal ions, such as calcium, magnesium and iron [Younes et al.,
2001,Roberfroid et al., 1995].
Gut microbial metabolism is inherently linked to host glucose and lipid homeostasis. Choline is
an essential dietary nutrient that is primarily metabolised in the liver. However, gut flora may
also metabolise choline to produce trimethylamine, the precursor of trimethylamine-N -oxide,
and dimethylamine. A high-fat diet is associated with increased microbial choline metabolism,
which reduces the bioavailability of choline to the host. Choline deficiency increases the host’s
susceptibility to obesity, insulin resistance, and non-alcoholic fatty liver disease (NAFLD) [Dumas
et al., 2006]. In connection, microbial choline metabolism to trimethylamine-N -oxide has been
shown to augment the accumulation of cholesterol in macrophages to produce so-called foam
cells, thus promoting atherosclerosis [Wang et al., 2011]. Gut microbiota may also contribute to
NAFLD via two microbe-sensing protein families: nucleotide oligomerisation domain receptors
(NLRs) and Toll-like receptors (TLRs). The loss of NLRP6 and NLRP3 inflammasomes, which
is associated with intestinal dysbiosis, results in abnormal accumulation of bacterial products,
such as lipopolysaccharides (LPS) and bacterial DNA, in the hepatic portal circulation. These
products are agonists of TLR4 and TLR9, respectively, leading to enhanced tumour-necrosis
factor (TNF)-α expression which drives NAFLD progression [Henao-Mejia et al., 2012].
High-fat diets have also been shown to significantly alter gut microbial composition in favour
of Gram-negative bacteria. This causes increased levels of LPS, a component of the outer
membranes of Gram-negative bacteria, to induce low-grade chronic inflammation (metabolic
150
endotoxemia) and in turn promote insulin resistance. The restoration of balance using prebiotics
has been shown to improve glucose tolerance and glucose-induced insulin secretion [Cani et al.,
2007]. In contrast, high Firmicutes (Gram-positive) to Bacteroidetes (Gram-negative) ratios have
been shown to increase susceptibility to obesity by increasing calorie releasing efficiency from
food intakes [Ley et al., 2006]. Germ-free mice have elevated levels of the gut epithelium-derived
fasting-induced adipose factor (Fiaf), a circulating lipoprotein lipase inhibitor, which is normally
selectively inhibited by gut flora. Fiaf induces the expression of genes encoding the peroxisomal
proliferator-activated receptor coactivator (Pgc-1α) and enzymes associated with fatty acid
oxidation. In addition, germ-free mice are also associated with increased AMP-activated protein
kinase (AMPK) activity in skeletal muscle and liver tissues, which phosphorylates acetyl coenzyme
A (CoA) carboxylase leading to decreased levels of malonylCoA. MalonylCoA is responsible
for controlling the rate limiting step of long-chain fatty acylCoA entry into mitochondria by
blocking the enzyme carnitine palmitoyltransferase. Therefore, the combinatorial elevation of
Fiaf and AMPK activity promotes fatty acid oxidation along with reduced de novo hepatic
lipogenesis and deposition of triglycerides in adipocytes and liver cells, thus conferring resistance
to diet-induced obesity [Bäckhed et al., 2007].
Bile acids are steroid acids produced from cholesterol in liver hepatocytes, the two primary bile
acids being cholic acid and chenodeoxycholic acid. These are then further metabolised in the liver
by conjugation to glycine and taurine, and then secreted into bile to facilitate the solubilisation,
digestion, and absorption of lipids and lipid-soluble vitamins in the small intestine. They are
subsequently reabsorbed in the distal ileum, whereupon entering the bloodstream are complexed
with plasma proteins and returned to the liver to complete the enterohepatic circulation. Despite
highly efficient reabsorption, approximately 5% of bile acids escape the enterohepatic circulation
on a daily basis and become substrates for gut microbial species. Microbial biotransforming
reactions initially involves deconjugation using bile salt hydrolases to generate free bile acids, and
is followed by hydroxyl group oxidation to form secondary bile acids, such as deoxycholic acid and
lithocholic acid, which are then reabsorbed. Bile salt hydrolases are expressed mainly by species
of the genera Bacteroides, Clostridium, Eubacterium, Lactobacillus, and Escherichia [Ridlon
et al., 2006]. Bile acid metabolites produced as a result of co-metabolism are ligands of the
Farnesoid X receptor (FXR), which is expressed in enterohepatic tissues. The activation of
FXR modulates the expression of genes associated with bile acid synthesis and transport, lipid
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and carbohydrate metabolism, and regulation of intestinal innate immunity. Attenuation of
FXR activation has been shown to exacerbate immune-mediated disorders, such as Crohn’s
disease, suggesting that FXR activation may have counter-regulatory effects on host innate
immunity [Vavassori et al., 2009]. For these reasons, therapeutically targeting bile acid signalling
pathways has been postulated to be beneficial in the management of pathological conditions like
metabolic syndrome, type 2 diabetes, and obesity [Thomas et al., 2008].
Besides metabolic functions, gut flora also have important trophic and protective functions,
some of which are related to bacterial metabolism. The major bacterially produced SCFAs have
been shown to regulate differentiation and proliferation of epithelial cells in the jejunum and
colon in vivo [Frankel et al., 1994]. In vitro, butyrate has been shown to inhibit cell proliferation
and promote cell differentiation of neoplastic epithelial cells to the normal phenotype [Siavoshian
et al., 2000,Gibson et al., 1992]. Therefore, butyrate may confer protection against pathological
states like chronic ulcerative colitis and colonic carcinogenesis [Guarner and Malagelada, 2003].
With respect to immunological protection, germ-free animals have been shown to have low
densities of intraepithelial lymphocytes (small specialised follicle structures) and low levels of
circulating immunoglobulins [Falk et al., 1998,Guarner and Malagelada, 2003, Butler et al.,
2000]. Following exposure to gut microbes, there is a sizeable expansion of intraepithelial
lymphocytes [Umesaki et al., 1993], an increase in germinal centre associated immunoglobulin
producing cells in follicles and the lamina propria [Cebra et al., 1998], and an increase in
serum concentrations of circulating immunoglobulins [Butler et al., 2000]. This suggests that
intercellular crosstalk between gut bacteria and host immune cells is essential to the development
of a competent gut immune system. Resident gut bacteria also provide a barrier effect to the
colonisation of exogenous bacterial species; therefore, representing a critical line of defence
against pathogenic invasions, including those from opportunistic bacteria with restricted luminal
growth [Cava et al., 2011]. There are several mechanisms that may contribute to this barrier
effect, including competition for attachment sites on intestinal epithelial cells [Bernet et al.,
1994], limiting nutrient availability [Hooper et al., 1999], and production of antimicrobial agents
called bacteriocins [Lievin et al., 2000,Brook, 1999].
Gut flora are involved in shaping the host immune system, and in turn the immune system shapes
the composition of the gut microbiome. Diverse interactions between microbes, epithelial cells,
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and gut-associated lymphoid tissue are involved in the establishment of memory mechanisms in
systemic immunity. However, the development of such complex mucosal-systemic immunoregula-
tory pathways via these interactions seem to be efficacious only in early life. For instance, gut
microbiota have been implicated in systemic unresponsiveness to repeated oral introductions of
a specific antigen, thus promoting oral tolerance [Moreau and Gaboriau-Routhiau, 1996]. In
adults, persistent interactions between the host and gut flora may reshape immunity. This is
exemplified by colonic Bacteroides fragilis, which constantly remodels its surface antigenicity by
producing distinct capsular polysaccharides in order to bypass host immunosurveillance. This
promotes the host’s defence to constantly adapt in order to actively keep its population in
check [Krinos et al., 2001].
Despite the many beneficial immunomodulatory effects of gut flora to GI health and overall
well being, they are also associated with the aggravation of some immunopathological situations.
Indigenous bacteria and their endotoxins normally continuously translocate at low baseline
rates from the GI tract; however, they are usually eradicated by the reticuloendothelial system
in immunocompetent individuals [Lichtman, 2001]. However, dysfunction of the gut mucosal
barrier may result in excessive translocation of indigenous bacteria, particularly Gram-negative
facultative anaerobes of the Escherichia, Proteus, and Klebsiella genera [Berg, 1995]. Following
passage across the epithelial barrier, they can travel via the lymph to various extraintestinal
sites, including the mesenteric lymph nodes, liver, and spleen, from where they may then
disseminate throughout the body to induce life threatening sepsis, shock, and multisystem organ
failure [Lichtman, 2001]. The three principal causes of extensive viable bacteria translocation are
bacterial overgrowth in the small intestine, increased permeability or damage of the gut mucosal
barrier, and compromised host immune defences [Berg, 1995]. Increased translocation may
occur during pathological states like liver cirrhosis, intestinal obstruction, inflammatory bowel
disease, haemorrhagic shock, and pancreatitis [Lichtman, 2001,Berg, 1995]. In inflammatory
bowel disease, gut flora like Bactereoides may cause unrestrained aggravation of inflammatory
responses [D’Haens et al., 1998, Swidsinski et al., 2002]. For instance, patients with Crohn’s
disease and ulcerative colitis have been shown to produce increased levels of mucosal IgG relative
to controls that were found to bind to proteins on a range of non-pathogenic faecal bacteria
[Macpherson et al., 1996]. Unlike normal IgA inflammatory responses, IgG-mediated responses
are associated with intestinal mucosal damage, complement activation, and eliciting a cascade
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of inflammatory mediators [Guarner and Malagelada, 2003]. Furthermore, the administration
of broad spectrum antibiotics have been shown to alleviate mucosal inflammation and colonic
lesions in animal models of inflammatory bowel disease [Videla et al., 1994]. Unfortunately,
antibiotics have not had much success in the clinical management of inflammatory bowel disease
due to the development of antibiotic resistant strains that impair sustained effects [Guarner and
Malagelada, 2003]. However, probiotic preparations do offer a promising alternative and are
currently under investigation [Gionchetti et al., 2000].
Indigenous bacteria may also contribute towards the development of cancer. Gut flora can
facilitate the production of carcinogens, which may contribute to the initial stages of colon cancer.
A diet comprised of high meat and fat increases faecal excretion of N -nitroso compounds that
are known to be genotoxic [Rieger et al., 1999,Hughes et al., 2001]. Heterocyclic aromatic amines
formed in cooked meats also represents another class of carcinogens. While some intestinal
bacterial species, such as those of the Lactobacillus and Bifidobacteria genera, are associated
with the consumption and detoxification of such carcinogenic substances, others strongly induce
genotoxicity in colonic cells, such as those of the Bacteroides and Clostridium genera. This
suggests that specific formulations of prebiotics and probiotics may be used to prevent colonic
tumorigenesis in high risk patients [Wollowski et al., 2001].
5.3.2 Bacterial utilisation of D-amino acids
L-amino acids clearly predominate in nature, serving as substrates for ribosome-based protein
synthesis. However, non-canonical D-amino acids are synthesised by diverse bacterial phyla
and can be found incorporated into bacterial proteins or utilised as key regulatory signalling
molecules to fulfil specific bacterial functions (Fig. 33). Bacterial species can express a
range of racemases that produce D-amino acids by altering the stereochemistry of the chiral
α-carbon atom in the L-isoform. The incorporation of D-amino acids into bacterial peptides
confers resistance to proteases that generally exhibit specificity towards L-configured peptide
residues [Cava et al., 2011]. Bacterial peptides are employed in the form of antibiotics against
competitive strains [Marahier et al., 1993,Kawai et al., 2004] and biosurfactants to aid bacterial
colonisation of surfaces [Morikawa et al., 1993].
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Figure 33. Bacterial uses of D-amino acids. D-amino acids are incorporated in bacterial
peptides and used as signalling molecules for a diverse range of bacterial functions.
D-amino acids may be employed directly as carbon and nitrogen sources to support bacterial
growth. The urinary tract is normally a sterile environment with a number of defence mechanisms
to prevent the colonisation of microbial species. These include the cleansing flow of urine,
numerous innate and acquired immune factors, and high osmolarity and sugar deficient conditions
which all challenge pathogenic manifestations [Zasloff, 2007,Oppenheim et al., 2003]. Escherichia
coli, a primary causative agent of urinary tract infections [Kaper et al., 2004], is hypothesised to
import and metabolise available carbon and nitrogen sources in the urinary tract [Anfora et al.,
2007]. It has been demonstrated to import and utilise, with sequential nutrient preference, serine
and asparate while producing acetate [Wolfe, 2005]. Urine provides a continuous supply of these
preferred nutrients to these bacteria, while simultaneously flushing the excreted acetate. D-serine
is among one of the most abundant amino acids in human urine with concentrations ranging from
3 to 115 µg/ml and can constitute up to 97% of total serine [Anfora et al., 2007]. E. coli expresses
D-serine deaminase (DsdA) which catabolises D-serine into pyruvate and ammonia; therefore,
making D-serine a valuable growth substrate for the sustenance of localised infection [Roesch
et al., 2003].
D-amino acids may also promote bacterial growth indirectly by serving as intracellular signalling
molecules. In the uropathogenic CFT073 strain of E. coli expressing mutant DsdA, net endoge-
nous accumulation of D-serine has been shown to act as an intracellular signal to hypermodulate
urinary tract colonisation. The mechanism is thought to involve activation of the D-serine-
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dependent transcription factor DsdC, which may promote the expression of virulent genes. DsdC
activation also enhances the transcription of the D-serine transporter DsdX to increase cellular
uptake of D-serine by a positive feedback mechanism [Anfora et al., 2007]. Another example of
D-amino acids being used for intracellular signalling is the opportunistic pathogen Pseudomonas
aeruginosa, which is the predominant cause of morbidity and mortality in patients with cystic
fibrosis [Oliver et al., 2000]. P. aeruginosa uses D-alanine as an activator of the transcriptional
regulator Lrp, as well as being a growth substrate. Lrp activation promotes the expression of the
alanine racemase DadX, which converts L-alanine to D-alanine. It also promotes the expression
of a component of alanine dehydrogenase (DadA), which is then responsible for oxidatively
deaminating D-alanine to pyruvate and ammonia for growth [Boulette et al., 2009].
D-amino acids can also regulate bacterial spore germination. Bacterial sporulation is a stationary
growth state that is initiated in adaptation to environmental stresses, such as nutrient depletion
and unfavourable pH conditions, which entails a finely controlled developmental program. It
involves assymetric cell division to generate a mother cell and a forespore with distinct fates. The
forespore matures into a spore, while the mother cell nurtures the spore, but ultimately undergoes
programmed cell death [Stragier and Losick, 1996]. Bacterial spores are metabolically dormant
and highly resistant to adverse environmental conditions, such as extreme pH, heat, and toxic
compounds [Setlow, 2003]. Specific nutrient germinants, like L-alanine, can reactivate metabolism
and vegetative growth by binding to receptors on the spore’s inner membrane [Setlow, 2003,Cava
et al., 2011]. In contrast, D-amino acids, such as D-alanine and D-histidine, are implicated as
anti-germinants [Halvorson and Spiegelman, 1952,Hu et al., 2007]. Bacillus species have been
shown to express alanine racemase in the exosporium, where D-alanine has been reported to
antagonise the binding of L-alanine to its nutrient receptor [Setlow, 2003,Atluri et al., 2006].
This auto-inhibitory mechanism may prevent premature germination in the presence of low
nutrient supplies and high population densities (quorum sensing) to ensure cell survival. This cell
survival strategy may be pivotal to the orchestration of pathological events. In the early stages
of pulmonary anthrax, Bacillus anthracis spores transit from the lungs to the blood, during
which they are susceptible to phagocytosis by resident macrophages [Mock and Fouet, 2001].
Preventing spore germination is critical to evading macrophage-mediated destruction during
this transition from localised to systemic infection. The timing of germination is thought to be
controlled by endogenous levels of D-alanine, which therefore, directly contributes to systemic
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infection.
Gram-negative bacteria have a single layer of peptidoglycan in the periplasm, whereas Gram-
positive bacteria have a thick cell wall comprised of many layers of peptidogycan. Bacterial
cell walls are essential to the cell’s shape, strength, and resistance to osmotic pressure, and
provides formidable protection against physical, chemical, and biological insults [Cava et al.,
2011,Young, 2006]. Peptidoglycans also serve as a scaffold for the anchorage of cell surface
moieties [Dramsi et al., 2008]. They are strong, yet flexible, net-like polymers composed of linear
glycan strands of repeating dissacharide units (N -glycan glucosamine and N -acetylmuramic
acid) cross-linked by pentapeptides. D-amino acids are incorporated into the pentapeptide
stems [Vollmer et al., 2008], thus contributing to the overall architecture. More importantly,
they also confer peptidoglycan resistance to proteases, which protects against bacterial cell wall
digestion. D-alanine and D-glutamate are by far the most common D-amino acid constituents
of peptidoglycan [Cava et al., 2011]; however, some bacterial species do incorporate other
D-amino acids. For example, Lactococcus and Enterococcus incorporate D-aspartate [Veiga
et al., 2006,Bellais et al., 2006], and vancomycin-resistant Staphylococcus aureus incorporates
D-serine [Reynolds and Courvalin, 2005]. These pentapeptide variations may give rise to different
polymer strengths and flexibilities. In addition to their contribution towards peptidoglycan
integrity, D-amino acids may also regulate cell wall remodelling by modulating the activities of
penicillin-binding proteins (PBPs), which are periplasmic enzymes that catalyse the synthesis or
modification of peptidoglycans. The accumulation of D-amino acids coincides with a transition
to stationary phase in the presence of environmental stress. Therefore, they are most likely
to down-regulate peptiodoglycan synthesis, thereby coupling the cell wall compartment to the
slow metabolic rates of cytoplasmic compartments. Rapid diffusion of D-amino acids in aqueous
environments enables the coordination of an immediate, synchronised response from the whole
bacterial population, which may be crucial for survival in conditions that threaten the cell’s
integrity [Cava et al., 2011].
Many bacteria can switch between existence as planktonic (single) cells or surface-associated
communities called biofilms. Biofilms are characterised by dense, highly hydrated collections of
bacterial cells that are held together by an extracellular matrix of bacterial origin. Bacterial
cells in biofilms express different phenotypic traits that are distinct from those expressed in the
157
planktonic state [Stewart and Franklin, 2008]. For example, the exopolysaccharide biofilms of P.
aeruginosa on pulmonary tissues have been shown to confer resistance to antibiotics and host
immune responses [Drenkard and Ausubel, 2002,Bjarnsholt et al., 2005,Jesaitis et al., 2003]. The
transition between planktonic and biofilm states is dependent on a variety of environmental and
physiological cues, including bacterial cell density, nutrient availability, and cellular stress [Cava
et al., 2011]. The accumulation of D-amino acids is associated with biofilm dissolution and
bacterial dispersal. For instance, B. subtilis has been shown to produce a nanomolar mixture of
D-amino acids (D-leucine, D-methionine, D-tryptophan, and D-tyrosine) that triggers disassembly
of mature biofilms. The mechanism of action was shown to involve D-amino acid-mediated
dismantling of extracellular matrix-associated amyloid fibres that are postulated to contribute
to its biofilm’s durability. Furthermore, the exogenous addition of D-amino acids to a planktonic
culture of P. aeruginosa and S. aureus has been shown to inhibit biolfilm formation altogether,
whereas a corresponding mixture of L-amino acids does not exert this effect [Kolodkin-Gal
et al., 2010]. As these bacterial species are not known to produce biofilm matrix-associated
amyloid fibers, the mechanisms of biofilm dispersal by D-amino acids are unlikely to be universal,
but rather species-dependent. D-amino acid signalling is hypothesised to be a response to
adverse local microenvironment conditions, such as limited nutrient supply and metabolic waste
accumulation, where escaping to the planktonic lifestyle is considered more favourable. In
biofilms comprised of mixed bacterial species, D-amino acids may act autocrine and paracrine
signalling molecules that regulate the bacterial community as a whole [Cava et al., 2011].
Given the various functions D-amino acids in bacteria, endogenous microbiota may represent a
key source of D-amino acids in mammals. Other mammalian sources of D-amino acids are dietary
intakes, spontaneous racemisation of the L-isoform liberated from polypeptides, and mammalian
amino acid racemases. The integration of chiral analysis to existing achiral approaches in
metabonomics introduces an additional dimension of information for a more comprehensive
overview of the metabolome. Probing D-amino acid profiles in biofluids may provide useful
insights into host gut microbial composition and growth rates, digestion, gut mucosal integrity,
and immune system functionality. These insights may be used to draw logical hypotheses that
can then be tested using more refined studies, such as the use of bacterial cell isolates or in vivo
animal models manipulated to express specific predominant gut bacterial species. D-amino acids
may also represent novel biomarkers of health and disease. For example, they may reveal the
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development of systemic or localised pathogenic manifestations and provide indications regarding
the host’s current immunological response status.
5.3.3 The benefits of bariatric surgery
Obesity is a major health pandemic associated with a number of comorbidities, including
diabetes [Whiting et al., 2011] and cardiovascular disease [Ashrafian et al., 2008]. In western
societies, there has been an alarming rise in the prevalence of obesity which is placing a huge
economic burden on healthcare systems [Withrow and Alter, 2011]. In the United States, the
prevalence of adult obesity has increased from 13% to 32% between the 1960s and 2004, and
its annual projection is estimated to be up to 0.9%, which will make 41% of adults obese by
2015 [Wang and Beydoun, 2007]. The majority of large scale, long-term epidemiological studies
have indicated that obesity is associated with a reduction in life expectancy [Flegal et al.,
2013,Sjöström et al., 2007]. Weight loss is often a difficult process and conventional therapeutic
strategies, including lifestyle changes, behavioural therapy, and pharmacotherapies, have only
produced marginal benefits for morbidly obese patients [Smith et al., 2008,Puterbaugh, 2009].
In contrast, bariatric (weight loss) surgery has been shown to cause long-term weight loss and
reduce overall mortality rates in comparison to conventional treatment approaches. Furthermore,
they are also successful in terms of achieving other favourable metabolic outcomes, such as
resolution of type 2 diabetes and hypertriglyceridemia, and increasing high-density lipoprotein
(HDL) cholesterol levels [Sjöström et al., 2004,Sjöström et al., 2007]. Although the underlying
mechanisms of these favourable metabolic outcomes remain unclear, it involves a combination of
both weight-dependent and -independent mechanisms [Cummings, 2005,Ashrafian et al., 2011].
The use of bariatric surgery has increased exponentially in recent years and is currently among
the most commonly performed GI operations. Although there are several bariatric procedures
(restrictive, malabsorptive„ and combined restrictive/malabsorptive), Roux-en-Y gastric bypass
(RYGB), which combines both restrictive and malabsorptive components, is the most commonly
performed procedure for treating morbid obesity, representing approximately 70 - 75% of all
bariatric procedures [Smith et al., 2008]. RYGB involves a rearrangement of the GI tract so that
ingested nutrients directly enter the jejenum following their transit through a small stomach
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Figure 34. Roux-en-Y gastric bypass surgery. A schematic to show the anatomical
rearrangement of the gut during an RYGB procedure and the altered flow of nutrients.
pouch (Fig. 34). As a result, nutrients bypass a large part of the stomach and duodenum.
Anatomically, this is achieved by initially separating the stomach to form a small pouch and
a larger stomach remnant. The small intestine is then cut at the distal end of the duodenum
and the cut segment is anastomosed to the small stomach pouch to form the alimentary (roux)
limb. The remaining stomach remnant and duodenum are anastomosed to the distal end of
the jejenum to form the biliopancreatic limb [Ashrafian et al., 2011]. RYGB achieves a number
of physiological effects, which are Bile flow alteration, Reduction of gastric size, Anatomical
gut rearrangement and altered flow of nutrients, Vagal manipulation, and Enteric gut hormone
modulation. These are collectively called the BRAVE effects [Ashrafian et al., 2010]. A decrease
in obesity is caused by a reduction in food intake, because of the restricted stomach cavity, but
also through an increase in energy expenditure and an improvement in metabolic parameters
due to metabolic adaptation [Carrasco et al., 2007].
Initially, it was considered that the resolution of diabetes occurs purely as a result of weight
loss; however, it is now well established that anti-diabetic effects occur within days after surgery,
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well before significant weight loss, which suggests that RYGB also has weight-independent
benefits [Pories et al., 1995]. Some of these weight-independent mechanisms can be classed using
the specific anatomical regions of the gut from which they originate. One proposed mechanism
for the observed anti-diabetic effects is an increase in insulin release due to the elevation of
incretins, glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), expressed
by L-cells found primarily in the ileum and colon and K-cells found primarily in the duodenum
and jejenum, respectively [Laferrère et al., 2008]. The upregulation of incretins is accompanied
by a downregulation of so-called "anti-incretins", which are normally constitutionally expressed
in the native foregut, most likely due to nutrient exclusion [Rubino et al., 2006,Rubino and
Marescaux, 2004,Ashrafian et al., 2011]. As of yet, the identity of these anti-incretins have
not been discovered [Ashrafian et al., 2011]. In the midgut, RYGB has been shown to increase
intestinal gluconeogeneis, mediated by an intact hepatoportal glucose sensing pathway, leading
to improved glucose homeostasis and insulin resistance [Troy et al., 2008]. In the hindgut, gastric
bypass increases gut hormone secretions within hours of surgery, including GLP-1 and PYY
produced by L-cells. This is stimulated directly by the introduction of nutrients that have not
undergone any foregut digestion and indirectly via neural pathways. GLP-1 is a neuropeptide
as well as a gut hormone, and can act on receptors of the CNS to induce satiety and reduce
calorific intake [Ashrafian and le Roux, 2009].
RYGB has also been shown to reduce the levels of systemic inflammatory markers, such as
interleukin-6 (IL-6) and C-reactive protein (CRP) [Holdstock et al., 2005,Kopp et al., 2003].
With considerable evidence linking systemic inflammation to insulin resistance [Tilg and Moschen,
2008,Bensinger and Tontonoz, 2008], this may represent another weight-independent mechanism
of improving glucose tolerance post-operation. However, despite these benefits to glucose
homeostasis, hyperinsulinemia and symptomatic hypoglycaemia due to over compensation
are seen in a small subgroup of patients with surgically-induced nesidioblastosis, which is
characterised by pancreatic β-cell hypertrophy and islet hyperplasia [Service et al., 2005]. With
respect to fat metabolism, RYGB modulates a number of adipose-derived hormones (adipokines),
including leptin, adiponectin, and resistin, most likely as a result of weight loss. While studies on
the modulation of leptin have yielded conflicting results and only few studies have addressed the
role of resistin post-surgery, the effect of a post-operative increase in plasma adiponectin has been
clearly demonstrated. The high molecular weight form of adiponectin mainly acts on the liver
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through AdipoR2 receptors to increase insulin sensitivity and decrease steatosis by activating
AMPK. In addition, post-operative levels of bile acids have been shown to increase following
surgery, and may confer anti-diabetic effects through FXR-mediated signalling mechanisms to
improve both glucose and lipid metabolism [Patti et al., 2009].
A previous study conducted by Li et al., 2011 showed that RYGB surgery induces substantial
shifts in predominant gut phyla in favour of Gammaproteobacteria in Wistar rats, specifically
Enterobacter hormaechei. In conjunction, there was also a decrease in the concentrations of
Firmicutes and, to a lesser extent, Bacteroidetes in comparison to sham-operated controls [Li
et al., 2011]. A decrease in Firmicutes to Bacteroidetes ratios has previously been associated with
leanness [Ley et al., 2006], thus implicating a gut microbial mechanism in weight loss as a result
of the RYGB procedure. Global changes in excretion profiles, including the reduction of urinary
amines and cresols and decreased levels of TCA intermediates (succinate, fumerate, citrate, and
α-ketogluterate), were also noted for RYGB-operated rats during the study. These profiles are
indicative of weight loss through increased energy releasing efficiency and calorie restriction. In
addition, faecal profiles revealed a decrease in bile acids and tyrosine with concomitant increases
in putrescine and diamainoethane, which suggests a RYGB-induced shift from host protein
degradation to putrefaction [Li et al., 2011]. Reduced levels of bile acids may be indicative of an
increase in upper intestinal lipids, which can stimulate the gut-brain-liver neural axis to achieve
earlier satiety and inhibit glucose production [Wang et al., 2008].
The integration of excretion profiles with a chiral perspective with bacterial genome sequencing
data may provide new insights into the dynamic host-gut microbiome interface. With the
presence of known drastic changes in gut microbial composition, biolfluids extracted from the
RYGB Wistar rat model used by Li et al., 2011 represent an ideal sample set to explore the
potential relationship between D-amino acid profiles and changes in gut microbial colonisation.
Here we performed relative enantioselective quantification of amino acids in plasma and urine
samples taken from RYGB- and sham-operated rats of this study to characterise any changes
in D-amino acid levels that may pertain to the reported alterations of the gut microbiome or
otherwise.
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5.4 Experimental methods
5.4.1 Materials
The following isotopically labelled compounds were obtained from Cambridge Isotope Labora-
tories: DL-glutamate-2,4,4-d3, DL-cysteine-3,3-d2, DL-aspartate-2,3,3-d3, L-glutamine-2,3,3,4,4-
d5, DL-proline-2,3,3,4,4,5,5-d7, DL-phenylalanine-ring-d5, DL-serine-2,3,3-d3, DL-valine-d8, L-
threonine-13C4,15N, DL-alanine-3,3,3-d3, L-isoleucine-d10, L-asparagine-15N2:H2O, and L-arginine-
guanido-15N2:HCl. DL-leucine-d10, DL-methionine-3,3,4,4-d4, DL-histidine-α,β,β-d3, DL-lysine-
4,4,5,5-d4, DL-tryptophan-2,3,3-d3, and DL-tyrosine-3,3-d2 were purchased from CDN isotopes.
5.4.2 Animal model and sampling
Details of the animal model and sample collection have previously been described [Li et al.,
2011]. In brief, gut microbial data for 12 non-obese male Wistar rats was gathered at 2 weeks
and 8 weeks post-surgery by performing 16S rRNA pyrosequencing of their faecal extracts. Of
these rats, 6 of them were randomised to the RYGB procedure and the remaining were subjected
to a sham procedure. The sham operation involved a 7 mm gastronomy on the anterior wall of
the stomach and a 7 mm jejunotomy, which were then closed. All rats were anaesthetised before
and after the procedure to minimise peri-operative and post-operative discomfort, respectively.
Following an initial wet diet (normal chow soaked in tap water) for 24 hours, regular chow was
offered from post-operative day 2. Urine samples were collected for 24 hours pre-operation and
at 2, 4, 6, and 8 weeks post-operation. Plasma samples were collected at 8 weeks post-operation.
All samples were stored as aliquots at -80 ◦C.
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5.4.3 Sample preparation
200 µM IS mix stock solution was prepared in advance and stored as aliquots at -80 ◦C. A fresh
aliquot was used for each new sample prep session. Rat urine samples were prepared in the same
manner as human urine samples as described previously (Section 3.4.2). However, the protein
precipitation step was omitted and the concentration of (S )-NIFE in acetonitrile was amended
to 12.5 mg/ml. Due to a lack of volume for some rat urine samples, the volumetric proportions
of sample preparatory reagent solutions were adjusted accordingly to maintain the same overall
dilution across samples.
Frozen rat plasma samples were thawed at room temperature and mixed thoroughly. 25 µl of 80
µM IS was mixed with 100 µl of plasma. This was followed by protein precipitation using 300 µl
of ice cold methanol, 1 h incubation at -80 ◦C, and centrifugation for 10 minutes at 20, 817 g
and 4 ◦C. The protein-free samples were then vaporised overnight at room temperature using
a centrifugal evaporator. The dry samples were reconstituted in 50 µl of H2O and 35 µl of
0.15 M sodium tetraborate solution, and left to incubate at room temperature for 10 minutes.
Derivatization was performed by adding 50 µl of 12.5 mg/ml (S )-NIFE dissolved in acetonitrile
at room temperature. After 20 min of derivatization, the reactions were terminated by adding 15
µl of 4 M HCl, and then diluted with 350 µl of H2O (total sample volume = 500 µl). The samples
were incubated at -20 ◦C for 10 min for salt precipitation and filtered using 10K centrifugal
devices. The filtrates were transferred to total recovery LC-MS glass vials and stored at -80◦C
until UPLC-MS analysis.
A method blank, quality control (QC) samples, and calibration standards were prepared alongside
both the rat urine and plasma sample preparations. QCs were prepared by pooling together
all samples in the batch. Calibration standards were also prepared using the pooled samples,
because of the considerable matrix effects. However, this was done using the isotopically labelled
amino acids rather than the standard addition method. This was due to the high endogenous
presence of L-amino acids that have the propensity to reach detection saturation, at which point
they are no longer within the range of linear quantification.
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5.4.4 Instrumental parameters and data acquisition
Separations for both rat urine and plasma samples were performed using an Aquity UPLC system
coupled to a Xevo TQS (Waters). UPLC conditions were kept the same as previously (Section
3.4.3); however, detection was carried out in +ESI mode using MS/MS in MRM mode. The
MS/MS parameters for the detection of both D- and L-amino acid derivatives were stored in the
same function, spanning a defined RT window that encompasses the responses of both isomers,
to facilitate comparisons. The electrospray capillary voltage was set to 2.7 kV, while the CV
and Ecoll for each amino acid derivative was optimised for the detection of their corresponding
daughter (fragment) ion. This was done by gradually incrementing these parameters in steps
of 4 and 2, respectively, to achieve the maximum response of the, less abundant, D-amino acid
during analysis. For rat plasma samples, additional untargeted data was also acquired in MS
Scan mode using a CV of 17 kV and Ecoll of 5 eV. Desolvation and cone gas flows were set to
1000 L/hr and 150 L/hr, respectively, and the desolvation temperature was adjusted to650 ◦C.
Data were acquired using the Waters MassLynx v4.1 software.
The chromatographic column was conditioned with repeated injections of pooled QC samples
(conditioning QCs) to achieve RT and response stability, thereby minimising variability during
the sample run. Calibration standards were run at the beginning to assess the linear response
ranges of target analytes. The run orders of rat urine and plasma samples were randomised
by a simple randomisation method using a random number generator to limit the influence
of changes in instrumental performance, such as detector sensitivity. This ensures that there
are no adverse effects on the acquired data set for unbiased data interpretation, because all
experimental groups will be equally affected. In addition to the use of internal standards, pooled
QC sample injections were performed after every 10 sample injections to monitor instrumental
performance throughout the sample run and scrutinise the validity of results.
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5.4.5 Data analysis
Automated smoothing and peak integrations of acquired targeted data were performed using the
TargetLynx Application Manager option within the Waters MassLynx v4.1 software. For untar-
geted data, integrations were performed as described previously (Section 3.4.4). Overlapping
peaks of interest were deconvoluted and integrated with the assistance of PeakFit v4.12 software.
Peak fitting was performed using a combination of the exponentially modified Gaussian (EMG)
model and the residuals autofit method, which identifies peaks on the basis of local maxima in
the smoothed data stream. Normalised analyte responses (analyte n) were determined using the
equation:
analyte n =
analyte m
IS
where analyte m is the endogenous analyte response. For D-amino acid enantiomers with no
corresponding isotopically labelled IS, the response of the labelled L-enantiomer or a labelled
structural homologue with the closest RT was used for normalisation. An IS variability criterion
of 75 - 125% of the mean IS response was used to identify faulty samples.
Correlation analysis was performed using either Pearson correlation (r) or Spearman’s rank
correlation (rs), depending on distribution normality. The mean ± s.d. was calculated where
n > 2, and differences between sample groups were tested using unpaired t-tests assuming
unequal variance with false detection rate (FDR) correction for multiple testing. FDR correction
was performed with a 5% significance level (p < 0.05) using the Q-Value software package [Storey,
2002]. The Smoother method was selected to estimate pi0 (the probability of the null hypothesis
being true) for the subsequent determination of q-values (adjusted p-values) for a given set of
p-values [Storey and Tibshirani, 2003].
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Figure 35. Parent and daughter ions selected for MS/MS analysis. A mass spectrum
of (S )-NIFE-L-Ala showing the parent ion (m/z 339.15) from which daughter ions (m/z 120.10)
are produced by collision-induced dissociation in Q2.
5.5 Results
5.5.1 Initial assessment and optimisation of UPLC-MS analysis on a triple
quadrupole instrument
In triple quadrupole instruments, such as the Xevo TQS, each quadrupole is associated with a
separate function to perform MS/MS analysis. The first quadrupole (Q1) serves as a mass filter
that scans across a preset m/z range to select parent ions of interest, the second quadrupole
(Q2) or collision cell is responsible for fragmenting the parent ions using an inert collision gas
(argon or helium), and the third quadrupole (Q3) acts as a second mass filter to select specific
daughter ions generated by collision-induced dissociation in Q2. Its selected reaction monitoring
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Figure 36. Chromatograms of (S)-NIFE-DL-AAs and their stable isotopically la-
belled internal standards. The data was acquired using MS/MS analysis on the Xevo TQS.
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(SRM) and MRM capabilities make it a highly sensitive for quantifying known metabolites of
interest in targeted metabolic profiling experiments [Want et al., 2010]. Its high sensitivity and
Table 5: MS/MS parameters and retention times of (S)-NIFE-DL-AAs and their
corresponding isotopically labelled standards on the Xevo TQS.
Compound MS/MS parameters RT (min)
Parent
ion
Daughter
ion CV (V) Ecoll (eV)
Dwell time
(s) tL tD
Alanine 339.22 120.10 20 30 0.016 10.26 11.75
Alanine-d3 342.22 120.10 20 30 0.016 10.25 11.72
Serine 355.20 120.10 13 28 0.017 9.60 10.06
Serine-d3 358.20 120.10 13 28 0.017 9.58 10.04
Proline 365.19 120.10 34 30 0.018 11.66 12.31
Proline-d7 372.19 120.10 34 30 0.018 11.57 12.25
Valine 367.23 120.10 25 30 0.022 12.79 14.07
Valine-d8 375.23 120.10 25 30 0.022 12.75 14.03
Threonine 369.17 120.10 5 20 0.016 10.07 11.61
Threonine-13C4,15N 374.17 120.10 5 20 0.016 10.07
Leucine 381.19 120.10 25 31 0.022 14.24 15.20
Leucine-d10 391.19 120.10 25 31 0.022 14.20 15.16
Isoleucine 381.19 120.10 25 31 0.022 13.97 15.02
Isoleucine-d10 391.19 120.10 25 31 0.022 13.93
Asparagine 382.20 120.10 27 34 0.017 9.24 9.76
Asparagine-15N2 384.20 120.10 27 34 0.017 9.24
Aspartic acid 383.12 120.10 25 17 0.043 5.32 5.67
Aspartate-d3 386.12 120.10 25 27 0.043 5.31 5.65
Glutamine 396.23 120.10 21 34 0.017 9.70 10.28
Glutamine-d5 401.23 120.10 21 34 0.017 9.68
Methionine 399.12 120.10 30 32 0.022 13.37 14.33
Methionine-d4 403.12 120.10 30 32 0.022 13.35 14.31
Histidine 405.23 110.10 24 42 0.016 10.04 10.70
Histidine-d3 408.23 110.10 24 42 0.016 10.03 10.69
Arginine 424.23 201.13 45 28 0.016 10.99 11.67
Arginine-15N2 426.23 201.13 45 28 0.016 10.99
Tryptophan 454.14 120.10 31 38 0.024 15.14 15.83
Tryptophan-d3 457.14 120.10 31 38 0.024 15.14 15.81
Cysteine 620.13 120.10 41 48 0.038 17.93 18.49
Cysteine-d2 622.13 120.10 41 48 0.038 17.92 18.49
Lysine 645.20 120.10 44 60 0.038 17.23 17.67
Lysine-d4 649.20 120.10 44 60 0.038 17.22 17.66
Tyrosine 680.13 120.10 43 60 0.106 19.86 20.81
Tyrosine-d2 682.13 120.10 43 60 0.106 19.69 20.47
CV, cone voltage; Ecoll, collision energy; tL, RT of L-amino acid; tD, RT of D-amino acid
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selectivity make it particularly useful for the trace analysis of D-amino acids with low biofluid
concentrations. In addition, the Xevo TQS is also equipped with a large dynamic range with
the capacity to perform linear quantification up to six orders of magnitude. The daughter ion
(m/z 120.10) represents the iminium ion that is generated from the phenylalanine portion of
(S)-NIFE in the diastereomeric derivative [El Aribi et al., 2004] (Fig. 35). This fragment was
chosen due to its high abundance in order to promote optimum assay sensitivity.
All obtained isotopically labelled compounds had ≥98% chemical purity to reduce their inter-
ference with the measurements of analytes. Unfortunately, due to commercial unavailability,
isotopically labelled standards were not obtained for all D-amino acids, namely those of threonine,
isoleucine, asparagine, arginine, and glutamine. While 13C and 15N labelled standards displayed
minimal deviation in RT, some of the deuterated standards were found to elute slightly earlier
than their unlabelled counterparts (Fig. 36 and Table 5). These deviations were all less than
Figure 37. Differences in IS retention times and responses relative to the analyte.
(a) RT comparisons of (S )-NIFE-DL-Tyr and (S )-NIFE-DL-Tyr-d2 in aqueous-organic solvent
and urine. (b) Differences in IS response relative to the analyte, yet consistency of IS/analyte
response ratios in solvent within the linear range of quantification.
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0.05 min, except for DL-tyrosine-d2 and DL-proline-d7 which had deviations of up to 0.34 min and
0.09 min, respectively. Interestingly, for unknown reasons despite high RT differences between
DL-tyrosine and DL-tyrosine-d2 in aqueous-organic solvent, they were negligible in complex
matrices, such as urine, which justifies its usage (Fig. 37a).
A couple of labelled standards exhibited reduced detector responses at equivalent concentrations,
namely DL-tyrosine-d2 and L-threonine-13C4,15N. D- and L-tyrosine-d2 exhibited 23% and 51% of
their unlabelled counterparts’ responses at equivalent concentrations in aqueous-organic solvent,
respectively, while L-threonine-13C4,15N exhibited 41% of the L-threonine response. Nevertheless,
they were still useful for quantification purposes as the IS/analyte response ratios were found to
remain constant throughout the linear response range (Fig. 37b). The most likely explanation
for the differences exhibited by some of the labelled IS compounds, with respect to RT and
recovery, is that the modifications, although minor, were enough to invoke changes in their
physicochemical properties, which are then reflected in their behaviour during derivatization or
analysis. For example, with respect to deuterated compounds, the C-D bond has been shown
to have a slightly shorter length in comparison to the C-H bond. This results in reduced bond
vibrations and a slightly increased ability to donate electron density via an inductive effect,
which results in the group of atoms containing deuterium having a smaller size [Wade, 1999].
More recently, it was shown that because of this difference in size, deuterium labelled compounds
exhibit different binding interaction energies to their non-deuterated equivalents when bound to
a stationary phase, such as in a chromatographic column, and will inevitably cause differences in
elution times. Binding energy values for analytes and their labelled IS can be obtained using a
molecular modelling approach that probes their interactions with a stationary phase [Iyer et al.,
2004].
5.5.2 Chiral amino acid profiling in rat urine
Chiral metabolic profiling was performed on urine and plasma samples obtained from an RYGB
Wistar rat model to determine whether there were any significant changes in D-amino acid
profiles as a result of considerable RYGB-induced shifts in gut microbial populations. The
enantioselective UPLC-MS assay was carried out on 24 h urine samples collected sequentially
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Figure 38. Pooled QC analysis and IS response variation in rat urine. (a) Pooled QC
response consistency for a representative panel of (S )-NIFE-D-AAs. (b) Changes in the relative
intensity of representative labelled IS compounds ((S )-NIFE-D-Ser-d3, (S )-NIFE-D-Trp-d3, and
(S )-NIFE-D-Leu-d10) across rat urine samples sorted by run order. The mean ± 25% of the IS
responses is indicated. (c) Correlation analysis of detector responses for (S )-NIFE-L-Gln-d5
with those of (S )-NIFE-D-Pro-d7, (S )-NIFE-D-Leu-d10, and (S )-NIFE-D-Lys-d4 to demonstrate
the global synchronisation in variation of different IS responses between samples.
over 5 time points (pre-operation and at 2, 4, 6, and 8 weeks post-operation) for RYGB- and
sham-operated rats. Pooled QC analysis revealed good RT consistency and minimal signal
deterioration (Fig. 38a), indicating minimal fluctuation in chromatographic performance, good
detector response stability, and no significant deterioration of the (S )-NIFE derivatives during
autosampler storage.
172
DL-cysteine-d2 exhibited very weak responses in all rat urine samples, with signals barely
exceeding the background noise. Generally, all samples were associated with very high IS response
variability, with up to 10 fold differences in IS response between samples (Fig. 38b). As a
result, a large proportion of samples exceeded the preset criterion for sample error identification
(75 - 125% of the mean IS response), thus drawing the validity of the current data batch
into question. There is currently no general consensus with respect to IS response variability
allowance [Viswanathan et al., 2007]. Although the nature of the criterion we used for assessing
IS variation is numerical and provides a clear cut approach to sample error identification, it
is an arbitrary one with no scientific rationale. An alternative and more scientific approach
is to conduct a trend analysis, whereby IS variation of known samples is used to define the
acceptability of IS variation of unknown samples. However, this approach can be overly subjective
and may lead to lapses in consistency for variability acceptance. Nevertheless, it is still the
more preferential approach for evaluating IS variation [Lowes et al., 2011]. Unfortunately, we
were unable to perform trend analysis as we did not have access to enough additional rat urine
samples for a sufficiently large alternate batch analysis for representative comparisons of IS
variation between known and unknown samples.
The IS responses were not associated with progressive deterioration to indicate a gradual change
in instrumental performance, as already implicated by the consistency of the pooled QC data.
Instead, the IS responses were found to vary randomly with no distinct high and low response
regions of clustering to indicate the presence of systematic error, such as incorrect injection
volumes for incurred samples (Fig. 38b). Therefore, we suspected that IS variability was
originating from inherent differences between rat urine samples, such as variable degrees of
matrix-induced ion suppression. We performed correlation analysis for responses of IS compounds
representing different analytes and found that the majority of responses were associated with
a strong positive correlation (Fig. 38c). This suggests that most IS responses varied in a
synchronous manner across samples. Although variable ion suppression effects from co-eluting
urinary constituents are likely to account for some variability for specific IS compounds, it is
unlikely to have been the cause of synchronous variations for all representative IS compounds
(total of 46) which each occupy disparate chromatographic regions that are associated with
different ion suppression effects. Therefore, we suspected that other matrix-related root causes
account for much of the observed IS variation.
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Figure 39. Correlation analysis of 1H NMR and UPLC-MS data for rat urine.
Spearman’s rank correlation analysis of chiral UPLC-MS data (raw and IS normalised) for (a)
(S)-NIFE-L-Trp and (b) (S)-NIFE-L-Tyr versus their corresponding achiral 1H NMR data. All
data represent relative intensities, and Spearman’s correlation coefficients (rs) and p values are
indicated.
IS variability does not necessarily predict batch reliability as it could still be part of the method to
deliver accurate and precise quantitative results, and should never be used as a batch acceptance
criterion. Therefore, to test batch acceptance we performed cross validation to compare some of
the raw and IS normalised UPLC-MS data to pre-existing 1H NMR data for the same rat urine
sample set. 1H NMR spectroscopy was chosen for comparison as it represents a highly reliable
technique for metabolite quantification with the capacity to perform linear quantification over a
large dynamic range without the need to employ isotopically labelled IS compounds for each
analyte. Tryptophan and tyrosine were chosen for correlation analysis, because negligible amounts
of their D-enantiomers were measured in rat urine; therefore, facilitating a fair comparison of their
respective (S )-NIFE-L-AA peak responses to their achiral 1H NMR resonances. Furthermore,
these amino acids were associated with isolated chemical shifts in the 1H NMR spectrum with
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no interfering resonances, which allowed for accurate and reliable signal integrations following
spectral alignment. Many (S )-NIFE-L-AAs, including (S )-NIFE-L-Trp and (S )-NIFE-L-Tyr, had
saturated signals, and therefore non-linear responses due to their inherent high abundances in
rat urine. Hence, a non-parametric test (Spearman’s rank correlation) was employed to compare
the two sets of data. Correlation analysis revealed no statistically significant correlation between
the UPLC-MS data, both raw and IS normalised, and 1H NMR data for both tryptophan and
tyrosine (Fig. 39). This clearly demonstrated that the rat urine UPLC-MS data was unreliable
for interpretation and provided a firm basis for sample batch rejection.
5.5.3 Investigating sources of high internal standard variability in rat urine
We investigated several potential sources of IS response variation in urine samples so that
amendments could be made to increase assay reliability and accuracy for future metabolic
profiling studies. First we investigated the presence of IS response dependency on the analyte
response. Of the labelled IS derivatives, only (S )-NIFE-L-Arg-15N2 and (S )-NIFE-L-Tyr-d2
displayed significant positive correlations with their unlabelled analogues (Fig. 40a), which
suggests that their responses are analyte concentration dependent. IS response dependability
is likely to be caused by the naturally occurring isotopic abundances of (S )-NIFE-L-Arg and
(S )-NIFE-L-Tyr. For (S )-NIFE-L-Arg, the naturally occurring monoisotopic peak with similar
m/z to (S )-NIFE-Arg-15N2 (m/z 426.24) represents 6.58% of the native monoisotopic peak
(Fig. 40b). For (S )-NIFE-L-Tyr, the monoisotopic peak with m/z 682.11, that is similar to
the m/z of (S )-NIFE-L-Tyr-d2, represents 10.62% of the native monoisotopic peak. Triple
quadrupole instruments have lower resolution capabilities in comparison to TOF instruments,
and therefore do not possess the same resolving power to discriminate between isotopic species
with small differences in m/z (≥ 1 decimal place), even at optimum quadrupole resolution
settings. Therefore, the chromatographic peak will represent the average mass, that is the
weighted mean of all isotopic species in the molecule. Naturally occurring isotopic distributions
may contribute significantly to (S )-NIFE-L-Arg-15N2 and (S )-NIFE-L-Tyr-d2 responses in the
presence of high sample concentrations of L-arginine and L-tyrosine, respectively, such as those
found in rat urine. This issue can be resolved by employing isotopically labelled compounds for
these analytes that are several mass units apart (typically > 3 amu). Interestingly, we did not
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Figure 40. Investigating sources of IS variability in urine. (a) IS response dependability
of (S )-NIFE-L-Arg-15N2 and (S )-NIFE-L-Tyr-d2 on their unlabelled analogue responses in rat
urine samples. (b) Natural isotopic distributions of (S )-NIFE-L-Arg and (S )-NIFE-L-Tyr. (c)
Change in relative responses of a panel of representative (S )-NIFE-D-AAs in 100 µl and 20 µl
of rat urine with increasing concentrations of (S )-NIFE. (d) Decrease in (S )-NIFE-D-Cys and
(S )-NIFE-L-Cys responses in vaporised and non-vaporised human urine samples (mean ± s.d.,
n = 3).
encounter IS dependence on analyte concentrations for (S )-NIFE-L-Asn-15N2, which also has a
difference of only 2 amu relative to (S )-NIFE-L-Asn. This may be due to confounding influences
on the correlation analysis from matrix-related factors.
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Since IS dependability on analyte concentration was not encountered for the majority of labelled
IS compounds used, we investigated other potential root causes of high IS response variation.
We then assessed (S )-NIFE concentration to check whether the concentration employed in the
study (12.5 mg/ml) was sufficient for complete derivatization of all analytes in rat urine samples.
3 randomly selected rat urine samples were pooled and 100 µl of the pooled sample (same volume
used in the RYGB study) was derivatized using incrementing concentrations of (S )-NIFE. The
responses for all amino acid derivatives were found to increase without stabilisation, even at
(S )-NIFE concentrations in excess of 12.5 mg/ml, suggesting that reactions were not proceeding
to completion (Fig. 40c). When reducing the urine volume from 100 µl to 20 µl, and hence the
volume of all reagents proportionally to preserve assay sensitivity, the responses for all amino
acids were found to plateau at 10 mg/ml (S )-NIFE. Complete derivatization is essential for
reliable and accurate quantification. In the presence of limited CDA, amino acids and other
urinary amines will compete for derivatization. Since urine samples vary remarkably in their
concentrations of these metabolites due to differences in urinary dilutions, as well as differential
systemic metabolic statuses of organisms, the high IS response variation may be explained
in large part by differences in the level of competitive derivatization between samples. This
also explains the correlative nature of responses for different labelled IS compounds in the rat
urine sample batch. A correlation analysis showing strong negative correlation between urinary
dilution factor and IS response would support this hypothesis. Unfortunately, information
pertaining to urinary dilution was not collected as part of the study.
Although sample vaporisation ensuing protein precipitation was performed in a centrifugal
evaporator set to room temperature, samples were still exposed to elevated temperatures
due to heat generated from the centrifugal rotor. Therefore, we tested analyte responses
in human urine samples with and without the sample vaporisation step. (S )-NIFE-D-Cys
and (S )-NIFE-L-Cys in particular were found to exhibit 85% and 83% response reductions
relative to non-vaporised samples, respectively (Fig. 40d), suggesting thermal decomposition.
No differences were observed for all other (S )-NIFE-AAs. Extensive thermal decomposition
during sample preparation explains the observation of very weak, highly variable signals for
(S )-NIFE-DL-Cys-d2.
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Figure 41. Pooled QC analysis and internal calibration assessment in rat plasma.
(a) Consistency of pooled QC responses for (S )-NIFE-D-AAs in rat plasma. (b) Confinement of
responses for representative labelled IS derivatives in rat plasma samples to within ± 25% of the
mean response.
5.5.4 Chiral amino acid profiling in rat plasma
Plasma chiral amino acid profiles were obtained on the Xevo TQS using MS/MS analysis for 6
RYGB-operated and 6-sham operated Wistar rats at 8 weeks post-surgery. Pooled QC analysis
showed no RT drifts or substantial peak response changes (Fig. 41a). Furthermore, the rat
plasma samples were not associated with high IS response variation, like that seen for the
rat urine samples, as all IS responses fell within ±25% of the mean response (Fig. 41b).
Unfortunately, 1H NMR data was not available for these rat plasma samples to cross validate
this data batch. However, the consistency of IS responses across samples suggests that the
(S )-NIFE concentration used here was adequate for complete derivatization of analytes and their
corresponding labelled IS in these samples, thus allowing for reliable quantification. This was
used as an indication for sample batch acceptance.
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Each enantiomeric pair of amino acids was stored in the same MRM function, and thus quantified
simultaneously using the same parameters during analysis. However, since we optimised these
parameters to enhance detection of D-amino acid derivatives, which are typically present at much
lower concentrations in biofluids than their matching L-isoform, many of the (S )-NIFE-L-AA
signals were saturated, and thus exhibited non-linear responses. So in addition to the targeted
MS/MS analysis, we also performed untargeted MS analysis for the rat plasma samples and
calculated the integrals of extracted chromatograms using less abundant, heavier monoisotopic
peaks for any (S )-NIFE-L-AAs exhibiting detector response saturation. In doing so, we were
able suppress all (S )-NIFE-L-AA responses to the linear response range for accurate relative
quantification.
(S )-NIFE-L-Arg-15N2 and (S )-NIFE-L-Tyr-d2 exhibited significant positive correlations with their
corresponding analytes in rat plasma (Fig. 42a), which is consistent with the rat urine data. In
addition to these positive correlations, we also observed negative correlations for some isotopically
labelled IS compounds and their unlabelled analogues, such as (S )-NIFE-L-Ala-d3, (S )-NIFE-L-
Ser-d3, and (S )-NIFE-L-Pro-d7 (Fig. 42b). Lower IS responses for higher concentrations of
analyte is suggestive of ion suppression, particularly considering thatL-amino acids are present
in high abundance in rat plasma. Ion suppression is most likely to have manifested as a result of
competition for charge or space on ESI droplets at the ion source. This issue may be resolved by
either diluting the sample or reducing the injection volume; however, both solutions come with
the cost of losing sensitivity for trace analysis of D-amino acids. This represents an unavoidable
obstacle to simultaneous analysis of D- and L-amino acids in biofluids, which are typically at
concentrations several orders of magnitude apart.
IS response dependability, regardless of the nature and cause, is a common feature for the
majority of L-amino acids and has the potential to significantly skew results leading to inaccurate
quantification and biased data interpretation. Therefore, to circumvent this problem we performed
transformations of the linear functions that represent IS dependability on analyte response to
obtain theoretical IS response values given the absence of analyte (IS t). The IS response is
represented by the equation:
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Figure 42. IS response dependability on analyte concentrations in rat plasma. (a)
Positive correlations for (S )-NIFE-L-Arg-15N2 and (S )-NIFE-L-Tyr-d2 with their corresponding
analytes in rat plasma. (b) Negative correlations for a representative panel of (S )-NIFE-L-AAs
and their corresponding deuterium labelled IS.
IS = m(analyte) + c (1)
where m and c represent the gradient and y intercept, respectively.
IS t = c (2)
Therefore, IS t was calculated using the following equation:
IS t = IS−m(analyte) (3)
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This eliminates the effect of the analyte on the IS response, while preserving normal IS response
variation between samples due to other factors, as exemplified in Fig. 43. Therefore, this
adjustment will also preserve the usefulness of subsequent analyte response normalisations using
the labelled IS for accurate quantification.
Figure 43. Transformation of linear functions to obtain IS t. Exemplary transformation
of (S )-NIFE-L-Ala-d3 responses exhibiting (S )-NIFE-L-Ala response dependability to obtain
theoretical (S )-NIFE-L-Ala-d3 responses given the absence of (S )-NIFE-L-Ala-d3.
Due to substantial thermal decomposition of DL-cysteine-d2, (S )-NIFE-DL-Cys together with
other (S )-NIFE-D-AAs lacking a corresponding labelled IS, were normalised using other labelled
homologues. In the absence of co-elution, these normalisations are unlikely to compensate for
analyte response variations occurring due to matrix-induced ion suppression, making these
measurements less accurate and reliable. However, these normalisations will compensate for
general errors or variations in sample preparation or instrumental performance.
Significant differences were observed between the chiral amino acid profiles of rat plasma obtained
from RYGB- and sham-operated rats (Fig. 44a). The following (S )-NIFE-AAs were associated
with significantly higher responses in RYGB-operated rats: (S )-NIFE-D-Ala and (S )-NIFE-L-Ala
(p = 0.016 for both), (S )-NIFE-D-Ser and (S )-NIFE-L-Ser (p = 0.016 and p = 0.047, respectively),
(S )-NIFE-D-Pro and (S )-NIFE-L-Pro (p = 0.031 and p = 0.016, respectively), and (S )-NIFE-D-
Leu (p = 0.007). (S )-NIFE-D-Arg responses were also found elevated in RYGB-operated rats,
although non-significant (p = 0.064). Meanwhile, (S )-NIFE-D-Thr and (S )-NIFE-L-Thr levels
were significantly reduced in RYGB-operated rats relative to the sham controls (p < 0.001 and
p = 0.016, respectively). Some (S )-NIFE-D-AAs were below the detection limits of the assay, and
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Figure 44. Plasma amino acid profiles of an RYGB rat model. (a) IS normalised
responses of (S )-NIFE-D-AAs and (S )-NIFE-L-AAs, and (b) relative D/L ratios in plasma
samples of RYGB- and sham-operated Wistar rats (mean ± s.d., n = 6). Statistical testing was
performed using unpaired t-tests assuming unequal variance with FDR correction. ∗, p < 0.05;
∗∗, p < 0.01; ∗ ∗ ∗, p < 0.001.
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therefore, could not be measured. These were (S )-NIFE-D-Gln and (S )-NIFE-D-Cys, although
the absence of (S )-NIFE-D-Cys may be attributed to thermal decomposition during sample
preparation as described previously.
A general increase or decrease in both enantiomers for the RYGB group relative to the control
group, as encountered for most amino acids, may indicate chirally non-specific responses to
the physiological effects of RYGB surgery rather than changes in gut microbial composition or
behaviour. Therefore, we calculated and compared the relative D/L ratios for each amino acid for
the two sample groups (Fig. 44b). Despite a decrease in the relative levels of (S )-NIFE-D-Thr
and (S )-NIFE-L-Thr, the relative D/L ratios for RYGB-operated rats were significantly higher
(p = 0.029). This indicates that the % depletion for L-threonine exceeds that of D-threonine
following RYGB surgery. Significant increases in D/L ratios were also observed for alanine
(p = 0.004), serine (p = 0.009), proline (p = 0.009), leucine (p = 0.007), and arginine (p = 0.028).
This suggests a predominating increase in the levels of the D-enantiomer for these amino acids
following RYGB surgery.
5.6 Discussion
LC-MS/MS has become a routine modern technique for measuring drug metabolites in biofluids,
such as plasma and urine, in the pharmaceutical industry. In this type of bioanalytical model, IS
calibrations are critical to ensure reproducibility and reliability by compensating for unavoidable
samples losses during sample preparation and analysis. Stable isotopically labelled standards
are the optimal choice for IS calibration, because they closely resemble the chemical structures
of their corresponding analytes with minor modifications. In theory, they are expected to have
similar physicochemical properties, and therefore, chromatographic behaviour. This means
they will experience the same fluctuations in detector response and ionisation efficiency as their
corresponding analogues. This is of particular importance in the context of MS/MS detectors,
which are typically less stable and robust than conventional detectors [Wieling, 2002]. Similar
physicochemical properties also imply that the labelled compounds will undergo the same changes
during sample preparation under the various experimental conditions employed.
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It is essential for the labelled standards to co-elute with their unlabelled analogues so that
they experience the same responses variations due to ion suppression and enhancement effects
from co-eluting matrix components. Although, most of the isotopically labelled standards we
employed met this criterion, some deuterium labelled standards in particular eluted slightly
earlier than their corresponding analyte in aqueous-organic solvent. This is most probably
due to reduced hydrophobicity as a result of the isotopic modifications. Regardless, these
deviations in RT were found to be minimal in complex matrices, warranting their use as internal
standards. Some D-amino acids did not have a commercially available isotopically labelled
analogue. As synthesising such compounds can be costly and time consuming, non-co-eluting
labelled structural homologues were used as substitutes for normalisation. While these may
not correct for response variations due to matrix-induced ion suppression, they may correct for
global response variations arising from general fluctuations in instrumental performance and
sample preparation errors.
In addition to differences in RT between labelled and unlabelled analogues, some labelled
compounds also exhibited diminished response recovery relative to their corresponding analyte at
equivalent concentrations. Deuterium labelled compounds in particular are associated with the
potential to undergo intramolecular exchange of deuterium atoms with hydrogen atoms [Wieling,
2002]. This exchange phenomenon, in conjunction with potential differences in physicochemical
properties through isotopic modification, may explain their less than expected measured responses.
Despite differences in response recovery, these labelled compounds are still useful for normalisation
and quantification as their labelled to unlabelled response ratio remained constant within the
linear range of quantification.
We applied the UPLC-MS assay for the relative quantification of D- and L-amino acids in rat
urine and plasma samples collected from a subset of RYGB- and sham-operated rats to evaluate
any significant differences between the groups. This sample set was particularly desirable for
conducting chiral analysis of amino acids due to the previous demonstration of substantial shifts
in main gut phyla in RYGB-operated rats between 2 and 8 weeks post-surgery. These changes in
gut microbiota were not evident for sham-operated controls. These changes comprised of higher
populations of Gammaproteobacteria (52 fold increase), specifically Enterobacter homaechei, and
lower populations of Firmicutes and Bacteroidetes (4.5 fold and 2 fold decreases, respectively) [Li
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et al., 2011]. This dramatic shift in gut bacterial balance was caused by the alteration of GI
anatomy during the RYGB procedure, which reroutes the flow of ingested nutrients directly
to the ileum without prior exposure to the main body of the stomach. In addition, the
surgery also causes reduced GI motility due to the effects of proximal surgical vagotomy and
the action of gut peptides, allowing nutrients to remain in the intestine for longer [Urbain
et al., 1990, Suzuki et al., 2005]. Therefore, the gut microbiota is flourished by a heavy load
of undigested nutrients with slow transit times. Hence, an upregulation of several microbial
metabolites, such as acetate, propionate, and ρ-cresol sulphate, was seen in the excretion profiles
during the study. Furthermore, changes in some excretory metabolites were found to strongly
correlate to specific classes of bacteria. For instance, Gammaproteobacteria were associated with
strong positive correlations with urinary ρ-hydroxyphenylacetate, ρ-cresol glucoronide, ρ-cresol
sulphate, creatine, phenylacetylglycine, and indoxyl sulphate. They were also strongly positively
correlated with faecal glycine, uracil, succinate, putrescine, diaminoethane, methylamine, and
formate [Li et al., 2011].
Bacterial species typically express a wide range of amino acid racemases in comparison to
mammals, and use D-amino acids to perform a diverse set of functions, such as quorum sensing,
cell wall synthesis, and biofilm dissolution [Cava et al., 2011]. Therefore, we hypothesised
significant differences in the D-amino acid profiles of biofluids extracted from RYGB-operated
rats in comparison to those from sham-operated controls, having undergone drastic changes to
their endogenous gut microbial ecosystem. Unfortunately, our rat urine sample analysis was
fraught with unreliability, as indicated by the presence of considerable IS response variation
between samples and later confirmed by cross validating the acquired UPLC-MS data to pre-
existing 1H NMR data. Nevertheless, the data served as a useful tool for dissecting the flaws
associated with the current UPLC-MS assay protocol and our inventory of isotopically labelled
amino acid standards. The main cause of IS variation in this dataset was narrowed down to the
lack of CDA, which led to incomplete derivatization of target amino acids and their corresponding
IS. As a result, each sample was associated with different degrees of competitive derivatization
yielding highly inaccurate and unreliable results. Although incomplete derivatization was the
primary cause of IS variation in this particular dataset, other sources of IS variation were also
discovered, including IS response dependability on analyte concentrations and thermal instability
during sample preparation.
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Protein precipitation was excluded during the preparation of rat urine, which may have had
adverse influences on data accuracy and reliability. Sample proteins can interfere with the
derivatization reaction or cause signal suppression of target analytes, which is particularly
problematic for less abundant metabolites. The urine of healthy human individuals contain
relatively little protein and other high molecular weight compounds due to renal tubule filtration.
Therefore, the omission of protein precipitation during human urine sample preparations is
justified. However, urine samples of rodents have been shown to be physiologically highly
proteinuric, containing proteins such as albumin and globulin [Finlayson et al., 1965,Roy and
Neuhaus, 1966]. In reference to Wistar rats specifically, a prostatic protein was identified in the
urine of young male Wistar rats with no pathological conditions [Perry, 1965]. This suggests the
need for a routine protein precipitation step during the preparation of rat urine samples.
The rat plasma data did not exhibit high IS variation like the urine, which suggests complete
derivatization of target compounds. This is most likely due to the absence of highly variable
dilutions, like those for urine, and reduced pools of derivatizable molecules. However, the issue
of IS dependability on analyte concentrations still persisted. Therefore, a simple adjustment was
made to the IS data prior to normalisation to eliminate the effects of plasma analyte concentrations
on IS responses, while preserving the magnitude of variation caused by other factors. This data
processing step maintains the overall integrity of the internal calibration method of normalisation
and ensures accurate and reliable quantification of endogenous metabolites.
Considerable differences were observed between RYGB- and sham-operated rats with respect
to the relative plasma levels of several D- and L-amino acids, namely DL-alanine, DL-serine,
DL-proline, DL-threonine, D-leucine, and D-arginine. These differences were unlikely to result
from dietary intakes as all rats were fed the same diet. However, there is a possibility that
the observed changes in D-amino acids are due to spontaneous racemisation of L-amino acids
liberated from polypeptides. Since we were primarily interested in changes to the levels of
D-amino acids as an indication of shifts in gut microbial phyla rather than chirally non-specific
alterations, we gave priority to the interpretation of relative D/L enantiomeric ratios.
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Despite the low statistical power of the current study, we found that RYGB-operated rats were
associated with significant increases in D/L ratios for the aforementioned panel of amino acids.
Since spontaneous racemisation is expected to occur at the same rate for each enantiomer, this
is unlikely to have an impact on D/L ratios. With the exception of threonine, the increase in D/L
ratios for amino acids were due to a predominant % increase in the D-amino acid. This may
reflect increased expression of these D-amino acids by the substantially elevated populations
of Gammaproteobacteria, reduced utilisation by diminished populations of Bacteroidetes and
Firmicutes, or a general gut microbial response to the increased bioavailability of incompletely
digested proteins as a result of bypassing the foregut. The notion of increased undigested protein
delivery to gut microbes is supported by pre-existing 1H NMR data of rat faeces, showing
significant changes in metabolites associated with microbial putrefaction. The faecal profiles
reveal an increase in several polyamines, such as putrescine and diaminoethane, which are
markers of microbial putrefaction [Li et al., 2011,Welters et al., 1999]. Furthermore, there
was also an increase in faecal γ-aminobutyric acid (GABA), a neuroactive peptide, which has
been shown to derive from microbial putrescine metabolism [Kurihara et al., 2010, Li et al.,
2011]. Statistical total correlation spectroscopy (STOCSY) analysis revealed strong, positive
correlations between Gammaproteobacteria and faecal putrescine and diaminoethane, suggesting
that the upreglation of these species after RYGB surgery is responsible for increased putrefaction,
and possibly, elevated colonic absorption of D-amino acids [Li et al., 2011].
Gammaproteobacteria represent the largest taxonomical class within the Gram-negative phylum
Proteobacteria and comprises of both aerobes and facultative aerobes. Genera from this class
include Escherichia, Enterobacter, Pseudomonas, Yersinia, and Vibrio [Williams et al., 2010].
Bacterial species of this subgroup have been identified not only in the colon, but also the ileum
and jejenum [Hayashi et al., 2005]. Like many bacteria, Gammaproteobacteria express a number
of amino acid racemases, and have previously been reported to use specific D-amino acids to
perform several functions [Cava et al., 2011], some of which were significantly upregulated in
RYGB-operated rat plasma samples.
Although Gammaproteobacteria are Gram-negative and lack a thick cell wall, they are still
associated with a single layer of peptidoglycan in the periplasm. D-amino acids, particularly
D-alanine and D-glutamic acid, are incorporated into the stem pentapeptides that crosslink linear
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glycan strands, contributing to the overall architecture and providing resistance to digestive
proteases [Nagata et al., 1998,Cava et al., 2011]. D-amino acids can also regulate the synthesis
and modification of peptidoglycans by interacting with periplasmic PBPs [Cava et al., 2011].
For some Gammaproteobacteria, like E. coli, an increase in D-amino acids, such as D-serine,
coincides with a transition to stationary phase [Lam et al., 2009,Anfora et al., 2007]. Therefore,
D-amino acids are likely to negatively regulate PBPs. In the presence of high cell densities of
Gammaproteobacteria, such as those encountered in the colon of RYGB-operated rats, these
species may opt to express D-amino acids to restrict further population expansion. This is called
quorum sensing and represents a cell survival mechanism to prevent bacterial overgrowth and
increased competition for nutrient supplies that could lead to cell starvation.
D-amino acids may also be used by Gammaproteobacteria as a direct nutritional source. The
genera Vibrio and Yersinia have been shown to possess the dadAX operon, where the first gene of
the operon encodes a small subunit of the respiratory D-amino acid dehydrogenase, which implies
that these bacterial species use D-amino acids as electron donors for respiration [Ravcheev et al.,
2007]. P. aeruginosa has been shown to express the alanine racemase DadX, and uses D-alanine
as a growth substrate following oxidative deamination by alanine dehydrogenase. In addition, D-
alanine is also used as an activator of the transcriptional regulator Lrp, which promotes expression
of DadX to facilitate its own production in a positive feedback loop [Boulette et al., 2009].
Similarly, E. coli express D-serine deaminase to use D-serine as a growth substrate by catabolising
it to form pyruvate and ammonia [Roesch et al., 2003]. D-serine also causes activation of the
transcription factor DsdC, which drives transcriptional expression of the D-serine transporter
DsdX to increase its own cellular consumption from the extracellular environment [Anfora et al.,
2007].
Another function of D-amino acids in Gammaproteobacteria is the regulation of biofilm formation.
For instance D-amino acids, such as D-leucine and D-methionine, have been shown to inhibit
bioflim formation in P. aeruginosa [Kolodkin-Gal et al., 2010]. In contrast, other Pseudomonas
species have been shown to incorporate D-amino acids in biosurfactants to facilitate surface-
adhered growth [Lim et al., 2009]. Although, surface-associated biofilm assembly on colonic
mucosal surfaces is favourable for more stable bacterial colonisation, escape to planktonic lifestyles
may be necessary during adverse microenvironmental conditions, such as limited nutrient supply
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and metabolic waste accumulation. To definitively attribute the observed changes in D-amino
acid profiles to increased Gammaproteobacteria, experiments with bacterial cell isolates with
conditions resembling the colonic environment need to be performed to observe the metabolic
outputs of these species.
Unlike the other amino acids, threonine was associated with significant reductions in both D-
and L-enantiomers in RYGB-operated rats. However, D/L ratios for threonine were significantly
higher than sham-operated controls. This suggests that although the levels of both enantiomers
decreased, there was a predominant % reduction in the levels of L-threonine relative to D-
threonine. This may either indicate reduced intestinal absorption of L-threonine due to reduced
liberation from dietary intakes or increased gut microbial utilisation. Alternatively, it may reflect
increased local or systemic preferential metabolic utilisation of L-threonine by the host.
There are two major drawbacks in the present study. The first is a limited sample size ( n=6),
which reduces the reliability of acquired data, and therefore its interpretations. The second
is that plasma samples were not collected pre-operation for pre-post pairwise comparisons of
RYGB-operated rats. This would provide a stronger evidence base to confirm the amino acid
profile changes observed. However, rat urine samples were collected pre- and post-operation;
therefore, a viable rat urine dataset would have served the same purpose.
In summary, stable isotopically labelled IS compounds were obtained for the majority of amino
acid enantiomers. The derivatives of these isotopically labelled amino acids generally displayed
similar chromatographic performance to the native amino acids. However, some of the labelled
L-amino acid standards, specifically those with a difference of < 3 amu relative to their unlabelled
analogues, proved to be unsuitable for the analysis of biofluids due to natural isotopic abundances
that allow the analyte to influence their response. Application of the UPLC-MS assay for relative
quantification of D- and L-amino acids in urine samples collected from a RYGB Wistar rat
model revealed that the assay was not optimal for yielding accurate and reliable results in this
matrix. In contrast, the assay proved to be adequate for the chiral assessment of amino acids in
rat plasma samples. The plasma profiles showed a general increase in D-amino acids following
RYGB surgery that is likely to reflect increased liberation of L-amino acids from proteins by
microbial putrefaction, and subsequent chiral conversion to the D-isoform by bacterial racemases.
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Increased microbial putrefaction following RYGB surgery stems from a combination of an
upsurge in the deliverance of incompletely digested proteins to the colon and a drastic increase
in Gammaproteobacteria. Therefore, we showed that chiral profiling of D-amino acids in biofluids
may be used as a means to probe the gut microbiome. These chiral profiles may also prove
useful for identifying predominating microbial species within the gut ecosystem, following further
characterisation of D-amino acid utilisation by specific genera through experiments conducted
using bacterial isolates.
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Chapter6
Quantitative metabolite panel expansion
and method validation
6.1 Overview
Widely targeted MS/MS analysis represents an intermediary between untargeted and targeted
analysis to provide highly sensitive, quantitative information on a large collection of known
endogenous metabolites. This chapter, herein, describes the further development of the enantios-
elective UPLC-MS assay to encompass a broader panel of endogenous amines that are detectable
in urine, some of which also exhibit chirality, thereby extending the stereochemical richness of
its multivariate data output. Method validation is an important step in the development of
bioanalytical assays, and more often than not, the quality of data acquired during analysis is
directly related to the rigour of the validation process. The US Food and Drug Administration
(FDA) guidelines for bioanalytical method validation is globally accepted and adopted by the
bioanalytical community. Therefore, these guidelines were largely used as the foundation for
performing partial method validation of the standardised UPLC-MS assay protocol for absolute
enantiomeric quantification of amino acids in human urine. The validated assay was then applied
to a small urinary sample set from a human dietary intervention study to obtain the absolute
concentrations of D- and L-amino acids.
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6.2 Aim and objectives
6.2.1 Aim
To expand the UPLC-MS assay’s chiral metabolic profiling capacity by incorporating an additional
panel of urinary amines for relative quantification and validating the method for absolute
quantification of D- and L-amino acids in human urine.
6.2.2 Objectives
• To search and screen a library of additional urinary amines that are susceptible to (S )-NIFE
derivatization and detection using the current UPLC-MS conditions with the intention of
expanding the assay’s quantitative panel of urinary metabolites.
• Optimise the MS/MS parameters for detection and quantification of all urinary metabolites
captured by the expanded quantitative panel.
• Rearrange the MRM functions to incorporate the new panel of detectable urinary amines
and minimise RT window overlap to allow higher dwell times for increased sensitivity.
• Perform method validation for absolute quantification of D- and L-amino acids in human
urine using FDA approved criteria.
• Apply the validated UPLC-MS assay to a small set of human urine samples to quantify in
absolute terms the concentrations of D- and L-amino acids and determine their enantiomeric
ratios.
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6.3 Introduction
6.3.1 Widely targeted LC-MS/MS analysis
Metabonomics deals with diverse metabolites that differ greatly in their physical and chemical
properties. As a result, the quantification of all metabolites in a biological sample may only be
achieved by integrating data from various analytical platforms that operate on different principals.
Untargeted MS-based approaches can be used to acquire broad metabolite profiles for biological
samples during high-throughput analysis. However, post-acquisition metabolite identification can
be a difficult and time consuming task. To circumvent these issues, widely targeted LC-MS/MS
may be used as an alternative approach for automated high-throughput analysis. Although
using this technique yields a diminished spectrum of metabolites, it is still capable of capturing
up to hundreds of target metabolites simultaneously to build a comprehensive metabolic profile
that can provide enough information to elucidate many biological processes. In addition, with
MRM using tandem quadrupole MS to monitor the turnover of product ions through precursor
Figure 45. (S)-NIFE derivatization of primary and secondary amines. Reaction
schemes for (S )-NIFE derivatizations of primary (top panel) and secondary (bottom panel)
amines.
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ion fragmentation for each metabolite, higher sensitivities and broader dynamic ranges of
quantification can be achieved [Sawada et al., 2009]. Therefore, it may serve as an intermediary
approach to bridge the gap between untargeted analysis and targeted analysis that looks at one
metabolite or a small group of metabolites relating to a specific metabolic pathway.
Amines represent a diverse, biologically important functional class of metabolites. They are
organic compounds containing nitrogen, and are formed from ammonia by replacement of one
or more hydrogen atoms by organic radicals. They can be distinguished as primary, secondary,
or tertiary depending on whether one, two, or three hydrogen atoms have been substituted,
respectively. (S )-NIFE is equipped with the potential to derivatize any primary or secondary
amine compound (Fig. 45). Therefore, we sought to expand the scope of the UPLC-MS assay
beyond the proteinogenic amino acid panel to analyse a more comprehensive catalogue of urinary
amines from a stereochemical perspective.
6.3.2 The Human Metabolome Database
As with any "omics" discipline, metabonomics is highly dependent on the availability and
quality of electronic databases. As metabonomics combines molecular biology with chemistry
and physiology, there is a growing need for a wide variety of electronic resources to support
such studies. There are at least five types of databases used in metabonomics research, each
with different designated purposes. These are metabolic pathway databases, compound-specific
databases, spectral databases, disease and physiology databases, and all-inclusive, organism-
specific metabolomic databases. The Human Metabolome Database (HMDB) represents a
highly informative metabolomics database for humans, which integrates all the information
from the other four types of databases into a single pooled resource to address the unique data
requirements of researchers involved in human metabolomics. The database was established as
part of the Human Metabolome Project (HMP) launched in 2004 as part of an effort to identify
and quantify all detectable metabolites in the human body [Wishart et al., 2007]. It currently
represents the largest and most comprehensive, organism-specific metabolomics database to
date, containing over 6800 human metabolites fully annotated with spectroscopic, quantitative,
analytic, molecular-scale, and biological information. The HMDB knowledge-base continues
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to expand with advances in metabolomics research and ongoing curated, data collection from
published literature, but also complementary independent experimental work [Wishart et al.,
2009].
6.3.3 Method validation for bioanalytical assays
Methods that are capable of obtaining high quality bioanlytical data to provide quantitative
information on analytes, such as drugs and their metabolites, in biofluids is critical for accurate
and reliable data interpretation. Method validation encompasses all the procedures required
to demonstrate that a bioanalytical method for the quantification of one or more analytes in a
specific biological matrix is reliable for an intended application. Technological advancements
have lead to the rapid emergence of LC-MS/MS based assays, which have largely replaced
conventional HPLC, GC, and GC-MS based assays, and currently represent one of the most
widely employed bioanalytical techniques. There are three types of method validation: full
validation, partial validation, and cross validation, each relating to different scenarios. A full
validation is required for a new bioanalytical method being implemented for the first time or
an existing one following the incorporation of additional metabolites. Partial validations are
conducted under circumstances such as bioanalytical method modifications or improvements
to support specific studies, and inter-laboratory method transfers due to expanding method
utilisation. A bioanalytical method may undergo several rounds of partial validation during
its evolution to ensure its continual reliability for modified applications. The extent of partial
validations can vary greatly from just a few tests to almost full validation, depending on the
nature of changes to its application. Cross validation refers to the comparison of two different
bioanlytical methods using the same or different analytical platforms, whereby an existing
validated method is used as a reference for the validation of a comparator. While validation of
each method stands in isolation, there may be situations where a comparison of methods may
be necessary, such as during a long-term study where more than one method has been employed
for measuring analyte concentrations [Shah et al., 2000].
In pharmaceuticals, guidelines are provided by several authoritative bodies, such as the FDA
and International Conference on Harmonisation (ICH), to provide a unified framework for
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method validation. Meeting the acceptance criteria of these guidelines is required for the
regulatory approval of data submitted by the pharmaceutical community [Green, 1996]. In
general, these guidelines include the following assay performance metrics: selectivity, linearity,
accuracy, precision, sensitivity, reproducibility, and stability [Shah et al., 2000]. Although there is
an agreement regarding the assay performance metrics that should be assessed, there is diversity
in the approach used to evaluate each one [Green, 1996]. This is a general concern, particularly
with the establishment of bioanalytical laboratories in regions outside the EU and North America,
which demands global harmonisation of guidelines to increase the quality, transparency, and
efficiency of data gathering [Timmerman et al., 2010]. Furthermore, validation requirements are
continuously changing with the introduction of new recommendations and clarifications, or the
replacement of existing ones as a result of growing expertise in the field of bioanalytics. Method
development and validation may be conjoined in an iterative cycle. A developer may want
to know whether the current assay conditions are acceptable before pursuing further method
optimisation. Meanwhile, method validation may indicate further development is required to
optimise the assay conditions [Green, 1996]. Following the initial method development and
validation cycle, the assay is typically applied to an actual sample set as a distinct phase in the
method validation procedure to test its robustness during actual sample analysis [Shah et al.,
2000]. Method validation can be a tedious process and there is often a tendency for several steps
in this process to be omitted due to time constraints. However, the quality of data obtained
during the analysis of biological sample sets is directly related to the rigorousness by which the
validation process is applied [Green, 1996].
The 2001 US FDA Guidance for Bioanalytical Method Validation is widely accepted and adopted
by the bioanlytical community worldwide. As a result, it represents the cornerstone of regulated
bioanalytical laboratory procedures. In subsequent years, several meetings and conferences
have been hosted to discuss, clarify, reconfirm, or amend essential validating parameters. The
outcomes of such proceedings have been published in White Papers in recognition of differences
between analytical techniques, recent advances in analytical technology, and exceptional issues
that have arisen in adhering to specific guidelines or acceptance criteria [Shah, 2007,Smith, 2010].
Here, we used the 2001 US FDA Guidance for Bioanalytical Method Validation in large part as
the basis for validating the current enantioselective UPLC-MS assay for absolute quantification
of D- and L-amino acids in human urine.
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6.4 Experimental methods
6.4.1 Sample preparation
Following the identification of inherent flaws associated with the previous sample preparatory
protocol for urine samples, although in rat urine, several amendments were made for the revised
method to process human urine. Frozen human urine samples were thawed at room temperature,
mixed thoroughly, and centrifuged for 20 min at 20,817 g at 4 ◦C to remove any particulates.
20 µl of urine was mixed with 25 µl of a custom mix of isotopically labelled amino acid standards,
each at various concentrations depending on their linear range. The samples were then mixed
with 35 µl of 0.15 M sodium tetraborate solution and left to incubate at room temperature
for 10 min. Sample derivatization was performed by mixing the samples thoroughly with 50 µl
of 12.5 mg/ml (S )-NIFE dissolved in acetonitrile. After 20 min of derivatization at room
temperature, the reactions were terminated using 15 µl of 4 M HCl and diluted with 55 µl
of H2O for a total sample volume of 200 µl (×10 dilution). The samples were incubated at
-20 ◦C for 10 min for salt precipitation and filtered using 10K centrifugal devices. The filtrates
were then transferred to total recovery LC-MS glass vials and stored at -80◦C until UPLC-MS
analysis. All post-derivatization steps were performed on ice to minimise potential deterioration
of derivatives.
Authentic amine standards were acquired from an expansive existing departmental chemical
standards repository and stock solutions were prepared at 1 mg/ml. 30 µl of the ×10 diluted
stock solutions were spiked into aqueous-organic solvent or urine and derivatized using the
revised sample preparation protocol.
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6.4.2 Instrumental parameters and data acquisition
Screening for additional derivatizable amines was performed using untargeted MS scan mode on
the Xevo TQS. Subsequent optimisation of CV and CE parameters for optimised detection of
each compound was performed as described previously (Section 5.4.4). Following optimisation,
all detectable amine compounds were compiled together with the DL-amino acids for MRM using
their predefined parent and daughter ion m/z values and retention times. The chromatogram was
segmented by time using regions in the absence of target signatures for RT window intersections.
MRM transitions for analytes eluting within a specific time segment were grouped into one MRM
function. A new column was used to perform method validation, which required an adjustment
in flow rate to 0.8 ml/min in order to accommodate some of the late eluting analytes.
6.4.3 Method validation
6.4.3.1 Specificity
The responses attained for pure racemic solutions of each amino acid (2.5 µM) were compared
to the responses obtained in a solution containing a mixture of all amino acids (each at 2.5µM
concentration). The responses in pure racemic solutions were also compared to those obtained in
a solution containing a mixture of all amino acids together with their labelled IS compounds. The
labelled IS compounds were all added at the concentration of their upper limit of quantification
(ULOQ). The same test was also performed for each labelled IS compound (2.5 µM) with all
analytes at their ULOQ concentration.
The matrix effect for both analytes and their corresponding labelled IS compounds was determined
by calculating the matrix factor (MF), which is the ratio of the spiked analyte peak response in
the presence of matrix ions (analyte ms) to the analyte peak response in the absence of matrix
ions as follows:
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MF =
(
analyte ms
analyte
)
× 100% (1)
The standard addition method was employed, whereby analytes were added to a representative
pooled urinary matrix comprised of 6 independent urine sources. The unspiked urinary matrix
was used to subtract the response attributed to the endogenous presence of analytes to obtain
the response that is solely attributed to the spiked concentration, that is analyte ms.
Normalised response ratios (ratioA/IS) were determined in 3 independent urine samples, with a
total of 3 technical replicates per sample, by spiking in both the analyte and its representative
labelled IS compound. analyte ms was initially normalised to obtain analyte n by dividing it by
its representative IS:
analyte n =
analyte ms
IS
(2)
The ratio of analyte molar concentration spiked (CA) to IS molar concentration spiked (CIS)
was then used to determine ratioA/IS:
ratioA/IS =
CA/CIS
analyte n
(3)
6.4.3.2 Linearity
The linear ranges were ascertained by performing an 11 point calibration curve (0 µM, 0.25 µM,
0.5 µM, 1.25 µM, 2.5 µM, 5 µM, 12.5 µM, 25 µM, 50 µM, 100 µM, and 200 µM) using a
pre-prepared stock solution of all analytes. The calibration curve was prepared in duplicate
using the standard addition method in a pooled urinary matrix. To determine the ULOQ for
each analyte, the endogenous molar concentration of analyte in the pooled matrix ( mCA) was
first deduced using the y-axis intercept (c) of the calibration curve, which represents analyte m:
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mCA = CA
(
analyte m
analyte ms
)
(4)
ULOQ is then the summation of mCA and the last CA (max CA) before the observation of
concentration-response non-linearity:
ULOQ = mCA + max CA (5)
The acceptability of linearity was determined by linear regression to obtain the correlation
coefficient (r) and coefficient of determination (R2).
6.4.3.3 Limits of detection and quantitation
The LOD and LOQ of each analyte in urine was determined using the S/N method as described
previously (Section 3.4.4). The 0 µM calibration standard was used to calculate LOD and
LOQ for urine after determining mCA using the following equations:
LOD =
3 mCA
S/N
(6)
LOQ =
10 mCA
S/N
(7)
6.4.3.4 Precision
A pooled urinary matrix was spiked with low (5 - 20% ULOQ), medium (30 - 60% ULOQ), and
high (70 - 100% ULOQ) molar concentrations of analyte (LQC, MQC, and HQC, respectively),
and a fixed concentration of IS (n = 6). The inter-assay precision of analyte n for each QC level
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was evaluated using the relative standard deviation (RSD), also known as the coefficient of
variation, expressed as a percentage.
RSD =
(
s.d. analyte n
mean analyte n
)
× 100% (8)
6.4.3.5 Accuracy
Accuracy was evaluated by preparing LQC, MQC, and HQC samples using two different urinary
matrices, one diluted and the other concentrated, with IS (n = 3 per matrix). ratioA/IS was
determined in the concentrated urinary matrix and then applied in the calculation to predict CA
(calc.CA) for both matrix dilutions at each QC level. The accuracy for each QC was assessed by
working out the relative error (δ x), expressed as a percentage, of determined calc.CA values:
δ x =
(
calc.CA − CA
CA
)
× 100 (9)
6.4.3.6 Carryover
Sample carry over was assessed by injecting two double blanks (containing no analyte or IS)
following the injection of a ULOQ calibration standard. Carry over was deemed acceptable if
< 20% of the LOQ.
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6.5 Results and discussion
6.5.1 Extending metabolite coverage to other urinary amines
(S )-NIFE has the potential to react with any primary or secondary amine, of which there
are many in human urine. Some of these amines are also chiral, and it may be possible to
discriminate and quantify their enantiomers in urine along with those of the proteinogenic
amino acids. Therefore, we wanted to expand the enantioselective UPLC-MS assay to capture
this additional panel of amines in the urinary profiles it generates. The enhanced metabolite
coverage will provide an opportunity to perform more comprehensive analysis to decipher the
human metabolome with respect to amine metabolism. We searched the HMDB for previously
detected and quantified primary and secondary urinary amines to generate a hit list of potentially
derivatizable candidates that may be detected using the assay. Authentic standards for these
metabolites were obtained and derivatized with (S )-NIFE. The parent ions of the derivatives
were then screened using untargeted MS scans. Of the 81 amine compounds screened, 74
were detected. Some of these metabolites were chirally discriminated using the assay, such as
DL-ornithine, DL-citrulline, and DL-pipecolic acid (Fig. 46). A few of these metabolites had
similar m/z and RT values to some of the chiral proteinogenic amino acids. For instance, ( S )-
NIFE-β-Ala was found to co-elute with (S )-NIFE-L-Ala and (S )-NIFE-L-homoserine co-eluted
with (S )-NIFE-L-Thr. This prevents reliable quantification of these metabolites in unknown
human urine samples. Furthermore, urinary drug metabolites, such as penicillamine, and those
with very low assay sensitivity (S/N < 10 in urine) were omitted, which reduced the additional
amine panel size to 50 (Table 6).
Following initial detection and characterisation of the new metabolite panel, we optimised
their MS/MS parameters for the best sensitivity. However, the MS/MS parameters of some
metabolites had to be deoptimised later due to their high abundance in human urine in order to
limit their detector responses within the linear range of quantification (Table 6). The sensitivity
of MRM UPLC-MS/MS is critically dependent on the tuning of instrument parameters, such as
CV, Ecoll, and dwell time. Therefore, we explored each of these parameters for individual MRM
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Figure 46. MRM UPLC-MS/MS chromatograms of targeted (S)-NIFE derivatized
urinary amines. 1) asp-glu, 2) O-phospho-DL-serine, 3) L-aspartic acid, 4) D-aspartic acid, 5)
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DL-glutamic acid, 6) asp-ala, 7) O-phosphoethanolamine, 8) 4-hydroxy-L-proline, 9) L-asparagine,
10) L-serine, 11) D-asparagine, 12) D-serine, 13) L-alanine/β-alanine, 14) DL-methionine sulphox-
ide, 15) sarcosine, 16) D-citrulline, 17) L-arginine, 18) L-2-aminobutyric acid, 19) 5-aminovaleric
acid, 20) D-arginine, 21) L-anserine, 22) D-proline, 23) N -acetyl-L-cysteine, 24) L-valine, 25)
ethanolamine, 26) 3-hydroxy-L-kynurenine, 27) histamine, 28) D-valine, 29) D-methionine, 30) L-
kynurenine, 31) D-isoleucine, 32) D-leucine, 33) putrescine, 34) 3-hydroxytyramine, 35) serotonin,
36) tyramine, 37) L-ornithine, 38) D-ornithine, 39) L-cysteine, 40) D-cysteine, 41) L-tyrosine, 42) D-
tyrosine, 43) tryptamine, 44) cadeverine, 45) β-asp-gly, 46) L-α-aminoadipic acid, 47) L-glutamine,
48) glycine, 49) D-glutamine, 50) D-homoserine, 51) 5-aminolevulinic acid, 52) L-carnosine, 53)
D-threonine, 54) D-alanine, 55) α-aminoisobutyric acid, 56) D-3,4-dihydroxyphenylalanine, 57)
L-pipecolic acid, 58) D-pipecolic acid, 59) L-isoleucine, 60) L-tryptophan, 61) cystathionine,
62) D-tryptophan, 63) L-2,4-diaminobutyric acid, 64) L-saccharopine, 65) L-citrulline, 66) L-
threonine, 67) hypotaurine, 68) taurine, 69) L-β-aminoisobutyric acid, 70) D-β-aminoisobutyric
acid, 71) L-homocarnosine, 72) L-proline, 73) D-3-aminobutyric acid, 74) D-2-aminobutyric
acid, 75) L-methionine, 76) 3-hydroxy-D-kynurenine, 77) DL-cystine, 78) L-histidine, 79) γ-
aminobutyric acid, 80) L-3-aminobutyric acid, 81) 3-methylhistidine, 82) N -acetyl-L-ornithine,
83) L-3,4-dihydroxyphenylalanine, 84) N -methyl-L-histidine, 85) S -(5-adenosyl)-L-homocysteine,
86) 3-nitro-L-tyrosine, 87) L-leucine, 88) 3-hydroxyanthranilic acid, 89) DL-2,6-diaminopimelic
acid, 90) reduced L-glutathione, 91) 5-hydroxy-L-lysine, 92) L-lysine, 93) D-lysine. MRM transi-
tions were grouped by retention time into predefined time segments as shown.
transitions to manipulate urinary responses to the desired range of intensities. CV is the electrical
potential exerted between the capillary, or nozzle, and skimmer of the ESI source. High CV
is associated with increased in-source fragmentation upfront of collision-induced dissociation
in the collision cell (Q2), and may be used to obtain MS/MS-like spectra in the absence of
a tandem analyser using a single quadrupole or TOF instrument. The charged species can
undergo collisions with the residual or bath gas on their path between the nozzle and skimmer.
Changes in CV can alter the ion velocity, and consequently, the collision energy [Pashynska
et al., 2006]. In MS/MS, excessively high CV can lead to reduced parent ion species entering
Q1, thus reducing detector responses. Ecoll is the energy imparted on precursor ions from Q1 to
collide with neutral gas molecules in Q2 and is expressed in the units eV [Busch, 2011]. During
collision, kinetic energy is translated into internal energy, which induces molecular decomposition.
Therefore, higher Ecoll is associated with increased fragmentation of parent ions and detection of
daughter ions. However, excessively highEcoll can result in the loss of valuable stable fragment
peaks. Dwell time is the amount of time spent on an MRM transition during each scan cycle.
Theoretically, a saturated detector response should remain saturated regardless of the time
spent monitoring the analyte. Therefore, although reducing dwell times will reduce the analyte
response, it is not expected to have an effect on its linear response range. However,
204
Table 6: Instrumental parameters for the expanded UPLC-MS assay.
Compound MS/MS parameters RT (min)
Parent
ion
Daughter
ion CV (V) Ecoll (eV)
Dwell time
(s)
asp-glu 512.30 119.90 30 34 0.123 1.46
O-phospho-DL-serine 435.12 119.92 30 34 0.200 2.56
L-aspartic acid-d3 386.21 119.91 24 20 0.015 4.04
L-aspartic acid 383.17 119.91 24 20 0.015 4.06
β-asp-gly 440.24 119.91 25 28 0.003 4.24
D-aspartic acid-d3 386.21 119.91 28 20 0.043 4.30
D-aspartic acid 383.17 119.91 28 20 0.043 4.34
DL-glutamic acid-d3 400.22 119.90 32 20 0.003 4.78
DL-glutamic acid 397.25 119.91 32 20 0.003 4.80
L-α-aminoadipic acid 411.27 119.91 35 26 0.002 4.95
L-saccharopine 526.23 119.92 10 44 0.025 4.98
asp-ala 454.26 119.92 20 30 0.025 6.01
O-phosphoethanolamine 391.15 119.90 35 22 0.005 6.72
4-hydroxy-L-proline 381.21 119.91 15 22 0.007 7.82
L-asparagine 382.29 119.91 16 28 0.003 8.35
L-asparagine-15N2 384.26 119.91 16 28 0.003 8.35
L-serine-d3 358.19 119.96 16 24 0.008 8.70
L-serine 355.13 119.97 16 24 0.002 8.72
L-glutamine-d5 401.25 119.91 20 20 0.008 8.83
L-glutamine 396.29 119.91 20 20 0.001 8.85
D-asparagine 382.29 119.91 28 20 0.010 8.93
L-citrulline 425.24 119.93 30 34 0.008 8.93
glycine 325.26 119.98 24 22 0.001 9.16
D-serine-d3 358.19 119.96 16 24 0.003 9.17
L-threonine-13C4,15N 374.24 119.95 32 20 0.010 9.17
D-serine 355.13 119.97 16 24 0.003 9.19
L-threonine/L-homoserine 369.26 119.91 32 20 0.002 9.19
L-histidine-d3 408.30 119.93 48 20 0.030 9.19
L-histidine 405.30 119.88 48 20 0.006 9.21
L-alanine-d3 342.27 119.96 28 20 0.010 9.33
L-alanine/β-alanine 339.19 119.96 28 20 0.002 9.36
D-glutamine 396.29 119.91 16 20 0.030 9.44
DL-methionine sulphoxide 415.17 119.90 20 28 0.003 9.52
hypotaurine 359.20 119.90 25 22 0.010 9.52
sarcosine 339.23 119.90 15 22 0.011 9.67
taurine 375.14 119.90 30 24 0.002 9.72
D-homoserine 369.28 119.91 25 18 0.011 9.74
γ-aminobutyric acid 353.27 120.01 30 22 0.011 9.77
D-citrulline 425.24 119.93 10 34 0.011 9.84
5-aminolevulinic acid 381.21 119.97 10 28 0.011 9.92
L-β-aminoisobutyric acid 353.20 119.95 20 22 0.001 9.93
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Table 6: (Continued)
L-3-aminobutyric acid 353.26 119.91 30 24 0.011 9.96
3-methylhistidine 419.24 119.91 35 34 0.001 10.05
L-arginine 424.27 120.03 40 38 0.011 10.11
L-arginine-13C6 430.23 119.91 40 38 0.011 10.11
D-β-aminoisobutyric acid 353.20 119.95 20 22 0.011 10.15
L-carnosine 476.29 119.94 60 46 0.011 10.18
L-2-aminobutyric acid 353.23 119.94 20 34 0.005 10.43
5-aminovaleric acid 367.23 119.95 25 24 0.003 10.57
L-homocarnosine 490.25 119.91 15 48 0.023 10.57
L-proline-d7 372.36 119.94 28 20 0.010 10.64
D-threonine 369.26 119.91 20 20 0.023 10.66
N -acetyl-L-ornithine 424.23 119.90 20 26 0.023 10.68
D-alanine-d3 342.27 119.96 28 20 0.002 10.73
L-proline 365.25 119.92 28 20 0.003 10.74
D-alanine 339.19 119.96 28 20 0.002 10.77
L-3,4-DHP 447.29 120.01 20 34 0.023 10.78
D-arginine 424.27 120.03 16 38 0.023 10.79
D-3-aminobutryic acid 353.26 119.91 20 24 0.023 10.85
α-aminoisobutyric acid 353.15 120.01 20 22 0.023 10.87
N -methyl-L-histidine 419.26 119.90 35 34 0.004 10.88
L-anserine 490.26 119.91 25 42 0.002 11.14
N -acetyl-L-lysine 438.25 119.90 15 34 0.002 11.17
D-proline-d7 372.36 119.94 28 20 0.023 11.46
D-proline 365.25 119.92 28 20 0.023 11.55
N -acetyl-L-cysteine 413.14 119.90 20 22 0.042 11.83
L-valine-d8 372.29 119.93 28 18 0.016 12.05
L-valine 367.26 119.91 28 18 0.002 12.11
D-3,4-DHP 447.29 120.01 25 28 0.042 12.24
L-SAH 634.26 119.96 50 40 0.042 12.25
D-2-aminobutyric acid 353.23 119.94 35 22 0.042 12.35
ethanolamine 311.25 120.00 30 20 0.001 12.46
3-hydroxy-L-kynurenine 474.22 119.93 30 34 0.042 12.66
L-pipecolic acid 379.31 119.90 10 20 0.042 12.70
L-methionine-d4 403.32 119.90 32 22 0.004 12.78
L-methionine 399.25 119.90 32 22 0.004 12.81
D-pipecolic acid 379.31 119.90 10 18 0.029 13.22
histamine 361.33 119.91 25 28 0.029 13.39
L-isoleucine-d10 391.39 119.91 36 20 0.005 13.40
L-isoleucine 381.32 119.96 36 20 0.005 13.45
3-nitro-L-tyrosine 476.25 119.91 15 28 0.029 13.45
3-hydroxy-D-kynurenine 474.22 119.93 45 30 0.029 13.50
D-valine-d8 372.29 119.93 36 18 0.029 13.52
D-valine 367.26 119.91 36 18 0.029 13.56
L-leucine-d10 391.39 119.91 36 20 0.002 13.69
L-leucine 381.32 119.96 36 20 0.002 13.74
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Table 6: (Continued)
D-methionine-d4 403.32 119.90 12 22 0.029 13.82
D-methionine 399.25 119.90 12 22 0.029 13.84
3-hydroxyanthranilic acid 403.28 119.87 40 18 0.029 13.91
L-kynurenine 458.31 119.91 25 34 0.010 14.06
D-isoleucine 381.32 119.96 28 22 0.020 14.63
D-leucine-d10 391.39 119.91 28 22 0.020 14.69
L-tryptophan-d3 457.22 119.97 24 28 0.002 14.69
L-tryptophan 454.25 119.84 24 28 0.015 14.70
D-leucine 381.32 119.96 28 22 0.002 14.74
putrescine 529.30 119.90 30 34 0.020 14.95
DL-2,6-DPA 689.31 119.90 45 46 0.020 14.99 15.0815.27
cystathionine 721.29 119.90 40 46 0.002 15.00
DL-cystine 739.20 119.91 50 52 0.010 15.14 15.28
3-hydroxytyramine 403.20 119.89 35 26 0.015 15.32
D-tryptophan-d3 457.22 119.97 36 26 0.020 15.37
D-tryptophan 454.25 119.84 36 26 0.020 15.39
reduced L-glutathione 806.27 119.90 55 40 0.020 15.34
serotonin 426.22 119.90 40 28 0.047 15.87
tyramine 387.27 119.90 30 26 0.020 16.13
5-hydroxy-L-lysine 661.31 119.92 60 46 0.002 16.26
L-ornithine 631.27 119.95 25 42 0.002 16.40
L-2,4-diaminobutyric acid 617.31 119.90 25 42 0.047 16.44
L-lysine-d4 649.36 119.90 32 38 0.020 16.71
L-lysine 645.29 119.92 32 38 0.002 16.72
D-ornithine 631.27 119.95 25 34 0.030 16.78
D-lysine-d4 649.36 119.90 24 44 0.002 17.09
D-lysine 645.29 119.92 24 44 0.002 17.11
L-cysteine 620.25 119.90 40 38 0.003 17.31
D-cysteine 620.25 119.90 40 38 0.047 17.80
L-tyrosine-d7 687.27 119.94 44 38 0.008 18.83
L-tyrosine 680.27 119.96 44 38 0.001 19.04
tryptamine 410.24 119.90 30 26 0.049 19.61
D-tyrosine-d7 687.27 119.94 44 38 0.100 19.77
D-tyrosine 680.27 119.96 44 38 0.100 20.11
cadeverine 601.33 119.90 55 40 0.049 21.27
MS/MS parameters and retentions times of urinary amines and isotopically labelled standards on the
Xevo TQS for the standardised enantioselective UPLC-MS assay.
CV, cone voltage; Ecoll, collision energy; RT, retention time
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interestingly we found that lowering the dwell times for saturated analytes successfully confined
their responses within the linear range of quantification. Although the objective of suppressing
the signals of highly abundant urinary metabolites can be achieved using any one of these three
MS/MS parameters, dwell time adjustment has the added benefit of redistributing the available
scan time in favour of low abundance metabolites. This provides the opportunity to enhance
weak signals while simultaneously suppressing saturated ones. For analytes with excessively
high urinary concentrations or very high assay sensitivity, such as L-glutamine and L-lysine,
combinatorial adjustment of multiple MS/MS parameters had to be made to constrain responses
to the target range. To that effect, another way is to select a less abundant representative parent
or daughter ion for the transition, such as a naturally occurring isotope or an alternative adduct.
MRM transitions were sorted according to predefined chromatographic time segments, whereby
those of analytes eluting within a specific time segment were grouped into one MRM function
(Fig. 46). A time segmented approach ensures fewer concurrent MRM transitions per scan
cycle, allowing longer dwell times to be assigned to metabolites at low urinary concentrations,
like the majority of D-amino acids, for added sensitivity and better S/N values. However, for
chromatographic regions that are particularly enriched with target metabolite signatures, it was
not possible to create non-overlapping time segments without disrupting an analyte peak. Even
in the presence of minimal overlap between time segments, all MRM transitions across those
MRM functions are monitored simultaneously during the scan cycle. This considerably reduces
the dwell times for each MRM transition within the overlapping RT windows and compromises
sensitivity. One way to prevent time segment overlap is to modify the gradient elution profile to
intentionally introduce quiet zones in the chromatogram. However, this is likely to increase the
run time per sample, which is problematic considering the current run time of the method is
already relatively long for a high-throughput analysis (26 min). The scan time was adjusted to
achieve a minimum of 12 data points per peak. Manually increasing the dwell times of MRM
transitions for low abundance analytes has the effect of increasing the overall scan time. This
reduces the number of data points acquired per peak, which may compromise the ability to
produce accurate and reproducible peak integrations post-acquisition, particularly for narrow
peaks. In general, we found that it was compulsory to implement the auto-dwell feature in
the MassLynx software for one or more MRM transitions in an MRM function for dynamic
optimisation of scan times in order to acquire an adequate number of data points. Given these
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circumstances, adding more analytes to the method may require complete redevelopment of the
MRM transition assortment or revision of the chromatography.
An alternative approach to time segmentation for MRM transition compilation is to define
narrow time windows for every analyte transition. This way, analytes are only monitored when
they elute from the column over very short windows, thereby on average reducing the number
of concurrent MRM transitions monitored during each scan cycle. This is accompanied by an
increase in analyte dwell times for improved S/N and data quality. This is akin to the dynamic
MRM feature on Agilent 6400 Series triple quad instruments and the scheduled MRM algorithm
employed by AB Sciex Analyst software v1.5 [Schreiber and Pace, 2010, Stone et al., 2009].
However, this approach is associated with the risk of missing peaks or acquiring partial peaks
if the defined RT window is too narrow. Therefore, it is essential to define RT windows by
taking into consideration analyte peak width and RT stability, in the context of both variable
biological matrix conditions and potential changes in instrumental performance during the course
of extended sample runs. Widely targeted MS/MS methods have previously been developed
using this approach to routinely monitor up to a few hundred MRM transitions in a single
analytical run [Sawada et al., 2009,Schreiber and Pace, 2010,Stone et al., 2009]. However, these
methods have not been applied to urine samples.
For the current assay, we were confronted by two problems which prevented us from using more
concentrated samples that would enable us to use lower average dwell times and still achieve
adequate detection. The first is the need to use low sample volumes in order to achieve complete
derivatization and ensure that the acquired data is reliable. The second is the highly variable
nature of urinary metabolites, which make it difficult to subdue all analyte responses within the
linear range of quantification. As a result we found that it was necessary to distribute much of
the dwell time associated with each scan cycle to monitor the prioritised D-amino acids with
little residual time for the remaining metabolites.
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6.5.2 Method validation for absolute quantification of D- and L-amino acids
in human urine
Validation represents a key phase in the establishment of a novel or an existing modified
bioanalytical method for routine application. It ensures that acquired bioanlytical data is of high
quality for reliable data interpretation. Here we performed validation of the enantioselective
UPLC-MS assay for the absolute quantification of D- and L-amino acids in human urine using
the current US FDA Guidance for Bioanalytical Method Validation that was officially published
in May 2001 [Food and Administration, 2001]. This guidance is almost universally adopted
by pharmaceutical and contract research industries as a standard approach for validating and
implementing bioanlytical methods that are used to generate data to support medicinal product
applications [Smith, 2010]. However, for justified reasons there were many instances where we
deviated from the FDA guidelines for a more fitting validation of the current assay. As the
scenario presented here represents the use of a modified existing assay in a new laboratory, only
a partial validation was required according to the FDA guidelines.
6.5.2.1 Specificity
Specificity, or selectivity, is the ability of the method to measure an analyte response in the
presence of all potential sample components. It is already well established that the current
assay is non-specific to DL-amino acids, because of substantial (S )-NIFE cross-reactivity with
other endogenous amines. The highly non-specific nature of the current assay is what makes
it appealing for widely targeted metabolic profiling. However, this comes with the risk of
analyte interferences that may prove obstructive to the absolute quantification of D- and L-amino
acids. We have already shown during our screen for additional detectable amine compounds
that (S )-NIFE-L-Ala and (S )-NIFE-L-Thr are subject to interferences from (S )-NIFE-β-Ala
and (S )-NIFE-L-homoserine, respectively, which impedes on reliable quantification of these
analytes in unknown biological samples. In addition, (S )-NIFE-DL-His was associated with
an extremely elevated, sloped baseline (Fig. 47). This was apparent both in the presence
and absence of urinary matrix ions. Due to the low urinary abundance of (S )-NIFE-D-His,
in particular, it was difficult to reliably distinguish its peak from the elevated baseline for
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Table 7: Response interferences and matrix effects for amino acid derivatives.
Amino acid Standard
(%)
Standard
+ IS (%)
MF
(%) Labelled IS
Standard
+ IS (%)
MF
(%)
D-Alanine 98.7 90.3 30.2 D-Alanine-d3 91.8 61.3
L-Serine 111.9 98.7 30.5 L-Serine-d3 97.8 61.9
D-Serine 96.2 84.5 27.1 D-Serine-d3 84.3 39.6
L-Proline 109.4 102.5 53.7 L-Proline-d7 98.2 81.9
D-Proline 111.8 105.6 88.9 D-Proline-d7 89.4 87.7
L-Valine 96.8 92.4 28.5 L-Valine-d8 103.7 37.1
D-Valine 94.8 96.9 86.6 D-Valine-d8 103.2 88.0
D-Threonine 89.9 89.4 28.3
L-Leucine 101.3 96.8 48.3 L-Leucine-d10 101.5 80.5
D-Leucine 105.7 102.6 33.0 D-Leucine-d10 90.0 36.1
L-Isoleucine 105.7 101.8 54.0 L-Isoleucine-d10 99.6 82.8
D-Isoleucine 107.6 113.0 79.3
L-Asparagine 97.1 90.0 53.8 L-Asparagine-15N2 95.1 76.7
D-Asparagine 96.6 89.7 83.3
L-Aspartate 105.8 108.6 74.0 L-Aspartate-d3 101.6 91.9
D-Aspartate 111.8 113.1 91.1 D-Aspartate-d3 101.5 91.5
L-Glutamine 92.6 89.3 12.9 L-Glutamine-d5 91.2 41.0
D-Glutamine 92.4 89.9 81.5
L-Methionine 92.9 91.7 77.7 L-Methionine-d4 88.3 89.9
D-Methionine 104.0 105.0 96.1 D-Methionine-d4 93.7 97.7
L-Histidine 105.0 110.6 57.1 L-Histidine-d3 95.1 53.3
L-Arginine 104.5 100.2 14.6 L-Arginine-13C6 88.9 14.5
D-Arginine 107.6 96.0 88.3
L-Tryptophan 93.9 84.4 25.0 L-Tryptophan-d3 91.0 47.3
D-Tryptophan 95.7 99.4 85.2 D-Tryptophan-d3 98.4 92.8
L-Cysteine 101.2 110.0 77.4 L-Cysteine-d2 2,204.1 1,830.9
D-Cysteine 99.7 108.2 97.3 D-Cysteine-d2 2,438.1 1,824.8
L-Lysine 101.9 94.7 26.1 L-Lysine-d4 100.6 72.4
D-Lysine 109.2 100.8 69.4 D-Lysine-d4 104.5 81.6
L-Tyrosine 102.9 97.1 88.1 L-Tyrosine-d7 98.6 66.2
D-Tyrosine 101.8 82.7 80.3 D-Tyrosine-d7 89.3 98.8
DL-Glutamate 106.2 104.1 85.2 DL-Glutamate-d3 99.7 96.3
The responses of D- and L-amino acid derivatives and their corresponding labelled IS in standard mixes
and human urine expressed as a % relative to the responses observed in standard solutions of the pure
compound. All values represent the mean of two technical replicates.
Standard, a mixture of all analytes or labelled IS compounds; Standard + IS, a mixture of all analytes
and labelled IS at ULOQ or labelled IS and analytes at ULOQ; MF, matrix factor
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accurate and reliable quantification. (S )-NIFE-L-His, on the other hand, is clearly visible in the
urine chromatogram despite baseline elevation due to its high abundance, and therefore, can
be quantified to some degree. There are several causes of baseline drift, including temperature
fluctuation, solvent impurities, and column contamination. The column was operated in an oven
to keep the temperature in check (60 ◦C) and mobile phases were prepared freshly using high
grade solvents prior to each analytical run, which rules out both these factors. Employing a
new chromatographic column and flushing the LC system made no difference on the baseline
drift, suggesting that a gradual build up of contaminant is also unlikely to be the cause. As
we were unable to identify and remedy the source of baseline elevation for (S )-NIFE-D-His, its
quantification, along with that of (S )-NIFE-L-Ala and (S )-NIFE-L-Thr, was not pursued further
as part of this method validation procedure.
To assess whether the remaining D- and L-amino acids were subject to interferences amongst
Figure 47. Chromatograms of (S)-NIFE-DL-His. MRM UPLC-MS/MS chromatograms
of (S )-NIFE-DL-His in aqueous organic solvent and human urine acquired using the Xevo TQS.
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themselves we compared the responses of standard solutions containing the racemic mix of
one amino acid to the responses of a solution containing a mixture of all amino acids, and
a solution containing a mixture of all amino acids and their corresponding labelled IS at
ULOQ concentrations. The responses of IS compounds were also assessed in a similar manner
against a solution containing IS and analytes at ULOQ concentration (Table 7). With the
exception of (S )-NIFE-DL-Cys-d2, the responses for all analytes and labelled IS compounds
remained relatively comparable as responses did not deviate by more than 17.3%. The responses
for (S )-NIFE-DL-Cys-d2 were elevated substantially in the standard mixture by 2438% and
2204%, respectively. This is most likely due to heavy IS response dependence on the amount
of (S )-NIFE-DL-Cys and its natural isotopic abundances (similar to that seen previously for
(S )-NIFE-L-Arg-15N2 and (S )-NIFE-DL-Tyr-d2). Therefore, (S )-NIFE-DL-Cys-d2 is unsuitable
for the purpose of internal calibration.
The matrix effect is the direct or indirect alteration of analyte responses caused by the endogenous
presence of interfering substances in the sample [Shah et al., 2000]. The quantitative measurement
of the matrix effect is termed the matrix factor (MF) and is defined byEq. 1. We determined
the MF for analytes and their corresponding labelled IS compounds using a representative pooled
urinary matrix. Due to the endogenous presence of amino acids in urine, the standard addition
method was used to determine the recovery of spiked analytes in the pooled matrix. Many of the
compounds, both native and labelled, were considerably influenced by matrix effects to variable
degrees (Table 7). For instance, the response of (S )-NIFE-D-Pro was reduced in urine by 11.1%
relative to that achieved in the pure racemic solution, whereas (S )-NIFE-L-Gln exhibited an
87.1% reduction. The 2001 FDA Guidance only briefly mentions matrix effects; however, the
2007 White Paper deals with the topic more comprehensively [Viswanathan et al., 2007]. The
guidelines specifically state that a high MF is not required for a reliable bioanalytical assay.
However, a highly variable MF for individual samples is a cause for a lack of reproducibility
during analysis.
FDA guidelines indicate that the matrix effect should be assessed using at least six different
sources of matrix to ensure that the matrix effect is consistent across samples for reliable
data acquisition. We assessed the matrix effect in three independent urinary matrices. As
the MF is calculated using the analyte response alone, it was subject to fluctuation between
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Table 8: Normalised response ratios (ratioA/IS) in human urine.
Amino acid Urine 1 Urine 2 Urine 3
D-Alanine 1.010± 0.052 0.949± 0.070 0.954± 0.048
L-Serine 6.457± 0.022 6.925± 0.023 6.855± 0.726
D-Serine 0.961± 0.012 0.919± 0.046 0.955± 0.072
L-Proline 3.259± 0.240 3.341± 0.670 3.513± 0.174
D-Proline 0.812± 0.010 0.809± 0.006 0.735± 0.013
L-Valine 5.706± 0.217 5.503± 0.025 5.998± 1.073
D-Valine 1.208± 0.010 1.128± 0.029 1.125± 0.037
D-Threonine 0.279± 0.008 0.229± 0.007 0.219± 0.010
L-Leucine 1.347± 0.120 1.410± 0.001 1.353± 0.069
D-Leucine 2.038± 0.101 2.336± 0.161 1.934± 0.083
L-Isoleucine 1.327± 0.026 1.296± 0.050 1.282± 0.160
D-Isoleucine 0.501± 0.012 0.448± 0.004 0.440± 0.006
L-Asparagine 1.305± 0.068 1.496± 0.042 –
D-Asparagine 0.490± 0.025 0.541± 0.083 0.586± 0.030
L-Aspartate 0.595± 0.048 0.669± 0.040 0.588± 0.024
D-Aspartate 0.716± 0.014 0.768± 0.011 0.719± 0.026
L-Glutamine – – –
D-Glutamine 0.043± 0.002 0.040± 0.004 0.046± 0.001
L-Methionine 0.826± 0.018 0.829± 0.031 0.757± 0.055
D-Methionine 0.792± 0.001 0.798± 0.005 0.764± 0.010
L-Histidine – – –
L-Arginine 2.314± 0.018 2.277± 0.148 2.230± 0.131
D-Arginine 0.350± 0.018 0.332± 0.036 0.341± 0.005
L-Tryptophan 5.638± 0.052 – 5.845± 0.207
D-Tryptophan 1.121± 0.019 1.141± 0.008 1.080± 0.023
L-Cysteine 1.305± 0.053 1.111± 0.026 0.895± 0.036
D-Cysteine 1.770± 0.045 3.227± 0.044 0.596± 0.072
L-Lysine 9.862± 0.463 9.481± 0.909 –
D-Lysine 1.314± 0.007 1.371± 0.017 1.244± 0.042
L-Tyrosine 0.524± 0.012 0.569± 0.008 0.564± 0.021
D-Tyrosine 0.727± 0.005 0.697± 0.006 0.755± 0.014
ratioA/IS was determined for each analyte across urine samples using the standard addition
method and represents the mean ± s.d. of three technical replicates.
– Endogenous concentration too high for standard addition
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analysed samples due to differential concentrations of constituents responsible for ionisation
suppression or enhancement effects. Therefore, relying on the absolute response is likely to
yield irreproducibility between samples during analysis. MF fluctuation is likely to be more
pronounced in urine samples as opposed to other human biofluids, such as plasma and CSF, due
to its highly variable dilutions. In contrast to MF, the IS normalised MF, which is calculated
by replacing the analyte responses in Eq. 1 with the IS normalised analyte responses in the
presence and absence of matrix ions, is likely to be much more stable across samples due to the
compensation for response variations offered by the labelled internal standard [Viswanathan
et al., 2007]. Although we did not calculate the IS normalised MF, we did compare the normalised
response ratios (ratioA/IS) across the evaluated urine samples, which was calculated using Eq.
3 and forms the basis of all absolute quantifications in unknown samples using the IS. Due to
the unsuitability of DL-cysteine-d2 for internal calibration, we normalised (S )-NIFE-D-Cys and
(S )-NIFE-L-Cys to alternative labelled homologues with the closest RT ((S )-NIFE-L-Tyr-d7 and
(S )-NIFE-D-Lys-d4, respectively). D-amino acids with no corresponding labelled IS were also
normalised in a similar way. ratioA/IS remained fairly consistent across samples for all analytes,
except for (S )-NIFE-D-Cys and (S )-NIFE-L-Cys (Table 8). This indicates that, for the most
part, the employed labelled IS compounds effectively compensate for the variable matrix effects
across urine samples.
Some of the D-amino acid peaks, namely D-leucine, D-glutamine, and D-threonine, were associated
with interferences from co-eluting peaks of matrix origin. This represents a major hindrance
to absolute quantification of these analytes, because the accuracy of calculated concentrations
is heavily reliant on the quality of peak integrations during post-acquisition data processing.
This issue may be resolved during analysis by altering the chromatographic conditions to ensure
that analyte peaks elute at different times to interfering matrix components for clean peaks.
Alternatively, software with in-built peak modelling algorithms may be using to deconvolute
overlapping peaks for accurate integration (Supplementary Fig. 2).
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Table 9: LODs and linear ranges of quantification for D- and
L-amino acid derivatives in human urine.
Amino acid LOD (nM) LOQ (nM) ULOQ (nM)
D-Alanine 461.2 1,537.2 128,516
L-Serine 1,815.3 6,051.0 453,868
D-Serine 298.5 995.0 197,063
L-Proline 58.2 193.9 19,795
D-Proline 1.7 5.7 2,608
L-Valine 1,361.5 4,538.3 78,480
D-Valine 8.4 28.0 2,948
D-Threonine 35.2 117.2 246,948
L-Leucine 263.6 878.7 52,260
D-Leucine 8.5 28.5 5,663
L-Isoleucine 46.1 153.6 19,152
D-Isoleucine 4.4 14.8 2,793
L-Asparagine 1,461.4 4,871.2 262,313
D-Asparagine 394.3 1,314.4 39,325
L-Aspartate 22.6 75.2 26,415
D-Aspartate 12.2 40.6 25,068
L-Glutamine 5,245.3 17,484.5 951,655
D-Glutamine 41.3 137.7 9,660
L-Methionine 75.1 250.3 32,885
D-Methionine 4.8 16.0 2,680
L-Histidine 2,106.5 7,021.7 478,765
L-Arginine 117.0 390.1 107,348
D-Arginine 59.3 197.7 19,090
L-Tryptophan 394.2 1,314.2 113,370
D-Tryptophan 2.7 8.9 5,245
L-Lysine 300.8 1,002.6 467,836
D-Lysine 61.9 206.3 17,278
L-Tyrosine 295.7 985.8 100,000
D-Tyrosine 9.7 32.3 5,000
DL-Glutamate 222.9 743.1 50,758
All values represent the mean of two technical replicates.
LOD, limit of detection; LOQ, limit of quantification; ULOQ, upper limit of
quantification
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6.5.2.2 Linearity
Demonstrating linearity verifies that the sample solutions are in a concentration range where the
analyte response is linearly proportional to the its concentration, which is crucial for accurate
quantification. According to FDA guidelines, linearity should be evaluated by producing a
matrix-based standard calibration curve with a minimum of 6 standard points to ensure detection
of curvature in the plotted data. Due to the different physiological dynamic ranges of D- and
L-amino acids, we used 11 calibration standards to build our matrix-based calibration curve to
ensure adequate definition of the relationship between concentration and response with complete
coverage of all physiological dynamic ranges. Furthermore, standard points which lie outside
the linear range may serve as so-called "anchoring points" in the asymptotic low and high
concentration ends of the standard curve, and may improve the overall curve fit [Food and
Administration, 2001]. Since it is not possible to obtain a blank matrix (a urinary matrix in the
absence of amino acids) as suggested by the FDA guidelines, the calibration curve was performed
using the standard addition method. Although this was adequate for accurately defining the
relationship between concentration and response in urine for analytes with low abundances, it was
less so for analytes with high endogenous concentrations in the upper quantification range. As a
result, only a couple of the higher calibration standards exhibited non-zero responses following
the subtraction of the endogenous response from the unspiked matrix. The FDA guidelines
indicate that at least 4 non-zero standards in a 6 point calibration curve, should represent the
linearity of responses without substantial deviation from nominal concentrations [Food and
Administration, 2001]. With too few points to adequately represent the relationship between
concentration and response, the reliability of the defined linear quantification range for high
abundance amino acids is questionable.
The MS/MS parameters for each analyte were intentionally varied to accommodate for the
various physiological dynamic ranges. Consequently, the ULOQs of each analyte also differed
dramatically (Table 9). The residuals for the calibration curves (n = 2) of all analytes were
randomly dispersed around the horizontal axis with no observable trends, indicating that a linear
regression model is more appropriate for the data fit than non-linear models (Fig. 48). r and
R2 exceeded 0.99 and 0.98, respectively, for calibration standards falling within the linear range
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across all calibration curves, except for those of D- and L-cysteine. Interestingly, (S )-NIFE-D-Cys
and (S )-NIFE-L-Cys were found to exhibit a sigmoidal concentration-response relationship in
urine, despite a linear relationship in the absence of matrix ions. It is uncertain whether this
behaviour in the presence of matrix components manifests as a result of derivatization or analysis.
Nevertheless, this non-linear relationship explains its variability in ratioA/IS across urine samples.
In the absence of a model to describe the concentration-response relationship, it is not possible
to determine the absolute molar concentrations of D- and L-cysteine in unknown samples using
the current assay.
6.5.2.3 LOD and LOQ
The FDA guidelines do not give specific recommendations for the determination of LOD. However,
it does provide details regarding the establishment of LOQ (also known as the lower limit of
quantification, LLOQ). There are two conditions that need to be met for the acceptability of
Figure 48. Standard addition calibration curves in urine. Exemplar calibration curves
for (a) D-serine and (b) D-asparagine illustrating the linearity of responses in human urine. r,
correlation coefficient; R2, coefficient of determination.
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LOQ. The first is that the analyte response is at least 5× the response of the blank to ensure
that it is discrete and easily identifiable. The second is that the analyte response should be
reproducible with a precision of at least 20% and an accuracy that does not deviate by more than
20% of the nominal concentration. To meet these criteria, it is necessary to sequentially increase
the analyte concentration, starting with the LOD, until the concentration can be measured to
within the specified precision and accuracy [Food and Administration, 2001]. However, this can
only be performed given a blank matrix. Our goal was to specifically determine the LOD and
LOQ in urine instead of solvent, in light of the substantial matrix effects. Therefore, due to
the presence of unremovable endogenous analytes to produce a a blank matrix, we employed
the S/N approach. This represents one of the common methods used for estimating LOD and
LOQ, which are each defined by using an S/N of 3 and 10, respectively [Shrivastava et al., 2011].
However, one caveat associated with the S/N approach is when there is a complete absence of
noise within the peak’s vicinity. Such is the case for analytes with very low dwell times, which
generates very high S/N values leading to underestimated LOD and LOQ calculations.
As with the ULOQ, LOD and LOQ were highly variable between analytes due to drastic
differences in MS/MS parameters to deliberately optimise the responses of low abundance
urinary analytes, while simultaneously deoptimising those of highly abundant ones (Table
9). For instance, (S )-NIFE-D-Pro was associated with an LOD and LOQ of 1.7 nM and 5.7
nM, respectively, whereas (S )-NIFE-L-Gln had an LOD and LOQ of 5245.3 nM and 17,484.5
nM, respectively. Despite the high LOD and LOQ for many of the (S )-NIFE-L-AAs and some
(S )-NIFE-D-AAs, such as (S )-NIFE-D-Ala and (S )-NIFE-D-Ser, they are perfectly adequate for
reliable measurements in human urine, where their concentrations typically far exceed these
values.
6.5.2.4 Precision
Precision refers to the amount of variability encountered in the measurements obtained from
repeat analysis of the same homogeneous sample under the prescribed conditions. To evaluate
inter-assay precision, we performed 6 determinations for an unspiked urine sample at each QC
level (LQC, MQC, and HQC). For L-glutamine and L-histidine, it was not possible to employ
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Table 10: Inter-assay precision and accuracy in human urine.
Amino acid Precision (%) Accuracy (%)
Unspiked LQC MQC HQC LQC MQC HQC
D-Alanine 3.87 16.36 5.54 4.85 13.71± 14.11 9.32± 5.02 8.54± 4.44
L-Serine 1.37 11.98 3.28 3.41 9.24± 4.66 6.28± 3.48 8.72± 3.71
D-Serine 2.11 2.23 5.45 8.07 6.63± 2.08 5.44± 5.15 5.19± 6.84
L-Proline 2.12 19.55 5.63 7.53 13.62± 12.19 6.50± 5.26 5.09± 5.50
D-Proline 3.18 1.70 1.04 1.20 3.17± 1.75 2.42± 1.06 0.78± 0.84
L-Valine 1.17 3.81 6.94 4.65 3.68± 3.49 4.91± 6.60 5.86± 4.38
D-Valine 1.81 1.10 1.48 0.86 4.87± 1.05 6.38± 1.39 6.65± 0.80
D-Threonine 4.46 9.27 3.00 1.03 16.56± 6.46 15.87± 0.86 12.74± 3.81
L-Leucine 1.57 28.07 8.86 7.97 24.52± 6.37 7.74± 5.43 6.26± 4.13
D-Leucine 2.56 15.32 7.46 3.22 11.82± 13.11 5.66± 4.67 2.40± 1.85
L-Isoleucine 3.18 6.66 7.73 1.96 4.15± 5.06 6.20± 1.06 2.37± 1.97
D-Isoleucine 4.47 2.11 1.18 2.30 19.99± 0.36 14.01± 1.29 13.98± 1.98
L-Asparagine 1.68 13.09 9.45 6.83 17.67± 15.40 20.76± 1.41 4.69± 5.62
D-Asparagine 3.41 16.62 8.18 5.05 21.37± 16.08 10.29± 9.02 10.31± 5.57
L-Aspartate 7.39 15.69 1.61 0.69 13.53± 3.22 7.88± 1.74 12.37± 0.78
D-Aspartate 17.29 3.71 3.25 2.80 10.33± 3.33 4.92± 2.94 3.70± 2.28
L-Glutamine 4.37 3.41* 4.71* 2.43* 4.33± 4.21* 2.95± 1.89* 1.88± 2.93*
D-Glutamine 2.12 4.37 11.08 7.57 8.00± 4.02 12.03± 9.74 6.12± 5.16
L-Methionine 1.87 2.62 4.58 2.64 3.31± 2.71 6.46± 4.87 4.64± 2.76
D-Methionine 3.52 1.41 0.87 0.49 1.30± 1.43 0.87± 0.51 0.58± 0.49
L-Histidine 4.05 17.67* 5.15* 0.78* 18.12± 7.53* 4.98± 5.63* 0.53± 2.62*
L-Arginine 7.72 3.94 1.53 0.78 6.22± 3.69 4.58± 1.46 1.58± 0.76
D-Arginine 3.93 6.16 0.91 4.99 12.39± 0.80 6.07± 4.69 1.86± 0.95
L-Tryptophan 5.39 9.01 0.70 0.92 28.71± 6.75 0.72± 0.40 0.63± 0.50
D-Tryptophan 12.82 3.07 1.06 0.04 4.93± 2.91 4.10± 1.01 3.96± 0.04
L-Lysine 5.85 12.43 4.48 – 8.74± 7.38 6.24± 4.20 –
D-Lysine 5.80 5.42 5.50 2.79 9.11± 5.91 4.37± 1.43 4.38± 2.91
L-Tyrosine 11.60 0.35 1.23 1.49 6.99± 0.32 4.87± 1.17 6.98± 1.59
D-Tyrosine 10.59 0.96 0.99 0.43 14.39± 0.82 16.23± 0.83 14.62± 0.37
Precision was determined using the relative standard deviation expressed as a % for 6 technical replicates
using unspiked and spiked samples of a representative pool of six independent urine samples. Accuracy
is represented by the mean ± s.d. and was evaluated by using the ratioA/IS derived by the standard
addition method in one urinary matrix to calculate the spiked concentrations of another.
LQC, low quality control (5− 20% ULOQ); MQC, middle quality control (30− 60% ULOQ); HQC, high
quality control (70− 100% ULOQ)
– Concentration above linear response range
* Data acquired in the absence of matrix (in aqueous-organic solvent) due to endogenous concentrations
being too high to use the standard addition method
220
the standard addition method due to high abundances of these metabolites in urine. Therefore,
QCs were prepared and evaluated for precision and accuracy in aqueous-organic solvent instead.
The FDA defines acceptable precision to be an RSD that is less than 15%, except at LOQ
where it should be less than 20%. For the unspiked urine sample, all analytes were associated
with an RSD ≤ 15%, except (S )-NIFE-D-Asp (17.29%) (Table 10). The high instability of
responses for (S )-NIFE-D-Asp around the mean value is due to a combination of both, low urinary
abundance and low S/N. Overall, these RSD values demonstrate that the assay is associated
with acceptable precision for the quantification of target amino acids in urine. With respect to
the various QCs, lower precision is expected, particularly for the LQCs, due to the employment
of the standard addition method whereby the response attributed to the standard addition is
determined by subtracting the mean endogenous response of independently prepared unspiked
matrices. Nevertheless, most analytes exhibited an RSD ≤ 15% at LQC, and all analytes were
associated with acceptable precision at MQC and HQC.
There are three main types of precision, of which we only assessed intra-assay precision (repeated
analysis of independent preparations of the same sample in a single run). Further method
validation is required to assess the other main types of precision, which are instrumental precision
(or injection repeatability) and inter-assay precision. Instrumental precision involves repeated
injections of the same sample to test the performance of the chromatographic instrument. For
inter-assay precision, aliquots of an homogeneous sample are prepared and analysed independently
on multiple days. Other forms of precision include testing with multiple analysts, instruments,
and laboratories.
6.5.2.5 Accuracy
The accuracy of the method represents the degree of closeness of the determined concentration
to the nominal or known true concentration under the prescribed conditions [Shah et al., 2000].
Accuracy for each analyte was evaluated using 3 replicates of LQC, MQC, and HQC, prepared
using the standard addition method. This was performed for two urinary matrices, a dilute and
concentrated urinary pool, giving a total of 6 determinations. Based on the assumption that
concentrations of urinary constituents are largely determined by urinary dilution, the dilute
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urinary matrix is theoretically representative of a sample with low matrix effects, while the
concentrated urinary matrix is expected to have high matrix effects. In addition to calculating
the standard addition concentrations of each QC within the dilute urinary matrix, the ratioA/IS
derived from this matrix was also used to calculate the spiked concentration of each analyte
in the concentrated urinary pool. The intra- and inter-matrix calculations were found to be
comparable across analytes suggesting that both matrices exhibit similar ratioA/IS. This is
consistent with the data obtained previously during the assessment of MF variability between
individual urine samples. The average δ x± s.d. was calculated using all 6 determinations for
each QC level to represent accuracy (Table 10). Most analytes were associated with acceptable
accuracy for all QC levels, as per the FDA guidelines (δ x ≤ 15%).
6.5.2.6 Carryover
Carryover is the contamination of a sample by the analyte of interest arising from a previous
sample injection. There are many physical and chemical contributors to carryover, including
the adsorption of analytes to surfaces and trapping of dead volumes within system flow paths.
Although any portion of the UPLC-MS system that comes into contact with the analyte is liable
for carryover contributions, the autosampler is often the main source of carryover due to the
exposure of a variety of surface materials to high concentrations of analyte and a large number of
interrupted flow paths. For instance, friction generated in the injection valve and syringe during
routine operation can lead to degradation of their respective surfaces forming small reservoirs
that may trap analytes. Other potential sources of carryover from the autosampler include,
improper tubing connections, creating dead volumes to physically trap analytes, and chemical
and physical attraction of analytes to packing material and the walls of the chromatography
column [Williams et al., 2012].
The presence of carryover contamination can affect the accuracy and precision of quantification,
particularly at low concentrations. Therefore, it is important to take necessary steps to minimise
the presence of any carryover interferences. To minimise the risk of carryover for analyses using
the current assay, the chromatographic column was flushed with high solvent B for 2 minutes
(90 - 100%), during which the injection valve was actuated to wash valve surfaces. The injection
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needle was also washed with a mixture of H2O, methanol, acetonitrile, and isopropanol at a
1:1:1:1 ratio.
The FDA guidelines do not provide any details regarding the assessment of carryover; however,
the issue is dealt with in the 2007 White Paper [Viswanathan et al., 2007]. There is currently
no standard acceptable magnitude of carryover for passing a bioanlytical assay. Therefore, we
objectively applied a carryover limit for approval of the current assay (≤ 20% LOQ). The blank
responses for all analytes following the injection of a ULOQ standard were ≤ 20% LOQ. In
fact, most analytes did not have a blank response that could be reliably distinguished from
the background noise, and thus quantified. This indicates that the assay is associated with
minimal carryover. Therefore, no additional measures were implemented with respect to flushing
the UPLC system between successive sample injections. However, carryover from residues
in rotary sampling/switching valves may affect chromatograms several samples down the run
sequence [Viswanathan et al., 2007]. Therefore, several blank samples may need to be injected
following a high concentration standard or sample for the assurance of no carryover contamination
during run sequences.
6.5.2.7 Stability
For routine analysis of many samples, it is essential that the derivatized products are stable
enough during analysis and under defined storage conditions should the instrument not be
immediately available for analysis. Short-term stability experiments involve the evaluation of
freeze-thaw cycles, bench top stability, and autosampler stability. Samples and standards should
be tested over a predefined analytical time frame (usually 48 hours) and compared to those which
are freshly prepared to evaluate any signs of analyte deterioration [Viswanathan et al., 2007].
Although we did not evaluate autosampler stability as part of this method validation procedure,
it was assessed previously during the analytical run of Wistar rat urine samples for the RYGB
study. QC sample data collected from this run spanned an analytical time frame of∼26 hours,
during which all analytes were associated with no significant deterioration in response. For
substantially lengthier analytical runs, an autosampler stability test will be required to ensure
no significant loss of derivatives over the longer time frame. Alternatively, samples can be split
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into 24 hour batches and analysed sequentially in a single run.
The FDA recommends that the influence of freeze-thaw cycles is studied using a minimum
of three cycles at two concentrations in triplicate [Food and Administration, 2001]. We did
not assess freeze-thaw cycle stability; therefore, it is recommended that samples undergo a
minimal number of cycles to avoid potential analyte deterioration. As bench top stability was
not evaluated either, it is recommended that all samples are prepared on ice and then stored at
-20 ◦C or less until analysis. In addition to the stability of analytes, it is also important to assess
the stability of standard solutions, reagents, and the mobile phase [Viswanathan et al., 2007].
The stability of sample preparatory reagents were not investigated; however, precautionary
measures should be taken to ensure their stability for routine applications. All reagents should
be stored in accordance to manufacturer guidelines. The efficacy of the (S )-NIFE derivatization
reagent must be tested using a representative pooled sample from the study of intended use to
ensure complete derivatization to indicate whether the reagent is fit for accurate and reliable
quantification. Reference solutions for calibration standard preparation should be prepared
freshly from their powdered state on a regular basis. Aliquots may be stored under frozen
conditions until required, but it is suggested that no aliquot once thawed s reused in successive
sample preparation sessions. Although ammonium bicarbonate is sufficiently stable in solution
at room temperature, it may still be susceptible to a degree of decomposition into ammonium,
carbon dioxide, and water [Nowak and Skrzypek, 1989]. Therefore, the mobile phase must always
be freshly prepared prior to each instrumental run. While short-term stability data is gathered
during the process of method validation, long-term stability is acquired post-validation following
an extended period of sample storage, and is also yet to be conducted.
6.5.2.8 Robustness
Robustness refers to the ability of a method to remain uninfluenced by small changes in sample
parameters, such as pH of the sample or mobile phase, buffer concentration, and temperature.
Each of these parameters may be evaluated one at a time or simultaneously as part of a factorial
experiment. To test robustness, we performed the assay on a small set of human urine samples
acquired from a dietary intervention study (n=8) in continuation of samples run for the definition
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Table 11: D- and L-amino acid concentrations and %D in human urine.
Amino acid Urine 1 Urine 2 Urine 3 Urine 4 Urine 5 Urine 6 Urine 7 Urine 8
L-Valine 35,378 25,649 44,959 62,889 38,437 19,604 22,534 31,496
D-Valine 572 469 606 635 865 285 157 378
L-Proline 6,448 4,924 7,211 4,983 9,742 2,039 2,446 2,261
D-Proline 36 33 63 14 47 23 17 6
L-Serine 185,738 53,071 141,806 100,507 162,244 19,408 28,648 27,893
D-Serine 82,160 77,829 117,306 65,721 107,970 36,537 25,033 26,921
L-Asparagine 272,919 67,387 216,287 144,835 267,019 33,645 39,346 47,825
D-Asparagine 17,905 9,741 16,325 9,134 30,869 5,985 3,271 3,945
L-Arginine 12,788 8,032 7,696 5,807 8,021 2,050 1,956 2,334
D-Arginine 2,874 1,948 2,745 1,710 3,956 666 233 467
L-Threonine 48,672 26,144 41,469 38,025 45,346 14,260 14,091 19,004
D-Threonine 360 280 307 415 526 205 165 280
D-Alanine 102,900 48,186 116,286 58,503 106,736 8,820 12,702 12,779
L-Aspartate 1,842 686 1,549 1,962 1,401 434 990 2,194
D-Aspartate 106 78 106 73 175 41 57 50
L-Leucine 36,544 14,554 22,050 23,052 42,132 5,091 4,801 7,653
D-Leucine 214 150 234 86 372 81 27 27
L-Isoleucine 8,594 4,307 6,622 5,899 16,906 1,697 1,415 2,197
D-Isoleucine 112 126 166 38 339 64 16 15
L-Glutamine 285,108 164,009 232,247 197,342 336,445 88,053 52,448 84,016
D-Glutamine 1,398 1,289 3,521 684 1,867 669 835 327
L-Histidine 438,980 158,824 305,450 316,264 433,111 50,554 56,786 136,220
L-Methionine 24,563 15,992 26,988 19,632 29,899 12,059 10,239 15,692
D-Methionine 253 88 302 88 379 68 37 56
L-Tryptophan 52,114 20,121 37,845 24,176 63,346 8,659 4,593 8,356
D-Tryptophan 106 52 135 22 242 43 44 12
L-Lysine 322,997 37,136 87,842 193,780 225,960 13,109 13,966 46,566
D-Lysine 6,672 3,397 4,616 2,592 15,384 1,513 960 1,139
L-Tyrosine 53,769 20,138 30,044 24,922 56,003 6,805 3,529 8,001
D-Tyrosine 186 156 201 73 485 134 55 40
%D of total
D-Valine 1.62 1.83 1.35 1.01 2.25 1.45 0.70 1.20
D-Proline 0.56 0.66 0.86 0.28 0.48 1.10 0.68 0.25
D-Serine 30.67 59.46 45.27 39.54 39.96 65.31 46.63 49.11
D-Asparagine 6.16 12.63 7.02 5.93 10.36 15.10 7.67 7.62
D-Arginine 18.35 19.52 26.29 22.74 33.03 24.53 10.64 16.66
D-Aspartate 5.46 10.18 6.39 3.58 11.09 8.60 5.42 2.22
D-Leucine 0.58 1.02 1.05 0.37 0.87 1.57 0.56 0.35
D-Isoleucine 1.29 2.84 2.44 0.63 1.97 3.64 1.11 0.69
D-Glutamine 0.49 0.78 1.49 0.35 0.55 0.75 1.57 0.39
D-Methionine 1.03 0.55 1.12 0.45 1.27 0.57 0.37 0.36
D-Tryptophan 0.20 0.26 0.35 0.09 0.38 0.50 0.95 0.14
D-Lysine 2.02 8.38 4.99 1.32 6.37 10.35 6.43 2.39
D-Tyrosine 0.35 0.77 0.67 0.29 0.86 1.93 1.55 0.50
Concentrations are given in nM and % D = D/(D + L)× 100% (n = 8).
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of previous method validation parameters. Each sample was subjected to a single analytical run.
This is considered adequate on the basis that precision and accuracy variabilities fall within the
acceptable tolerance limits. The chromatography was fairly reproducible with RT drifts < 0.1
min for all amino acids. The absolute concentrations were determined for all target analytes,
and subsequently, the %D relative to the total (Table 11). Most sample analyte concentrations
fell within the linear quantification range, for which there was acceptable precision and accuracy.
Urinary metabolite concentrations are typically reported in the literature following normalisation
to urinary creatinine (Ucr), such as ng mg−1 Ucr. As creatinine levels were not determined
for the sample subset analysed, we were unable to compare calculated urinary amino acid
concentrations to those acquired in previous human studies.
6.5.3 Conclusion
The enantioselective UPLC-MS assay is capable of detecting and quantifying a large panel of
chiral and achiral urinary amines, in addition to chiral proteinogenic amino acids. Therefore, the
assay is suitable for implementation to widely targeted metabolic profiling studies, representing
an intermediary between targeted and untargeted analysis. The assay was validated for absolute
enantiomeric quantification of most proteinogenic DL-amino acids over their physiologically
dynamic ranges in human urine. The defined assay performance parameters provide the basis
for good quantification using our own laboratory resources. Additional validation is required to
provide greater assurance that the method will generate data of comparable quality in other
laboratory settings where different operators, instruments, and reagents may be involved. It is
also advisable to conduct regular method performance checks, particularly if there is an extensive
time lapse between method validation and sample analysis, or equipment reconfiguration as a
result of multiple methods being run on the same instrument. Overall, the absolute enantiomeric
quantification of 29 D- and L-amino acids, together with relative quantification of 50 additional
urinary metabolites, makes the current UPLC-MS assay valuable for complementing current
metabolic profiling work flows. The additional dimensionality of the method pertaining to
metabolite stereochemistry, which is largely uncaptured by existing metabolic profiling methods,
may open up new avenues of research into the biological importance of chirality.
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Chapter7
Discussion
Chirality is an inherent feature in all biological systems, and is fundamental to the function of
biologically active molecules. Although at present, NMR spectroscopic- and MS-based methods
for metabolic profiling of biofluids and tissues are well advanced and have been successfully
implemented in a wide range of contexts, important stereochemical information on endogenous
metabolites remains largely uncaptured. The work in the previous chapters describe the efforts
to meet this analytical need in the field of metabolic profiling.
When employing CSAs for chiral discrimination of enantiomeric species in 1H NMR spectroscopy,
a stable internal reference compound is critical to determine the smallest changes in chemical
shift. As routinely used internal reference compounds in NMR metabolic profiling studies
are unsuitable for referencing in the presence of CSAs, initial efforts were diverted towards
establishing a stable mode of referencing. Despite successfully doing so, subsequent surveillance
NMR chiral approaches quickly revealed that attempts to permit untargeted differentiation
of enantiomers would be difficult to achieve. While exploring the utility of CSAs to perform
enantioseparation of chiral amino acids in aqueous solution, changes in chemical shift indicative of
CSA-substrate interactions were apparent. However, they were not enough to produce discernible
peak separations that were able to discriminate the enantiomeric species. Additional reagents
or alternative sample preparative techniques may be required to obtain desirable separations.
Nevertheless, changes in chemical shift patterns as a result of CSA interaction can introduce
additional complications to a biofluid spectrum that is already fraught with complexity in the
presence of a multitude of metabolites at varying abundances with highly overlapping peaks.
This can make spectral analysis extremely difficult, particularly when spectra exhibit complicated
patterns of behaviour. A series of spectra may need to be acquired with gradually incrementing
CSA-substrate molar ratios for accurate spectral interpretation, which is impractical in the
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context of a high throughput metabonomics workflow. Moreover, CSAs themselves tend to
generate predominant spectral resonances, which can mask some of the richness of spectral data
pertaining to metabolites in the same ppm region. Consequently, we turned our focus towards
MS-based chiral profiling methods.
Chiral separations are commonly performed by HPLC and may be achieved using a direct or
indirect approach based on the formation of reversible diastereomeric complexes with CSPs and
chiral selectors, or irreversible diastereomeric derivatives with CDAs, respectively. The indirect
method is associated with a number of advantages over the direct method, such as the availability
of a wide spectrum of commercially available homochiral CDAs with well characterised reactions,
and ability to choose from an ample range of chromatographic conditions. For these reasons, we
decided to explore the indirect chiral approach. The evaluation of an existing UPLC-MS assay
using the CDA, (S )-NIFE, for the enantiomeric quantification of chiral amino acids showed good
separation of diastereomeric derivatives, with high promise for routine application within the
metabonomics framework. However, the existing assay sample preparatory procedure was flawed
and unacceptable for reliable quantification in biofluids. The assay was, therefore, subject to
optimisation to improve sensitivity and reliability using a small quantitative panel of relevance
to ALS on the Q-Tof Ultima. The assay was successfully implemented in an ALS in vitro study
to provide some useful insight on the effects of SOD1 mutation on amino acid neurotransmitter
expression by neural cell lines. The assay was then transferred to the Xevo TQS, where its
capacity to perform MS/MS analysis with MRM, make it better adapted for high sensitivity,
targeted analysis. Following the optimisation of MRM transitions for the amino acid panel, the
assay was applied to rat plasma and urine samples as part of an RYGB study. Although the
assay was well suited to targeted analysis in plasma, urinary matrices represented an analytical
challenge. The assay was, therefore, further optimised for urinary matrices and expanded to
incorporate an additional, large quantitative panel of derivatizable endogenous metabolites.
The standardised assay protocol was subject to validation for absolute quantification of D- and
L-amino acids using FDA approved guidelines for bioanalytical assays, where it proved to be
sufficiently robust for accurate and reliable quantification.
Currently existing chiral approaches are typically employed to analyse chiral compounds in
standard solutions in the absence of a myriad of matrix ions which can potentially hinder their
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reliable quantification. Those which have been applied in the context of biofluids have only
been used to analyse one or a few compounds, such as a drug molecule and its metabolites,
or may be associated with tedious sample preparation. Such methods are unsuited to chiral
metabolic profiling of biofluids or current workflows in the field of metabomonomics. We have
developed a simplistic, semi-targeted chiral analytical assay for reliable enatiomeric quantification
in biological sample sets. Our work, thus, represents a considerable advance relative to existing
chiral approaches, providing a multivariate data output for a more holistic stereochemical
overview of metabolic phenotypes. With absolute quantification of 29 D- and L-amino acids
and relative quantification of a further 50 metabolites in single analytical run, the current
assay provides wide metabolite coverage that is akin to existing widely-targeted metabolomics
assays, such as the AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG) which permits rapid
identification and quantification of over 180 endogenous metabolites [Laiakis et al., 2013].
The current assay is associated with low sample volumes, a simple and rapid sample preparation
procedure, and the simultaneous acquisition of multiple chiral measures of the metabolome in a
single analytical run for high throughput data acquisition. These are all features concurrent with
the present day metabonomics workflow, making this assay suitable for integration to perform
parallel stereochemical analysis of endogenous metabolites. However, the assay comes with the
cost of a long analysis time of 26 minutes per sample, which represents a considerable obstacle
to high throughput data acquisition in the context of large scale studies. A long analysis time is
unavoidable to ensure adequate enantiomeric separation of chiral metabolites. Consequently,
chiral analysis may need to be performed on a randomly selected subset of samples from the total
collection. Nevertheless, the developed assay fulfils our initial hypotheses to develop a widely
targeted chiral analytical method that can be integrated into the modern day metabonomics
workflow, and routinely applied to biologically relevant sample sets to accumulate quantitative
information on chiral measures of the metabolome that would otherwise be invisible to the
analyst using achiral approaches.
A major limiting factor of the current standardised assay relates to the MRM transition time
segment-wise organisation, whereby the incorporation of additional MRM transitions has the
potential to disrupt existing dwell times of concurrent transitions reducing analyte sensitivity.
Rearranging MRM transitions into individual functions with narrower RT window specification
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to reduce the number of concurrent transitions may provide a better leeway for MRM transition
addition without disrupting existing ones. As mentioned above, one disadvantage of the current
assay is a long acquisition time, limiting high throughput analysis and creating dis-synergy
with existing metabonomics workflow. Chromatographic adjustments may be made to create a
shorter overall gradient elution profile, but this may cause a loss of resolution, and consequently,
well-defined enantiomeric peaks for clean integrations and accurate quantification. Another issue
with the assay specifically relates to the choice of representative IS compounds, which are not
subject to analyte dependence. Positively correlated analyte-IS relationships due to natural
isotopic abundances can easily be resolved by employing IS compounds with at least a difference
of 3 amu. However, negatively correlated analyte-IS relationships due to in-source competition
represents a more challenging conundrum. Competition for ionisation may be reduced by using
diluted sample concentrations; however, this will cause loss of sensitivity and the ability to
perform trace analysis of low abundance endogenous metabolites. Although not ideal, post-
acquisition transformation of the linear function describing the analyte-IS response behaviour
may be used to prevent this phenomenon from causing biased estimations of sample analyte
concentrations. Other limitations of the developed assay pertain to the quantification of specific
metabolites, such as those with peak interferences from matrix derived sources, irregular peak
shapes or baseline for accurate integration, and non-linear concentration-response relationships.
Many of these these issues can be rectified by refining the chromatographic conditions of the
basic mobile phase run, such as modulating the gradient elution profile and reducing pH.
Future work will entail a more complete validation of the existing chiral UPLC-MS assay, such
as the evaluation of inter-assay precision and long term stability of derivatives, and validation
for other biofluids besides urine. This is in addition to overcoming some of the assay limitations
mentioned above. (S )-NIFE has the potential to derivatize all primary and secondary amines,
and thiols, of which many are found in biofluids and have not all been exhaustively screened.
Therefore, further work regarding this specific assay may also encompass a more thorough screen
of additional metabolites that can be captured during analysis to further develop the existing
targeted quantitative panel of analytes. This will provide a larger multivariate output with
additional information connected to the stereochemistry of endogenous metabolites.
Clearly, there is room for other approaches to be developed that can potentially yield comple-
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mentary enantiospecific information following seemless integration into current metabonomics
workflows. Currently, analysis of biofluids and tissues by 1H NMR spectroscopy is limited by
resolution, as well as sensitivity, as result of spectral profiles with overlapping signals from
numerous metabolites and the limited range of proton chemical shifts. This work has indicated
that while seemingly attractive in terms of simplified sample preparation and the potential for
easy integration into existing workflows, CSAs lack the ability to sufficiently resolve enantiomeric
species in aqueous solution. Therefore, sample preparatory approaches that can potentially
strengthen CSA-substrate interactions or introduce differential chemical exchange kinetics need
to be explored, such as the use of other solvents like methanol- d4 and acetonitrile-d4, and the
addition of paramagnetic species like lanthanide (III) ions. With respect to spectral complexity,
2D NMR spectroscopic approaches, such as high resolution 2D J -resolved (JRES) spectroscopy,
may be explored to deconvolute heavy spectral congestion by an additional spectral dimension
for better identification and quantification [Huang et al., 2015].
MS analysis using a targeted panel of metabolites proved to be a pragmatic way of progressing
chiral metabolome analysis and forms the basis for evaluating other approaches. As assay
developed for this work has only considered endogenous amines, targeted methods are yet to
be developed for other predominant classes of chiral compounds, such as sugars, alcohols, and
organic acids. Such methods can be used to enantiomerically distinguish these metabolites and
characterise their relative systemic abundance and the metabolic pathways from which they arise.
The resulting data can be pooled and analysed simultaneously using multivariate statistics to
provide a wealth of stereochemical information on the metabolome. Established chiral analytical
approaches need to be implemented into routine metabolic profiling analyses for biologically
relevant sample sets.
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Final summary
• A stable internal referencing strategy in aqueous samples, critical for determining the
smallest of changes in chemical shift, was devised for 1 NMR spectroscopic studies utilising
CSAs for enantioseparations of chiral molecules.
• Small changes in chemical shift for insufficient separation of enantiomeric species, together
with high biofluid spectral complexity, makes 1H NMR spectroscopy using CSAs as
lone chiral discriminatory determinants in aqueous samples unsuitable for stereochemical
investigations of the metabolome.
• An existing chiral UPLC-MS assay for enantioselective analysis and quantification of
DL-amino acids was optimised for improved sensitivity and reliable quantitation.
• The developed assay was initially exploited for the relative quantitation of a small panel of
amino acid neurotransmitters expressed by neuronal and astrocyte cell lines representative
of an in vitro model for ALS to determine the effects of SOD1 mutation. Differences in
amino acid enantiomeric expression were identified between transgenic cultures, which
were consistent with the biological functions of each cell type and previous studies on the
effects of SOD1 mutations in neural cell lines.
• The UPLC-MS assay was applied for the analysis of rat urine and plasma samples obtained
from an RYGB study following amino acid panel development. The assay was initially
unsuitable for reliable enantiomeric quantitation in urinary matrices, but was adequate
for the analysis of plasma samples. Significant differences were observed with respect to
specific D-amino acids in plasma between RYGB- and sham operated rats, which may
reflect distinctive indigenous gut microbial composition and behaviour.
• The assay was further developed by tackling the analytical challenges presented by urinary
matrices to ensure reliable quantitation of target analytes.
• The quantitative panel of endogenous urinary amines, some of which also exhibit chirality,
was expanded to create a widely targeted analytical method.
• The standardised assay was subjected to partial validation for absolute quantification of
amino acids in human urine using current FDA guidelines for bioanalytical assays.
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• MS-based methods proved to be a more pragmatic solution for developing chiral analytical
approaches which are cooperative to the existing metabonomics workflow to provide a
complementary wealth of stereochemical information on endogenous metabolites. Future
work to progress chiral metabolome analysis will, therefore, mainly revolve around this
analytical platform.
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Appendix
Supplementary Figure 1. β-CD in urine. Overlay of 1D 1H NMR spectra for human urine
with (red) and without (black) 4mM β-CD.
Supplementary figure 2. Peak deconvolution. Deconvolution of (S )-NIFE-D-Thr and an
interfering peak arising from a urinary matrix component using Peakfit software.
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